A New Source of Stem Cells in Amniotic Fluid and Placenta in 1st Trimester of Pregnancy by Moschidou, Dafni & Moschidou, Dafni
  1 
A New Source of Stem Cells in Amniotic Fluid 
and Placenta in 1st Trimester of Pregnancy 
 
 
 
 
 
Dafni Moschidou 
 
 
 
 
A thesis presented in partial fulfilment of the degree of Doctor 
of Philosophy 
 
Institute of Reproductive and Developmental Biology 
Faculty of Medicine 
Imperial College London 
 
 
September 2009 
 
 
 
  2 
 
 
Abstract 
 
Mesenchymal stromal cells (MSC) are multipotent cells found in fetal, neonatal and 
adult tissues. Fetal MSC have advantageous characteristics over their adult 
counterparts, and the regenerative potential of fetal blood MSC has recently been 
shown in a model of skeletal dysplasia and renal failure. Although fetal blood MSC 
can be isolated during ongoing pregnancy, the clinical effectiveness of using fetal 
blood-derived MSC for prenatal fetal cell therapy is constrained by the invasive 
nature of blood sampling procedure. With amniocentesis and chorionic villus 
sampling (CVS), fetal MSC can be obtained with minimal invasion. 
 
The aim of this study was to characterise stem cells from 1st trimester amniotic fluid 
(AF) and placenta by comparing their phenotype with MSC from 1st trimester bone 
marrow and 2nd trimester AF. Cells from all sources have similar immunophenotype, 
express pluripotency markers and telomerase, but 1st trimester AF stem cells have 
higher kinetics. The cells can differentiate into 3 lineages (bone, fat and cartilage), 
form embryoid bodies (EB) in vitro and can be transfected with high efficiency 
using non-viral methods.  
 
The migration potential of fetal MSC was also investigated using in vitro migration 
assays, to recapitulate the in vivo mechanisms involved in donor cell recruitment to 
various tissues and delineate the pathways involved. Fetal blood MSC and AF stem 
cells were shown to express CXCR4, the stromal cell-derived factor-1 (SDF-1) 
receptor, intracellularly but not on the cell membrane and migrate to SDF-1 
gradients and to osteoblast cultures derived from the Osteogenesis Imperfecta mouse 
(oim), but not wild type bones. Pre-stimulation with oim plasma up-regulated 
CXCR4 and increased chemotaxis to SDF-1 and oim bone.  
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Conclusively, 1st trimester AF and placenta are a new source of stem cells with great 
potential for future cell therapy applications. Also, initial experiments indicate the 
importance of the SDF-1/CXCR4 axis for stem cell recruitment to the site of injury. 
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Chapter 1. Introduction 
 
1·1. Stem cells 
 
1.1.1. General 
 
Stem cells are undifferentiated cells with the ability to self-renew for a prolonged 
period in culture, differentiate into at least two cell types and repopulate a host in 
vivo (Smith, 2006). Stem cell plasticity varies depending on the age, tissue of origin, 
stage of differentiation and experimental conditions the cells are cultured in. 
Multipotent cells can give rise to fully functional cell types of their tissue of origin, 
while pluripotent cells have the ability to differentiate into all the cells types present 
in the embryo, but not trophoblastic cells. Totipotent cells can give rise to an entire 
organism (Smith, 2006). The differentiation potential of a stem cell is dependent on 
the genetic make-up of the cell, but also on the microenvironment in which the cell 
is growing (Watt and Hogan, 2000). Stem cells have been isolated at different 
developmental stages from embryo to adulthood, and from different sources. 
Derived stem cells are classified according to their origin and have different 
properties and potential applications, in tissue engineering, cell and gene therapy. 
 
1.1.2. Embryonic stem cells 
 
Embryonic stem cells (ESC) are isolated from the inner cell mass of the developing 
embryo and have been successfully obtained from mice (Evans and Kaufman, 1981), 
and non-human primates (Thomson et al., 1995). Human ESC were first isolated by 
Thomson et al. at the University of Wisconsin (Thomson et al., 1998). Human ESC 
are pluripotent and can be maintained in culture, possibly indefinitely. Yet, research 
on ESC and their potential applications is limited by the ethical restrictions of the 
destruction of a developing embryo, because ESC can only be derived if the entire 
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inner cell mass is harvested and cultured in vitro. In addition, their inherent 
characteristics would limit their use for cell therapy. When severe combined 
immunodeficiency (SCID) mice are injected with undifferentiated ESC teratomas 
are formed. This is one of the defining properties of ESC (Thomson et al., 1998) and 
an indication of stem cell pluripotency.  
 
At the same time as Thomson et al. (Thomson et al., 1998), another group led by 
John Gearhart was working on the derivation of human embryonic germ (EG) cells 
from the gonadal ridge and mesenchymal compartment of 5 to 9 weeks fetal tissue 
(Shamblott et al., 1998). EG cells are derived from primordial germ cells, which 
would normally develop into the gonads. EG cells are pluripotent cells, similar to 
ESC in many aspects in that they can give rise to cells of all three germ layers and 
express pluripotency markers. However, EG cells have a more limited proliferation 
capacity in vitro than ESC (Shamblott et al., 2001), and when injected into 
immunocompromised mice they do not form teratomas, unlike ESC (Shamblott et 
al., 1998). 
 
ESC are routinely cultured with the use of feeder cells, usually mouse embryonic 
fibroblasts (Skottman and Hovatta, 2006), but they can also be grown on human 
fibroblasts in culture media without the addition of animal products (Rodriguez et 
al., 2006). Additionally, ESC can be grown without the addition of feeder cells, by 
using coating agents such as gelatin, laminin or Matrigel (Xu et al., 2001). This can 
be beneficial for applications where a large number of cells would be required, such 
as tissue replacement or drug screening, and where the handling of feeder layers 
would be challenging.  
 
In addition to adhesion to an extracellular matrix, mouse ESC require addition of 
leukaemia inhibitory factor (LIF) in the culture media, while human ESC require 
addition of basic fibroblast growth factor (bFGF) for maintenance of the 
undifferentiated state in vitro (Smith, 1991). However, current protocols used for 
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ESC culture do not maintain the population in a homogeneous undifferentiated state, 
as some colonies undergo spontaneous differentiation.  
 
In their undifferentiated state, ESC express various markers that have been 
associated with stem cell pluripotency, including octamer binding protein-4 (Oct-4), 
a transcription factor of the POU family critical for maintenance of self-renewal and 
pluripotency (Scholer et al., 1990), Nanog (Chambers et al., 2003), which works 
together with other transcription factors such as Sox-2, a transcription factor 
essential for maintenance of self-renewal in undifferentiated ESC (Stevanovic et al., 
1994), and stage specific embryonic antigens 1-4 (SSEA1-4). SSEA-1 is only 
expressed in mouse ESC, while SSEA3-4 are only expressed in human ESC (Smith, 
1991). SSEA3 and SSEA4 are globoseries glycolipid antigens expressed by 
undifferentiated ESC and their expression is downregulated during differentiation 
(Draper et al., 2002). Undifferentiated ESC also express Tra-1-60 and Tra-1-81, the 
keratan sulphate-related antigens (Andrews et al., 1984).  
 
Self-renewal is a function of stem cell populations that is tightly controlled. 
Telomeres, short double-stranded DNA sequences are essential for replicative 
stability, as they protect chromosomal ends. DNA polymerase cannot access these 
sequences, therefore they shorten with every cell division until they reach a critical 
length, which signals senescence (Epel et al., 2004). In ESC telomeres are protected 
from shortening by the action of telomerase, an enzyme responsible for extension of 
the telomeres after cell replication (Bodnar et al., 1998; Lustig, 1999). The 
importance of telomerase activity in stem cells and the implications of telomere 
shortening have become obvious with the early death of Dolly the cloned sheep at 
age 6, rather than the expected age of 11-12. Telomere analysis of cells from Dolly 
and two other cloned sheep indicated that the telomere size of the cells matched that 
of the transferred nucleus and not the actual birth age (Shiels et al., 1999). However, 
further studies on the telomerase status and any potential telomere repair in cloned 
organisms would have to be carried out before any conclusions could be drawn. 
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Differentiation of ESC can be mediated by removal of the cells from the feeder cells 
and the growth factors used in culture, followed by suspension culture and formation 
of embryoid bodies (EB). EB typically contain cells from all three germ layers 
(Smith, 1991). However, this method could lead to heterogeneous differentiation of 
cells, since the localisation of individual cells in the EB could be detrimental for cell 
exposure to different signals, leading to different cells within the EB differentiating 
into a different type of tissue. An alternative is the use of serum-free culture media 
supplemented with different growth factors, depending on the differentiation 
protocol (Smith, 1991). Yet, current differentiation protocols do not produce 
homogeneously differentiated cell populations, making it difficult to obtain cells 
differentiated to a specific lineage required for applications like tissue engineering, 
where terminally differentiated, functional tissues would be required to provide 
successful therapy. 
 
Overall, there is still much work required on the culture conditions and in vitro 
differentiation protocols of ESC, to be able to control the population and produce 
homogeneous cell types, without the need for feeder layers and components of 
animal origin. In addition, further studies would need to be carried out to fully 
understand the properties of ESC and the alterations that occur in vitro, before these 
cells can be used safely for clinical applications. 
 
 
 
1.1.3. Somatic stem cells 
 
The first report on the presence of plastic adherent, fibroblast-like cells with 
osteogenic potential in adult bone marrow came in 1974 by Friedenstein et al. 
(Friedenstein et al., 1974). Since then, work from many groups showed that these 
cells are capable of differentiating into various types of connective tissue at the 
clonal level, introducing the idea that these cells are stem cells (Pittenger et al., 
1999). Somatic stem cells have been isolated from a range of adult, neonatal and 
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fetal tissues. For instance, adult stem cells (ASC) have been isolated from the skin 
(Jones and Watt, 1993), liver (Fausto, 2004) and gut (Brittan and Wright, 2002). 
However the frequency of somatic stem cells declines with age, with only 1 in 
100,000 cells being a stem cell in teens, and 1 in 400,000 cells at the age of 50 
(Caplan, 2007). Somatic stem cells have different properties and potential depending 
on their tissue of origin and developmental age. Somatic stem cells are believed to 
reside in a specific ‘niche’ or stem cell microenvironment in each tissue, where they 
remain quiescent until they are recruited due to disease or tissue injury. The niche 
includes interactions between stem cells and extracellular matrix, cell-cell 
communication and various signalling molecules involved in this process. The niche 
microenvironment is believed to play a crucial role in defining the properties of stem 
cells, by controlling the expression of genes responsible for self-renewal or 
differentiation (Watt and Hogan, 2000). 
 
ASC differentiation is usually only limited to a specific cell type or a variety of cell 
types associated with the germ layer from which ASC are derived, thus making them 
multipotent. For example, neural stem cells (NSC) can be isolated from the brain, 
grown in culture and differentiated in vitro into neurons, astrocytes and 
oligodendrocytes. However, some evidence suggests that ASC may have the ability 
to differentiate into a tissue normally derived from a different germ layer than the 
one of the ASC. According to one theory, when ASC are implanted into a niche of a 
different germ layer than the one they originate from, they can potentially 
differentiate into cells found in the new environment. For instance, adult bone 
marrow stem cells have differentiated into neural cells in vivo after intraperitoneal 
transplantation into irradiated mice (Mezey et al., 2000) and neural stem cells have 
differentiated into blood cells in vivo after transplantation through the tail vain into 
irradiated mice (Bjornson et al., 1999). Most reports on ASC plasticity to date show 
that transplanted ASC integrate into mature host tissue and develop some of its 
characteristics. However, there is still limited evidence that ASC can successfully 
generate fully functional, differentiated cells able to restore loss of function in vivo.  
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Most of the studies on ASC plasticity involve cells isolated from the brain or the 
bone marrow, with the latter source having the best characterised populations of 
stem cells. Bone marrow contains two types of stem cells, with notably different 
properties. Mesenchymal stromal cells (MSC) can differentiate into mesodermal 
tissues such as bone, fat and cartilage, while hematopoietic stem cells (HSC) can 
differentiate into cells present in the hematopoietic system (Friedenstein et al., 
1974).  
 
 
1.1.4. Hematopoietic stem cells (HSC) 
 
HSC have been used therapeutically for many years in bone marrow transplantation 
and have been widely studied. HSC localise mainly in the bone marrow, but can also 
be found circulating in the blood and in other tissues like the liver and spleen (Jiang 
et al., 2002). HSC express a variety of surface markers such as CD34 and CD45, 
both present on hematopoietic cells, while they lack expression of HLA-DRE and 
CD38 (Jiang et al., 2002). HSC do not adhere to plastic cell culture dishes and 
require growth factors such as stem cell factor (SCF) to grow in culture. The 
inability of HSC to adhere to plastic is useful for cell isolation, as MSC selectively 
adhere to plastic and can therefore be separated from HSC. 
 
 
1.1.5. Mesenchymal stromal cells (MSC) 
 
While the frequency of MSC is quite high in the newborn (1 MSC in 10000 marrow 
nucleated cells), this frequency rapidly declines to 1 in 250000 marrow nucleated 
cells in adults (Caplan, 1994). Various groups have isolated MSC, using different 
isolation protocols and characterisation criteria and using different nomenclature. 
This has led to a difficulty in comparing the different studies and identifying 
whether the isolated cells are the same cell type, especially as the origin and specific 
identity of stromal cells is still unknown. The current term to describe stromal cells, 
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suggested by Dominici et al., is ‘multipotent mesenchymal stromal cells’. The 
minimal criteria for the isolation of these cells are plastic adherence, expression of 
CD73, CD90, CD105, lack of expression of CD34, CD45, HLA-DR and 
differentiation into osteocytes, adipocytes and chondrocytes in vitro (Dominici et al., 
2006). MSC are not a homogeneous population of cells, rather they are a mixture of 
stem cells, progenitors and terminally differentiated cells. Thus, the acronym MSC 
describes the mixed population of mesenchymal stromal cells more accurately, 
rather than mesenchymal stem cells (Horwitz, 2007). 
  
There are three main approaches for MSC isolation, which can be used in 
combination for the isolation of a more homogeneous population. The first method 
takes advantage of the plastic adherence of the MSC and the elimination of 
hematopoietic cells by medium replacement (Friedenstein et al., 1974). Cell 
passaging can further enhance the homogeneity of culture obtained by this method, 
which allows the self-renewing stem cells to become enriched. Another isolation 
protocol involves the separation of cells based on cell density, using a Percoll 
gradient (Dazzi et al., 2006). A more specific approach is cell sorting of populations 
by flow cytometry, using a variety of markers such as Stro-1, CD44, CD90 to select 
the MSC fraction or CD14, CD34 and CD45 to remove the hematopoietic fraction of 
the population.  
 
Adult MSC can be isolated from the stromal fraction of bone marrow, where they 
are believed to respond to local injury by producing daughter cells capable of 
differentiating into various mesodermal tissue types (Short et al., 2003). Adult MSC 
have also been isolated from other tissue sources such as peripheral blood (Zvaifler 
et al., 2000), adipose tissue, lung, skeletal muscle, synovium (Tuan et al., 2003) 
trabecular bone (Alfirevic et al., 2003) and others, indicating that their distribution in 
vivo is diverse, with MSC from different sources having different characteristics, 
such as differentiation potency and proliferation potential (Baksh et al., 2004).  
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A variety of markers are being used in different laboratories to identify MSC. These 
markers include endoglin, also known as SH2 or CD105, which is part of the TGFβ1 
and β3 receptor complex and is involved in cytoskeletal organisation and migration 
(Barbara et al., 1999); CD73, also known as SH3/SH4 or 5’-nucleotidase, used as a 
marker for lymphocyte differentiation (Thomson et al., 1990); Stro-1, expressed by 
stromal progenitor cells in human bone marrow (Simmons and Torok-Storb, 1991); 
CD44 also known as HCAM1 or hyaluronan receptor, a cell surface glycoprotein 
involved in cell migration, adhesion and cell-cell interaction (Terpe et al., 1994); and 
CD90, also known as Thy-1, believed to play a role in cell-cell and cell-matrix 
interactions (Ades et al., 1980). Cells also express markers important for adhesion, 
such as CD29 (β1-integrin) and CD31 (PECAM-1) (Gronthos et al., 1994; Pittenger 
et al., 1999). Although these markers are generally used in the phenotypic 
characterisation of MSC, there is still no general consensus on a specific set of 
markers characterising MSC. This lack of MSC-specific markers has led to 
controversy in identifying whether MSC-like cell populations isolated by different 
laboratories are actually all the same type of cells, manifesting a variation in marker 
expression due to different culture conditions, age of donors or sample origin.  
 
MSC can differentiate in vitro, under permissive conditions, to various cell types of 
connective tissue. These include chondrocytes, adipocytes, osteocytes and myocytes 
(Muraglia et al., 2000; Oreffo et al., 2005; Taylor and Jones, 1982). Figure 1 
illustrates the differentiation pathways of MSC into bone, fat and cartilage. It has 
also been reported that adult bone marrow MSC can differentiate into hepatic (Lee et 
al., 2004) and endothelial (Oswald et al., 2004) cells, as well as neural cells (Ortiz-
Gonzalez et al., 2004). However, differentiation of MSC into cells from different 
germ layers is highly controversial, as these cells are not Oct-4 positive and 
therefore not pluripotent. Some data on the therapeutic effects of adult MSC are 
available, including evidence suggesting that adult bone marrow stem cells were 
able to migrate to injured lungs, where they differentiated into type II pneumocytes 
and other cells of mesenchymal lineage (Albera et al., 2005). A study on infracted 
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rat heart however indicated that, although bone marrow MSC migrate and remain in 
the heart, they fail to improve cardiac function (Carr et al., 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Differentiation of MSC into the mesenchymal lineage: osteocytes, 
chondrocytes and adipocytes. 
 
 
In order to transfer the culture conditions and practices currently used for MSC 
culture in laboratories to more clinic-based applications, it would be fundamental 
that the process could be controlled, reproducible and safe. Technology such as 
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bioreactors has been employed to scale up the propagation of stem cells, but also to 
monitor and control the properties of the cells as they are being cultured. Under 
bioreactor conditions, the cells can be expanded and differentiation to a particular 
cell type can be induced in a controlled manner (Polak and Mantalaris, 2008).  
 
Overall, ASC have limited proliferation capacity and differentiation potency in vitro, 
and low frequency, which is a limitation considering that stem cells used for 
therapeutic applications need to be expanded to clinically relevant numbers in vitro.  
 
 
 
1.1.6. Fetal MSC 
 
Somatic stem cells have also been isolated from most 1st and 2nd trimester fetal 
organs as well as umbilical cord blood. The fetal frequency of MSC is fairly high. 
For instance, MSC can be isolated from fetal blood at high frequency (1 in 700) until 
14 weeks (Campagnoli et al., 2001). The properties of MSC isolated from different 
sources differ. For example, evidence suggests that the osteogenic potential of MSC 
declines with age, with MSC isolated from individuals of different ages showing 
better osteogenic differentiation when isolated from younger donors (D'Ippolito et 
al., 1999).  
 
1.1.6.1. Neonatal/ Perinatal 
 
Neonatal umbilical cord blood is a rich source of HSC and MSC, and has been used 
as an alternative to BM and peripheral blood-mobilised HSC for transplantation 
(Rocha et al., 2004). The frequency of MSC in umbilical cord blood is low however, 
with MSC successfully isolated from only a third of all samples collected (Bieback 
et al., 2004). MSC from the umbilical cord blood express a variety of markers 
similar to those seen in adult MSC, including CD105, CD73 and CD90, but lack 
expression of CD34, CD45 and HLA-DR (Weiss et al., 2006). They have also been 
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reported to express Oct-4, Nanog and Sox-2 (Weiss et al., 2006). In terms of their 
differentiation potential, cord blood MSC can differentiate into bone, fat and 
cartilage (Baksh et al., 2007; Karahuseyinoglu et al., 2007), neural (Karahuseyinoglu 
et al., 2007) and endothelial cells (Wu et al., 2007). 
 
Another very rich source of mesenchymal progenitors is umbilical cord perivascular 
cells. These cells have a doubling time of 20 hours at passage two, producing over 
1010 cells in one month in culture, with a population doubling time of around 60-85 
hours (Sarugaser et al., 2005). These cells express SH2, SH3, Thy-1 and CD44, but 
are negative for CD34 and class I and II major histocompatibility antigens, which 
could be an advantage for using these cells for allogeneic therapy (Sarugaser et al., 
2005).  
 
Wharton’s jelly, the connective tissue of the human umbilical cord, is also a source 
of MSC with similar properties as other cord blood MSC both on the expression of 
markers and on the differentiation potential (McElreavey et al., 1991; Wang et al., 
2004). Additionally, one study has shown that these cells can be induced to 
differentiate into cells with a phenotype similar to that of neural cells, expressing 
neuron-specific enolase and other neural markers (Mitchell et al., 2003).  
 
 
1.1.6.2. Second trimester 
 
MSC have also been isolated from 2nd trimester sources. MSC from fetal lung tissue 
can differentiate into fat and bone (in 't Anker et al., 2003). Fetal pancreas is also a 
source of MSC with a classic multipotent phenotype. MSC isolated from fetal 
kidney do not express CD45 or CD34, express high levels of mesenchymal markers 
such as vimentin and laminin and can differentiate into bone and muscle (Almeida-
Porada et al., 2002). In addition, when transplanted in a fetal lamb model, MSC from 
fetal kidney showed site-specific engraftment and differentiation (Almeida-Porada et 
al., 2002). 
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Neural stem cells have also been found in many areas of the fetal brain in the mouse 
(Carpenter et al., 1999) as well as the hippocampus and subventricular zone in the 
adult central nervous system (CNS) (Johansson et al., 1999). Fetal NSC have the 
ability to self renew and differentiate into the three predominant cell types of the 
CNS: neurons, astrocytes and oligodendrocytes. When transplanted into 
immunodeficient newborn mice, they show engraftment, migration and site-specific 
neuronal differentiation up to seven months later (Uchida et al., 2000).  
 
 
1.1.6.3. First trimester 
 
MSC are present in the fetal circulation from early gestation and then progressively 
decline in frequency in fetal blood during the late 1st trimester, suggesting that they 
may play an important role in establishing 1st trimester haematopoiesis (Campagnoli 
et al., 2001). Their presence before initiation of bone marrow haematopoiesis, their 
ability to support haematopoiesis in co-culture, and their decline in frequency as 
haematopoiesis is established is consistent with the hypothesis that fetal MSC are 
migrating to the definitive site of haematopoiesis in the bone marrow where they 
adhere, in preparation for HSC engraftment and haematopoiesis. 
 
MSC are not only present in 1st trimester blood, but also in liver and bone marrow. 
In the presence of serum, these cells adhere to plastic and grow as spindle-shaped 
fibroblastic cells similar to adult bone marrow MSC. They are non-haematopoietic, 
non-endothelial, as they do not express CD45, CD34, CD14 and von Willebrand 
factor (vWF) and express a number of adhesion molecules including CD44, VCAM-
1 (CD106) and β1-Integrin (CD29). In their undifferentiated state, fetal MSC stain 
positive for fibronectin, laminin, vimentin and mesenchymal markers such as SH2, 
SH3 and SH4. They cycle faster than adult bone marrow-derived MSC, having a 
doubling time of 24-30 hours over 20 passages (50 population doublings) without 
differentiation (Campagnoli et al., 2001; Gotherstrom et al., 2003). Additionally, 
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human fetal MSC can differentiate into fat, bone and cartilage. More recent work 
shows that they may also be able to differentiate into skeletal muscle (Chan et al., 
2003). MSC from fetal blood, liver and bone marrow also express the pluripotency 
stem cell markers Oct-4, Nanog, Rex-1, SSEA-3, SSEA-4, Tra-1-60 and Tra-1-81. 
MSC from these sources also have longer telomeres, higher telomerase activity, 
express more hTERT, are more readily expandable and senesce later in culture when 
compared to adult bone marrow MSC (Guillot et al., 2007). 
 
MSC can also be isolated from umbilical cord blood in the 1st trimester by the use of 
an ultrasound-guided needle. 1st trimester cord blood MSC express the pluripotency 
markers Oct-4, SSEA3-4, Tra-1-60 and Tra-1-81 (McGuckin et al., 2005), can 
differentiate to bone, fat, cartilage, skeletal muscle (Gang et al., 2004) and also into 
cells of neural (Jeong et al., 2004), glial (El-Badri et al., 2006), and hepatic (Lee et 
al., 2004) origin.  
 
 
 
 
1.1.6.4. Amniotic fluid (AF) stem cells 
 
The AF cavity originates from the inner cell mass of the blastocyst, which also gives 
rise to the yolk sac and parts of the placenta (Crane and Cheung, 1988). The cellular 
composition of the AF changes throughout pregnancy (Bili et al., 2002; Torricelli et 
al., 1993). As the embryo develops, fetal and possibly placental cells are shed into 
the AF. Thus, a variety of different cells are present in the AF during pregnancy and 
the origin of these cells is still unclear. During the 1st trimester, AF cells are likely 
originating from the fetal skin and the amniotic membrane, while from the 2nd 
trimester onwards cells could also come from the respiratory and intestinal tracts, 
released during fetal micturition (Gosden, 1983). 
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Although AF cells have been widely used for prenatal diagnosis, little was known 
about the origin and properties of these cells. The first study on AF cells for an 
application other than prenatal diagnosis came in 2001, when Kaviani et al. isolated 
AF cells as a source for fetal engineering (Kaviani et al., 2001). In this study, AF 
cells with a mesenchymal phenotype were isolated from pregnant ewes, expanded in 
vitro and seeded in scaffolds, where they attached with no evidence of cell death. 
The same study was later carried out using human 2nd trimester AF cells, showing 
that human AF cells also have the ability to attach to polymer scaffolds with no cell 
death observed (Kaviani et al., 2003). 
 
The first indication that human AF may contain stem cells came in 2003, when a 
subpopulation of Oct-4 positive cells was identified in 2nd trimester AF, 
demonstrated by RT-PCR, western blot and immunofluorescence (Prusa et al., 
2003). The same subpopulation also had high proliferation potential, as shown by 
the high expression levels of cyclin A, a proliferation marker.  In the same year, In 
t’Anker et al. showed that 2nd trimester AF contains a population of cells positive for 
markers associated with MSC such as CD90, CD73, CD105 and CD166, but lacking 
expression of hematopoietic markers like CD14, CD34 and CD45 (In 't Anker et al., 
2003). The isolated MSC were of fetal origin as demonstrated by HLA typing, had a 
higher expansion potential than adult MSC and differentiated into osteocytes and 
adipocytes. Tsai et al. were the first to report that AF contains Oct-4-positive cells 
that also express CD44 and CD105 and lack expression of hematopoietic markers 
(Tsai et al., 2004). Expression of Oct-4 and Rex-1, a transcription factor involved in 
cell pluripotency, by 2nd trimester AF cells was also confirmed by two independent 
studies (Bossolasco et al., 2006; Karlmark et al., 2005). Despite the overlapping data 
obtained by these groups, it is difficult to determine whether they all describe the 
same type of cells present in AF.  
 
More recently, De Coppi et al. isolated cells from 2nd trimester AF with similar 
phenotype to MSC and expressing no hematopoietic markers, that could be clonally 
expanded (De Coppi et al., 2007a). A subpopulation of cells positive for c-Kit, the 
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tyrosine kinase receptor for stem cell factor, was selected. The clonality of the cells 
was confirmed by marking the cells with a retroviral vector. The authors were able 
to demonstrate using this method that a cell population derived from a single cell can 
differentiate into six different lineages (adipogenic, osteogenic, myogenic, 
endothelial, neuronal and hepatic) from all three germ layers, both in vitro and in 
vivo. When the cells were transplanted in vivo into SCID mice, they did not form 
tumours, unlike ESC. The same cells, when transduced with adenoviral vectors 
carrying reporter genes, retained expression of Oct-4 and SSEA4 and were able to 
differentiate into osteocytes and adipocytes in vitro (Grisafi et al., 2008).  
 
Differentiation of AF stem cells into cell types other than osteocytes, adipocytes (De 
Gemmis et al., 2006) and chondrocytes (Kolambkar et al., 2007; Kunisaki et al., 
2006) is, however, challenging. Results on neuronal differentiation of AF stem cells 
shown by De Coppi et al., for instance, were heavily criticised by Toselli et al., in 
that no differentiation into mature functional neurons in vitro or in vivo can be 
substantiated by the results shown (Toselli et al., 2008). The presence of neurogenic 
cells in AF was first suggested in 2003 by Prusa et al. (Prusa et al., 2004), however 
this observation mainly relied on RT-PCR for neuronal markers. The markers 
analysed, like nestin, are not specific to neuronal cells, as they can also be expressed 
by cells of mesenchymal or endothelial origin, as well as kidney cells (Wiese et al., 
2004). Later studies by McLaughlin et al. and Tsai et al. also suggested that 2nd 
trimester AF contains a population of cells with a neuronal dopaminergic phenotype, 
as indicated by expression of neuronal, dopaminergic and glial markers 
(McLaughlin et al., 2006; Tsai et al., 2006). However all these studies describe 
expression of markers of neural differentiation by the cells, rather than assessing 
whether the cells can differentiate into mature, terminally-differentiated cells types. 
A study by Orciani et al. on the effect of culture medium on the potency of AF cells 
to differentiate into neurons showed that expansion of cells in different culture 
media can promote or inhibit neuronal differentiation (Orciani et al., 2008). Thus, it 
is important to establish optimal expansion conditions for AF stem cells that will 
facilitate differentiation into lineages that have proven challenging until now, if they 
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are to be used in applications where terminal cell differentiation would be a 
prerequisite before use. 
 
In vivo results examining neural differentiation of AF stem cells also show 
variability. A study by Cipriani et al. in 2007 showed that human AF MSC, when 
transplanted into the striatum of ischemic rats, can survive, migrate to the injured 
region and express markers for immature neurons and astrocytes (Cipriani et al., 
2007). However this study did not look into the extent of differentiation of the cells, 
or whether any functional alterations took place. Another study using mouse AF 
cells showed that after the cells were injected into the cerebellum of mice after 
cerebral artery occlusion, a correction was observed in the affected cognitive 
functions (Rehni et al., 2007). However this study did not assess the fate of the cells, 
the extent of differentiation or whether the observed effect was maintained long 
term. A more recent study demonstrates that, although human AF cells express 
markers of immature dopamine neurons, the cells fail to differentiate into fully 
mature neurons in vitro, or after transplantation into a rat model for Parkinson’s 
disease (Iacovitti et al., 2008). Thus, further studies are required for the optimisation 
of the neural differentiation protocols used, before AF cells can be considered a 
useful tool for treatment of neurodegenerative conditions. 
 
Until now, limited information is available on the in vitro and in vivo capacity of AF 
stem cells to differentiate into cardiomyocytes. In 2005, Sartore et al. isolated MSC 
from pigs 3 days before delivery, expanded the cells in vitro and, after inducing 
myocardial infarction to pigs of the original litter, they transplanted the isolated cells 
into the ischemic area (Sartore et al., 2005). After 1 month they observed that the 
engrafted cells had differentiated into endothelial and smooth muscle cell types, but 
not cardiomyocytes. However, the effect of the cells on cardiac function was not 
assessed. Another study by Chiavegato et al. in 2007 showed that although human c-
Kit positive AF cells can differentiate into endothelial, smooth muscle and 
cardiomyocyte cells in vitro, when transplanted into the myocardium of normal and 
ischemic immuno-suppressed and immuno-deficient rats they are rejected and fail to 
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show niche-specific differentiation (Chiavegato et al., 2007). In addition, some of 
the transplanted cells formed masses of chondro-osteogenic origin in the 
myocardium of some of the animals. Thus, further studies in ex vivo myocardial 
differentiation of AF cells are required to be able to control the differentiation of the 
cells prior to myocardial transplantation of these cells. 
 
Single studies have provided limited data on the differentiation of AF stem cells into 
various other lineages. AF cells have been shown to differentiate into endothelial 
cells, forming heart valve-like structures when seeded onto heart valve scaffolds, 
manifesting functional opening and closing behaviour (Schmidt et al., 2007). 
However this was a proof-of-principle study assessing the possibility of fabrication 
of heart valve tissues in vitro and several steps are required before it can be applied 
to the clinic. Another recent study has shown that, when injected into the lungs of 
adult mice after hyperoxia injury, human AF cells can integrate into the epithelium 
and express alveolar and bronchiolar epithelial cell markers, depending on the type 
of injury induced (Carraro et al., 2008). De Coppi et al. in 2007, after inducing cryo-
injury to the bladder of rats, showed that although AF MSC show low levels of 
smooth muscle differentiation, they appear to regulate the regeneration of the organ 
after injury. No assessment was carried out on the possible mechanisms involved in 
the prevention of hypertrophy of local smooth muscle cells during tissue 
remodelling (De Coppi et al., 2007b). Another recent study investigated the renal 
differentiation potential of AF cells. After culturing embryonic kidney sections in 
vitro, the authors injected AF cells into the sections and found that the cells migrated 
throughout the section in a pattern similar to the one observed during organogenesis 
(Perin et al., 2007). In addition, the cells expressed markers usually expressed during 
early renal development, but failed to express late kidney gene markers, indicating 
that the cells did not reach a mature renal differentiation stage. 
 
Overall, further studies are necessary to understand the nature of stem cells available 
in human AF and the potential of these cells to differentiate into mature cell types of 
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all three lineages, before these cells can successfully be used for therapeutic 
applications. 
 
 
1.1.6.5. Placenta stem cells 
 
Another fairly accessible source of cells for autologous use is the placenta, a 
fetomaternal organ essential for the nourishment of the developing fetus. Techniques 
such as chorionic villus sampling (CVS) isolate placental cells with minimal 
invasion during the 1st and 2nd trimesters. In addition, the volume of term placenta 
makes it an attractive source of stem cells, as on average human term placenta 
weighs more than 590 grams (Bolisetty et al., 2002). Human placenta contains 
various types of cells of different developmental origin. Cells of the chorion and 
decidua are derived from trophectoderm, while amnion is derived from the epiblast 
of the developing embryo (Crane and Cheung, 1988).  
 
MSC have been successfully isolated from 2nd and 3rd trimester placental 
compartments, including the amnion, chorion, decidua parietalis and decidua basalis 
(In 't Anker et al., 2004; Soncini et al., 2007), and represent <1% of cells present in 
the human placenta (Alviano et al., 2007; Zhang et al., 2004b). Limited studies also 
suggest the presence of MSC in 1st trimester placental tissues (Poloni et al., 2008; 
Portmann-Lanz et al., 2006).  
 
Stem cells isolated from the placenta express stromal markers such as CD166, 
CD105, CD73, CD90 and others, while they are negative for the hematopoietic 
markers CD14, CD34 and CD45 (Igura et al., 2004; Sudo et al., 2007). Additionally, 
placenta-derived MSC have been shown to express pluripotency markers such as 
SSEA3, SSEA4, Oct-4, Nanog-3, Tra-1-60 and Tra-1-81 (Battula et al., 2007; Yen et 
al., 2005). Table 1 shows a summary of the immunophenotype of mesenchymal stem 
cells from different sources during development, from the 1st trimester (fetal blood, 
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liver and bone marrow), to second trimester (amniotic fluid), term (placenta and 
umbilical cord blood) and adult bone marrow. 
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Table 1. Immunophenotype of mesenchymal stem cells from different sources (Adapted from Guillot et al., 2006). 
 
         1st trimester   2nd trimester                  Term                   Adult  
 
Antigen Fetal Blood Fetal Liver Fetal Bone Marrow Amniotic Fluid     Placenta    Cord Blood Bone Marrow 
CD14           -         -   -            -    -         -   - 
CD34           -         -   -            -    -         -   - 
CD45           -         -   -            -    -         -   - 
CD31           +         +   +            +   +         -   + 
CD29           +         +   +            +   +         +   + 
CD44           +         +   +            +   +         +   + 
CD105           +         +   +            +   +         +   + 
CD73           +         +   +            +   +         +   + 
Vimentin                  +         +   +            +   +         +   + 
Laminin          +         +   +            +   +         +   + 
Fibronectin          +         +   +            +   +                  +   + 
vWF           -         -   -            -    -              -   - 
CD90           +         +   +            +   +         +   + 
Nestin           +         +   +            +               + 
CK18           +         +   +            +   +         +   + 
Oct-4           +         +   +            +   +         -/+  - 
Nanog           +         +   +            +   +         +   - 
SSEA3          +         +   +            -/+   +             - 
SSEA4          +         +   +            -/+   +          -   - 
Tra-1-60                   +         +   +            +   +             - 
Tra-1-81          +         +   +            +   +             - 
+, positive, +/-, weakly positive/low expression, -, negative. 
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Placental MSC can differentiate into adipogenic, chondrogenic and osteogenic cells 
in vitro (Ilancheran et al., 2007; Portmann-Lanz et al., 2006). In addition, Portmann-
Lanz et al. have provided data on myogenic differentiation (Portmann-Lanz et al., 
2006), although further assessment would need to be carried out to test the myogenic 
potential of placenta stem cells. Alviano et al. have tested the endothelial 
differentiation potential of amniotic membrane MSC in vitro, and showed that the 
cells express endothelial-specific markers, although no functionality tests were 
carried out (Alviano et al., 2007). Also, MSC from the amniotic membrane have 
recently been suggested to have some characteristics of cardiomyocytes in vitro at 
the RNA level, although no data were given on contractile function indicating 
differentiation (Zhao et al., 2005). Tamagawa et al. and Chien et al. also tested the 
hepatic differentiation potential of placenta MSC, and found that the cells are able to 
differentiate into cells with some characteristics of hepatocytes in vitro and have the 
ability to store glycogen (Chien et al., 2006; Tamagawa et al., 2007). Some studies 
have also been carried out on the potential of placenta stem cells to differentiate into 
neurogenic lineages in vitro, however no functionality data were shown, and the 
differentiation potential was based only on the upregulation of neuronal-specific 
markers (Miao et al., 2006; Portmann-Lanz et al., 2006; Yen et al., 2008). Overall, 
further studies are required to assess the potency of placenta cells to differentiate 
into mature cell types of all three lineages both in vitro and in vivo. 
 
Placenta stem cells also have the ability to engraft in vivo (Bailo et al., 2004) in 
neonatal swine and rats, and in rat fetuses after intrauterine transplantation (Chen et 
al., 2009). In addition, a study by Kaviani et al. showed that MSC from human 
placenta can attach firmly to polyglycolic acid scaffolds in vitro, with no evidence of 
cell death (Kaviani et al., 2002).  
 
The presence of accessible stem cells in the 1st trimester placenta would be of major 
significance for clinical applications, especially ones that would benefit from the 
availability of cells so early in gestation. Yet, further comparative studies would 
need to be carried out in order to verify the limited results presented so far and 
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identify the full potential of these cells for use in therapy, together with an 
understanding of the actual phenotype of the population of stem cells found in this 
organ. 
 
In summary, stem cells can be classified into two main categories depending on their 
time of isolation during development, the ESC and the somatic stem cells. ESC are 
pluripotent and can be maintained in culture, possibly indefinitely. Yet, research on 
ESC and their potential applications is limited by the ethical restrictions of the 
destruction of a developing embryo, as ESC are isolated from the inner cell mass. In 
addition, their inherent characteristics would limit their use for cell therapy. 
  
Somatic stem cells can be of fetal, perinatal or adult origin and have different 
properties depending on their developmental age. Adult somatic stem cells can be 
isolated from a variety of adult tissues where they are believed to localise in specific 
niches within the organs. Most work has been carried out on ASC isolated from the 
brain and the bone marrow. Fetal stem cells can be isolated in early, mid and late 
gestation either autologously during an ongoing pregnancy from the AF, fetal blood 
or placenta, or allogeneically after fetal termination from most fetal organs including 
the liver, bone marrow and pancreas. Perinatal somatic stem cells are mainly isolated 
from umbilical cord blood. 
 
 
1·2. Use of stem cells in therapy  
 
MSC have been used experimentally in a broad spectrum of applications in cell 
therapy and regenerative medicine. Intrauterine cell therapy is a therapeutic 
approach that could facilitate the treatment of conditions in utero, thus preventing or 
correcting any defects before birth. There are two approaches to intrauterine cell 
therapy using fetal stem cells. Cells are more easily collected for allogeneic use from 
abortal tissue, which does raise ethical concerns, yet such material would otherwise 
be discarded. Allogeneic cell engraftment may also be limited due to immune 
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incompatibility. Autologous fetal stem cell collection from cord blood or fetal 
tissues for ex vivo fetal gene therapy not only ensures the use of immunologically-
identical cells that are less likely to be rejected by the fetus itself but also obviates 
the ethical concerns associated with ESC and allogeneic fetal stem cells. Yet, it still 
involves invasive procedures, associated with an increased fetal loss rate (Orlandi et 
al., 1990). 
 
1.2.1. Allogeneic use of stem cells 
 
To date, most of the work on intrauterine cell therapy has been carried out using 
allogeneic stem cells, mainly HSC. These cells however have only been successfully 
transplanted into fetuses with immunodeficiency disorders, despite the 
immunological advantage in early gestation. Indeed it has been observed after 
transplantation in E14 fetal mice that, compared to cells from congeneic donors, 
allogeneic HSC can elicit an immune response (Peranteau et al., 2007). 
 
In contrast, fetal MSC have advantageous properties for use in intrauterine cell 
therapy, since they have an immunological privilege, can engraft widely into 
multiple organs after intrauterine transplantation in animal models (Liechty et al., 
2000) and can differentiate at the site of engraftment (Schoeberlein et al., 2005). 
Also, fetal MSC have been shown to have a ten-fold engraftment advantage over 
adult bone marrow cells (Taylor et al., 2002). A disease model that has been used for 
allogeneic intrauterine fetal MSC transplantation is the model for Osteogenesis 
Imperfecta (OI). 
 
 
1.2.1.1. Osteogenesis Imperfecta (OI) 
 
OI is a disease caused by mutations in the α chain of collagen type I, affecting the 
COL1A1 or COL1A2 genes and leading to abnormal collagen production and 
protein folding by osteoblasts. OI occurs in 1 in 10,000 births, with symptoms 
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including generalised osteopenia, excessive bone fragility and fractures, skeletal 
deformities and short stature. Depending on the genetic features and the severity of 
the disease, it can be classified to different types, from the milder type I to the more 
severe types III and IV, with type II OI being lethal perinatally (Sillence et al., 
1979). There is currently no cure for OI, although the use of biphosphonate therapy 
has been shown to reduce osteoclast-mediated bone resorption, fracture rates and 
pain in children with OI (Glorieux et al., 1998). More recently, experiments carried 
out in six patients with type III OI treated with allogeneic adult bone marrow-
derived MSC resulted in a marked increase in bone mineral content and reduced 
bone fracture frequency, despite the low levels of engraftment of less than 1% 
(Horwitz et al., 2002).  This was the first reported clinical trial using MSC for the 
treatment of a genetic disease. Similar engraftment levels were also observed in a 
clinical case of fetal MSC transplantation in a human fetus with OI, where no 
immunoreactivity was observed (Le Blanc et al., 2005).  
 
Osteogenesis Imperfecta mouse (Oim) is a mouse model of OI type III, of 
intermediate severity. Work with this model has shown that intrauterine 
transplantation of fetal MSC led to an amelioration of the phenotype, with increased 
bone length, strength and thickness and a two-thirds reduction in fracture incidence 
(Guillot et al., 2008a). The cells engrafted more in bone and kidneys compared to 
other tissues, which are both affected tissues in OI. The cells that engrafted in the 
bone expressed osteoblast-associated genes and produced osteopontin, an 
extracellular bone structural protein. The cells that engrafted in the kidneys, 
specifically in the glomeruli, contributed to the decrease of abnormal homotrimeric 
collagen type I levels found in the diseased glomeruli (Guillot et al., 2008b). 
Surprisingly, bone engraftment levels of only 5-10% mediated this improvement in 
phenotype.  
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1.2.2. Autologous use of stem cells 
 
Autologous fetal stem cell collection from cord blood or fetal tissues for ex vivo fetal 
gene therapy not only ensures the use of immunologically-identical cells that are less 
likely to be rejected by the fetus itself but also obviates the ethical concerns 
associated with ESC and allogeneic fetal stem cells. Yet, it still involves invasive 
procedures, associated with an increased fetal loss rate. Harvesting autologous fetal 
blood is technically challenging as collection is performed around 10-14 weeks, 
when the umbilical vessels are small. For instance, the size of the umbilical cord 
measures a 6.1 mm diameter at 12 weeks, while the corresponding size of the 
umbilical vein is 2.0 mm, as measured by ultrasound (Weissman et al., 1994). A 5% 
fetal loss rate has been associated with this approach (Orlandi et al., 1990). Fetal 
stem cells are more easily collected for allogeneic use from terminations of 
pregnancy, which does however raise ethical concerns. There are also some organs 
like the fetal bone marrow or brain where cell harvest in ongoing pregnancies for 
autologous use is highly unlikely. Cell harvest from sheep fetal liver has been 
reported, however this was associated with high mortality rates (Schoeberlein et al., 
2004). 
 
Thus, considerable challenges remain in the further development of autologous 
therapy. Firstly, safe techniques for stem cell collection in early pregnancy need to 
be developed. Yet, invasive procedures like amniocentesis or CVS are likely to be 
required for prenatal diagnosis to identify the disease as a first step, during which 
fetal cells could be harvested with no extra risk. Also, a large number of cells will 
have to be clonally-expanded from a small initial cell population in a relatively short 
period of time, therefore cells with high proliferation capacity are required. 
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1·3. Cell migration to sites of injury for repair 
 
To date, studies have shown that although there is some engraftment of stem cells to 
sites of injury after cell therapy, the levels are very low and of significant clinical 
relevance in only some occasions. A good understanding on the migration 
mechanism of MSC would therefore be highly beneficial for use of these cells in 
therapeutic applications, since by manipulating the activity of the pathways involved 
the migration ability of the cells towards sites of injury could be enhanced. 
Additionally, by manipulating the signalling pathways MSC could be mobilised into 
the bone marrow, where they would be more readily available for tissue engraftment 
and repair. 
 
In vivo experiments have shown that when 1st trimester fetal MSC are delivered in 
utero in a model of OI, they can migrate and engraft to sites of injury where they 
differentiate (Guillot et al., 2008a). The mechanism behind this is largely unknown, 
although some signalling pathways have been associated with this process. 
 
Studies of endogenous mechanisms have shown that MSC can detect tissue injury 
and respond by migrating to the site of damage, where they differentiate, thus 
promoting structural and functional repair. This has been observed in various 
conditions, including genetic defect (Horwitz et al., 2002), irradiation (Chapel et al., 
2003), myeloablative therapy (Koc et al., 2000) and myocardial infarction (Kawada 
et al., 2004). Stromal-derived factor-1 (SDF-1) and hepatocyte growth factor (HGF) 
are upregulated at the site of tissue injury, indicating that these factors and the 
pathways involved may play a role in MSC migration (Kucia et al., 2004; 
Ponomaryov et al., 2000). Other chemokines, which are cytokines able to induce 
chemotaxis, and growth factors have also been suggested as having a role in MSC 
migration. Members of the platelet-derived growth factor (PDGF) signalling 
pathway for instance are implicated in endogenous MSC recruitment to bone, and 
subsequent differentiation of the cells to osteoblasts (Fiedler et al., 2002; Jung et al., 
2006).  
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1.3.1. Candidate axes for MSC migration 
 
One of the candidate molecules involved in cell migration is HGF. HGF activity is 
mainly through the C-MET proto-oncogene, a transmembrane tyrosine kinase. HGF 
is involved in the regulation of HSC proliferation and differentiation (Nishino et al., 
1995). HGF- C-MET axis has also been described as a potential candidate involved 
in MSC migration. This has been supported by a recent study showing that the HGF- 
C-MET axis plays an important role in MSC chemoattraction in a model of wound 
healing (Neuss et al., 2004). The HGF axis appears to be closely involved in the 
SDF-1-CXCR4 axis regulation, as HGF can upregulate CXCR4, hence increasing 
responsiveness to SDF-1, as seen in endothelial as well as breast cancer cells 
(Matteucci et al., 2005). The synergistic effect of HGF and SDF-1 has been observed 
also in various cancer cells, including cervical carcinoma (Majka et al., 2006). 
Additionally, stress induction of murine liver resulted in elevation of SDF-1 levels, 
increased matrix metalloproteinase-9 (MMP-9) activity and elevated HGF 
expression, and recruitment of CD34+ cells, which also contributes to the idea that 
the SDF-1 and HGF work synergistically (Kollet et al., 2003). Further studies would 
be required to investigate the full involvement of the HGF- C-MET axis in MSC 
migration and engraftment to sites of injury. 
 
 
Another important molecule involved in cell migration is SDF-1. SDF-1, also known 
as CXCL12, is a strong chemoattractant, mediating its effect via the CXCR4 
receptor (Aiuti et al., 1997). SDF-1 is expressed by a variety of organs, including the 
bone marrow (McGrath et al., 1999). SDF-1 is expressed in the bone marrow even in 
the absence of stimuli such as tissue injury, indicating that SDF-1 is involved in 
bone marrow homeostasis (McGrath et al., 1999). In this regard, it is now well 
established that the SDF-1-CXCR4 axis is involved in HSC migration to the bone 
marrow (Peled et al., 1999). A study by Togel et al. showed that SDF-1 is 
upregulated in the kidney after injury, while a decrease in expression is observed in 
the bone marrow, indicating an alteration in the SDF-1 gradient that normally exists 
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between the bone marrow and peripheral organs (Togel et al., 2005). SDF-1 is also 
involved in HSC adherence to the endothelium (Grabovsky et al., 2000), expression 
of matrix metalloproteinases (MMPs) (Janowska-Wieczorek et al., 2000) and other 
functions important for HSC migration and engraftment. Furthermore, activation of 
the SDF-1-CXCR4 axis has been shown to support hematopoiesis by mainaining 
HSC in the bone marrow, where they are subjected to paracrine effects mediated by 
the release of growth factors by MSC (Van Overstraeten-Schlogel et al., 2006).  
 
SDF-1, by interaction with CXCR4, activates several pathways associated with cell 
motility, chemotaxis, cell adhesion and secretion of cytokines such as MMPs. Figure 
2 gives a summary of the biological processes mediated by the SDF-1-CXCR4 axis. 
Once SDF-1 is bound to CXCR4, it causes receptor dimerisation and activation via 
phosphorylation of the C-terminus of the receptor. The activated complex is then 
internalised very rapidly from the cell surface, and the process is mediated by G 
protein-coupled receptors (GRKs). The turnover of CXCR4 is very rapid, as it can 
rapidly be re-expressed on the cell surface (Ganju et al., 1998). Other molecules 
involved in the activation of the CXCR4 receptor are the p130Cas, paxillin, focal 
adhesion kinase (FAK), Crk and proline-rich kinase-2 (Pyk-2), the activation of 
which regulates the pathway of chemotaxis (Kucia et al., 2004).  
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Figure 2. Biological role of the SDF-1-CXCR4 axis and control of the chemotaxis 
response pathway. Abbreviations: SDF-1: Stromal-derived factor-1, MMPs: Matrix 
metalloproteinases, GRKs: G protein-coupled receptors, FAK: focal adhesion 
kinase, Pyk-2: proline-rich kinase-2. 
 
SDF-1 
CXCR4 
Cell motility 
Chemotactic 
response 
Adhesion 
 
Secretion of MMPs PI-3k 
Receptor 
internalisation 
GRKs 
FAK, paxillin, 
Crk, Pyk-2, 
p130Cas 
  46 
 
The importance of the SDF-1-CXCR4 axis throughout development has also been 
demonstrated by knockout models for SDF-1 or CXCR4, leading to lethal defects 
affecting the normal development of various systems: impaired haematopoiesis in 
the fetal bone marrow (Nagasawa et al., 1996), defects in the early development of 
the heart, (Nagasawa et al., 1996), defects in angiogenesis (Zou et al., 1998) and 
neural development (Lu et al., 2002).  
 
Considering the importance of the SDF-1-CXCR4 axis during development and in 
adult life, it is not surprising that the axis is tightly regulated and modulated by a 
variety of factors. For instance, molecules associated with inflammation and tissue 
damage, such as vascular cell adhesion molecule-1 (VCAM-1), fibronectin, 
thrombin, fibrinogen and others appear enhance the migratory activity of HSC to 
low doses of SDF-1. This is mediated by an enhancement in the incorporation of 
CXCR4 into membrane lipid rafts in the cell membrane (Wysoczynski et al., 2005). 
It has also recently been reported that inflammatory cytokines such as tumour 
necrosis factor α (TNF-α) can stimulate and upregulate the response of MSC to 
SDF-1 (Ponte et al., 2007). CXCR4 functionality is also tightly controlled at 
different levels: the amount of receptor expressed on the cell surface, the N-terminus 
sulfation status of the receptor, the availability and elevated expression of SDF-1 in 
tissues, as well as the incorporation of CXCR4 into membrane lipid rafts (Kucia et 
al., 2004).  
 
 
1.3.2. The SDF-1-CXCR4 axis and MSC migration 
 
A few recent studies have attempted to delineate the role of the SDF-1-CXCR4 axis 
in MSC migration and engraftment to tissues. Son et al. working with adult and cord 
blood-derived MSC confirmed the involvement of the SDF-1-CXCR4 axis in MSC 
migration, in conjunction with the HGF axis and dependence on MMPs (Son et al., 
2006). Jung et al. provide evidence of stem cell recruitment to the developing 
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marrow by an SDF-1 gradient created between the marrow with an increased 
expression of SDF-1 and the serum with a decreased SDF-1 expression (Jung et al., 
2006). Wynn et al. showed that CXCR4 is present at low levels on the surface of 
MSC, being primarily located intracellularly, and that CXCR4 is involved in 
migration of MSC to the bone marrow (Wynn et al., 2004). Although these studies 
have provided an insight into the involvement of the SDF-1-CXCR4 axis in MSC 
migration, these results refer mainly to adult MSC, leaving the fetal MSC migration 
mechanisms largely unknown.  
 
 
1·4. Gene therapy 
 
One therapeutic application where fetal stem cells could be used is autologous 
therapy for genetic conditions. However, as autologous cells would inevitably carry 
the genetic mutation the therapy is needed for, the cells would have to be genetically 
manipulated ex vivo, prior to reinfusion. 
 
One application of intrauterine therapy of genetic diseases would be the direct 
delivery of the transgene into the fetus, via a direct injection of vectors into different 
fetal compartments. Work in animal models has demonstrated that it is possible to 
deliver vectors to various fetal compartments, including the peritoneal cavity, the 
umbilical vessel or most of the other fetal organs (Waddington et al., 2005). Proof-
of-principle experiments of this approach include treatment of Leber’s congenital 
amaurosis, a lack of rhodopsin caused by a mutation in the RPE65 gene (Dejneka et 
al., 2003) and Haemophilia B, a factor IX deficiency (Waddington et al., 2004). 
 
Two main approaches have been developed for the delivery of transgenes into cells. 
The first and most popular approach uses integrating viral vectors, as they are able to 
confer a permanent delivery of the desired transgene to the cells. The second 
approach was developed largely due to the disadvantage of random integration 
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associated with the viral approach. This safer but less efficient approach involves 
gene delivery to the cells by a variety of non-viral methods. 
 
1.4.1. Viral gene therapy 
 
Integrating vectors, such as onco-retroviral or lentiviral, have been favoured as a 
method of gene delivery because they confer long-term delivery of the desired 
transgene to target cells (Chan et al., 2005). However, the dependency of onco-
retroviruses on mitosis for nuclear entry prevents the use of these vectors in non-
dividing and terminally differentiated cells. Lentiviral vectors on the other hand 
avoid the need for dividing cells.  
 
A few pre-clinical studies have been carried out to date using genetically modified 
MSC as vehicles and adenovirus (Lou et al., 1999; Musgrave et al., 1999; Peterson 
et al., 2005; van Tuyn et al., 2005), adeno-associated virus (Goncalves et al., 2006; 
Lu et al., 2005; Ortiz-Gonzalez et al., 2004), baculovirus (Ho et al., 2005) or 
lentivirus (Chan et al., 2005; Kyriakou et al., 2006; Totsugawa et al., 2002; Zhang et 
al., 2004a) as the vector. However, there are considerable risks associated with the 
viral approach. Insertional mutagenesis, a rare but possible consequence of the 
disruption of genetic sequences within the genome, may occur via the inactivation of 
a tumour suppressor gene or trans-activation of an oncogene. This phenomenon was 
observed in the French X-linked SCID trial, where 3 out of 11 treated patients 
developed leukaemia after disruption of the LMO-2 locus on chromosome 11 
(Hacein-Bey-Abina et al., 2003). One locus the disruption of which leads to acute 
myeloid leukaemia is the MDS1/EVI1 locus (Russell et al., 1994). In this regard, 
studies in rhesus macaques transplanted up to 7 years earlier with autologous CD34+ 
cells transduced with an MLV retrovirus containing reporter genes, showed that in 9 
animals the mds1/Evi1 locus was disrupted in circulating granulocytes, without 
leading to leukaemia or other malignancies. These results indicate that the 
insertional pattern of retroviruses does not disrupt normal cell proliferation or 
differentiation (Calmels et al., 2005). 
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Another concern associated with in vivo viral delivery is the transduction of the 
germ line of the patient. In a recent study, 6 out of 19 animals which underwent 
intrauterine transplantation using onco-retroviral vectors had proviral sequences in 
their spermatocytes, Sertoli cells and other somatic cells (Porada et al., 2005).  One 
way of overcoming the problems associated with the in vivo viral approach is to 
manipulate the cells ex vivo, allowing for screening, selection and expansion of 
transduced cells that have safe genomic insertion sites. Potential transduction of the 
germ line or other somatic cells would also be avoided with this approach. 
 
 
1.4.2. Non-viral gene therapy 
 
Non-viral vectors have been developed in an attempt to overcome the problems 
associated with the use of integrative viral methods. Most non-viral methods involve 
delivery of a plasmid to the nucleus, where it resides as a non-integrating episome. 
Non-integrating episomal vectors, such as the scaffold/matrix attachment regions 
(S/MAR) have been developed as vectors for gene transfer, since they can avoid the 
problems associated with insertional mutagenesis (Giannakopoulos et al., 2009). The 
long-term efficiency of this approach is rather limited however, thus non-viral 
systems that encourage integration have been developed but to date with not much 
success.  
 
In terms of intracellular gene delivery, the most commonly methods used for the 
transfection of MSC are lipofection (Clements et al., 2007) and electroporation 
(Helledie et al., 2008). Lipofection involves transfection of the cells using various 
commercially available lipofection reagents, such as liposomes, cationic lipids or 
polymers (Garnett, 1999). Nucleofection is a novel type of electroporation method 
combining electrical parameters with solutions developed for specific cell types, 
which allows the delivery of DNA or other forms of nucleic acids directly to the 
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nucleus (Aluigi et al., 2006; Aslan et al., 2006; Gresch et al., 2004). The 
disadvantage of cell transfection is that all transfection methods have a lower 
efficiency than viral transduction approaches and decreased cell viability due to 
toxicity with some approaches (Loisel et al., 2001).  
 
At present, the use of integrating non-viral vectors is hindered by three key barriers: 
transgene internalisation into cells, transport across the nuclear membrane and 
integration ideally at a predefined safe genomic locus. With these in mind, two main 
systems of non-viral DNA integration have been developed. The first one uses 
meganucleases, able to stimulate integration of a DNA fragment carrying a 
transgene of interest by homologous recombination (Chamberlain et al., 2004).  
 
The second and possibly more efficient method involves the use of vectors 
developed from eukaryotic DNA transposons, such as Sleeping Beauty (Izsvak and 
Ivics, 2004) and Mariner (Lampe et al., 1998). Transposons are DNA fragments 
made of an open reading frame (ORF) flanked by inverted terminal repeats (ITRs) at 
their extremities. The ORF encodes an enzyme, the transposase, which is able to 
trigger all steps of the transposition process. Gene transfer in chromosomes using a 
transposon vector is obtained by co-injecting a plasmid construct containing a 
transposon in which the transposase ORF is substituted by a transgene of interest, 
together with a transposase source that can be an expression plasmid, transposase 
messenger ribonucleic acid (mRNA) or a purified recombinant transposase. Mariner 
vectors have been widely assayed in vitro in bacteria and are capable of integrating 
DNA while ensuring a combination of clean ends and no tandem repeats.  However, 
the use of transposons does not rule out the possibility of insertional mutagenesis. 
Sleeping Beauty can cause insertional mutagenesis in the mouse germline (Takeda et 
al., 2008), which would make its safety as a non-viral vector for gene therapy 
questionable.  
 
Illegitimate recombination and integration could be avoided if the transposition is 
efficient and an excess of DNA delivery is avoided. The development of novel 
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transposons systems would be required for this, to ensure site-specific integration. In 
the setting of cell therapy, the transgene would have to be retained into the nucleus, 
safely integrated into the genome without disrupting normal gene function and 
segregated after cell division. A combined approach would need to be applied to 
achieve permanent gene integration, by using non-viral transfection methods for 
gene delivery to the nucleus as the first step, and non-viral integration systems such 
as transposons for integration of the gene to a selected site in the genome. However, 
there are still a number of hurdles to overcome before non-viral gene manipulation 
can be used efficiently for therapy. The efficiency levels achieved with most 
liposome-based transfection systems are very low for some primary cells, including 
MSC (Hamm et al., 2002). Another disadvantage is that most non-viral transfection 
methods deliver the nucleic acids to the cytoplasm rather than the nucleus, making 
them more prone to degradation. Thus, the novel transposon systems developed 
would need to overcome three key barriers associated with ex-vivo gene delivery: 
internalisation of the transgene in stem cells, by successfully passing the cell 
membrane, transport of the transgene across the nuclear membrane and integration at 
a predefined genomic locus, selected for its safety in order to avoid disruption of 
normal gene function and insertional mutagenesis. Controlled transposition could 
benefit this approach, since by limiting the number of transposition events the 
probability of illegitimate insertion events can be lowered. This can be achieved by 
providing the transposase enzyme in limited amounts, in the form of RNA or 
protein, which would ensure that transposition is transient but yet enough to confer 
expression of the transgene at desirable levels. 
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1·5. Outlines: Specific questions addressed 
 
 
In this project I will test the following hypotheses: 
 
1. Human 1st trimester AF and placenta contain a population of embryonic-like 
stem cells  
2. The SDF-1-CXCR4 axis is involved in the mechanism of cell migration of 
fetal MSC 
3. Stem cells from 1st trimester fetal sources can be transiently transfected by 
non-viral methods, without affecting their stem cell properties 
 
More specifically: 
 
For the first hypothesis I will address the following points: 
 
• In depth characterisation of stem cells from 1st trimester AF and placenta 
• Proliferation potential of the cells by measuring the doubling time and 
growth rate 
• Expression of lineage and pluripotency markers 
• Differentiation potential of the cells into bone, fat and cartilage and 
formation of EB in vitro 
• Telomerase activity and telomere length of the cells 
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For the second hypothesis I will examine the following: 
 
• Intracellular and extracellular expression of CXCR4 by the cells 
• Alteration in expression pattern of CXCR4 in cells stimulated with cytokines 
or tissues from oim and wild type (WT) mice 
• Expression and any up- or down-regulation of SDF-1 in injured and non-
injured tissues from oim and WT mice 
• Migration potential of cells stimulated with a variety of agents or non-
stimulated, towards cytokines or tissues from oim and WT mice 
 
For the third hypothesis I will examine the following: 
 
• Efficiency of lipofection on isolated cells, using a variety of lipid constructs 
for encapsulation of plasmid DNA 
• Efficiency of nucleofection as a way of transient transfection for the cells 
• Transfection of different types of nucleic acids 
• Effect of transfection to the stem cell properties of the cells 
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Chapter 2: Characterisation of human 
amniotic fluid and placenta fetal stem 
cells 
 
2.1. Introduction 
 
Fetal stem cells have been isolated from a variety of tissues in the 1st trimester, with 
an intermediate phenotype between ESC and adult MSC (Guillot et al., 2006). Fetal 
stem cells are more suitable for use in cell therapy, compared to adult stem cells, as 
they have advantageous characteristics; they express pluripotency markers, have 
longer telomeres and higher telomerase activity, higher growth rate and superior 
plasticity (Guillot et al., 2008c; Guillot et al., 2007) Additionally, the regenerative 
potential of 1st trimester fetal blood stem cells was recently shown in a mouse model 
of OI. Cells transplanted in utero preferentially migrated to bones, differentiated into 
functional osteoblasts, leading to reduced fracture rate and improved bone structural 
and mechanical properties without the formation of teratomas (Guillot et al., 2008a).  
 
Fetal stem cells isolated from fetal blood and bone marrow in particular are the best 
candidates for treatment of skeletal dysplasias, as they have higher osteogenic 
capacity in vitro and in vivo (Guillot et al., 2008c). However, only fetal blood can be 
isolated during the 1st trimester in ongoing pregnancies, with a maximum of 67% 
success rate and by invasive blood sampling procedures constraining the clinical 
effectiveness of these cells (Chan et al., 2008). 
 
AF is a more accessible source of stem cells that can be used for cell therapy. Work 
on stem cells derived from the AF has been limited to the 2nd trimester, mainly due 
to the availability of samples after amniocentesis at that gestational stage. The same 
applies to studies on placenta-derived stem cells, as most samples are available 
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during the early 2nd trimester, after CVS. If these cells could be isolated during the 
1st trimester of gestation, they could be used in fetal medicine to treat a variety of 
genetic conditions diagnosed in early pregnancy.  
 
The biology of stem cells in the 1st trimester could also provide an insight into the 
transition from the pluripotent ESC to the more limited, multipotent stem cells found 
in the adult. To date, limited work has been carried out in cells from various fetal 
organs in the 1st trimester, but the availability of stem cells in 1st trimester AF has 
not been tested. In terms of the placenta, only a single study has been carried out in 
the 1st trimester (Portmann-Lanz et al., 2006). Hence, the isolation, propagation and 
biological potential of stem cells in 1st trimester AF and placenta are largely 
unknown areas of study. 
 
In this chapter I present data on the collection of 1st trimester AF and placenta and 
the isolation of stem cells from these two sources. I also show data on the properties 
of these cells, including cell morphology, cell origin, kinetics, expression of lineage 
and other markers and expression of markers associated with pluripotency. In 
addition, I assess the telomerase activity of these cells and their differentiation 
potential, including formation of EB. In parallel to 1st trimester stem cells, I show 
work on 2nd trimester AF stem cells and a sample of stem cells from fetal bone 
marrow. 
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In this chapter I will present in depth characterisation of stem cells from 1st trimester 
AF and placenta. 
 
More specifically I will examine: 
 
a. Proliferation potential of the cells by measuring the doubling time and 
growth rate 
b. Expression of lineage and pluripotency markers 
c. Differentiation potential of the cells into bone, fat and cartilage and EB 
formation 
d. Telomerase activity and telomere length of the cells 
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2.2. Methods 
 
2.2.1. Amniotic fluid and placenta sample collection and culture 
 
1st trimester samples were collected after clinically indicated termination of 
pregnancy procedures, while 2nd trimester AF samples were collected by 
amniocentesis. The work was carried out under approval from the Research Ethics 
Committee of Hammersmith and Queen Charlotte’s Hospitals. Informed consent 
was obtained for the collection of all samples.  
 
For AF samples, the obtained AF was centrifuged at 1500 revolutions per minute 
(RPM) for 5 minutes and the cell pellet was plated in a 10 cm plastic adherent 
culture dish (Corning, Sigma-Aldrich Company Ltd., Dorset, U.K.) in Dulbecco’s 
modified eagle’s medium (DMEM, Sigma) supplemented with 2 mM L-glutamine, 
500 U/ml penicillin, 50 µg/ml streptomycin (Gibco/Invitrogen) and 10% fetal bovine 
serum (FBS, Gibco/Invitrogen Ltd.), while the supernatant was plated in a different 
plate. The cells were then cultured in a 95% humidified 5% carbon dioxide (CO2) 
chamber at 37 ºC (incubator by BINDER, Incheon, Korea). All procedures 
associated with cell culture were carried out in a cell culture hood (Class II 
Biological Safety Cabinets, NuAire Corporation, USA).  
 
The samples were then allowed to grow for 1-2 weeks and daily observation of the 
plate was carried out for the detection of adherent cells. In the initial stages of 
culture, only a small number of cells, up to 10 in each sample, was adherent. This 
initial cell population divided further and was allowed to reach confluence of around 
70%, upon which the cells were trypsinised using 1 ml of 1X 0.25% trypsin with 
ethylenediaminetetraacetic acid (EDTA, Gibco, Invitrogen Ltd., Paisley, UK) and 
replated for further cell expansion. This was considered passage 1 of each sample.  
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For the collection of 1st trimester placenta cells, pieces of placenta were isolated 
from the fetal side of the obtained sample, washed thoroughly in phosphate buffered 
saline (PBS, Gibco/Invitrogen) to remove any remaining blood and then the pieces 
were minced using a surgical blade and trypsinised for 30 minutes. Following that, 
culture medium was added to the samples and they were allowed to grow for 1-2 
weeks and daily observation of the plate was carried out for the detection of adherent 
cells. The day following the plating, a small number of adherent cells was visible, 
again up to 10 cells per sample, which were allowed to proliferate until 70% 
confluence was reached. At this stage, recorded as passage 1, the cells were 
trypsinised and replated for further cell expansion.   
 
Cell freezing was carried out for long-term cell storage. For this, 70% confluent cells 
were trypsinised, centrifuged at 1500 RPM for 5 minutes, the supernatant was 
removed, the cells were resuspended in 1 ml of DMEM supplemented with 2 mM L-
glutamine, 500 U/ml penicillin, 50 µg/ml streptomycin, 10% FBS and 10% dimethyl 
sulfoxide (DMSO, Sigma) and transferred to cryogenic vials (Corning, Sigma). The 
cells were then placed at -20°C for 1 hour, overnight at -80°C and then placed in a 
liquid nitrogen tank for long-term storage. 
 
2.2.2. Cell culture of other cell types 
 
Fetal stem cells from fetal blood and bone marrow used in this study had been 
collected by previous members of the group and kept at liquid nitrogen. For the 
thawing of these samples, cells were briefly warmed in a 37 °C waterbath and 
followed by gradual addition of DMEM supplemented with 2 mM L-glutamine, 500 
U/ml penicillin, 50 µg/ml streptomycin and 10% FBS. The cells were then 
centrifuged at 1500 RPM for 5 minutes, the supernatant was removed, the cells were 
resuspended in culture media as before and plated in 10cm cell culture dishes.  
 
293T and sarcoma osteogenic (SAOS) cell lines were obtained from the American 
type culture collection (ATCC, Manassas, USA). DMEM supplemented with 2 mM 
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L-glutamine, 500 U/ml penicillin, 50 µg/ml streptomycin and 10% FBS was also 
used as the culture medium for these two cell lines and cells were passaged at 70% 
confluence. These two cell lines served as control in the telomerase activity and 
immunofluorescence experiments respectively. 
 
 
2.2.3. Fluorescence in situ hybridisation (FISH) 
 
Cells were grown on chamber slides, fixed with 4% paraformadehyde (PFA) and the 
area of interest was marked. The slides were then heated at 80 ºC in 2x saline 
sodium citrate (SSC) for 15 minutes, dried, and fixed with methanol. XY probe was 
then added (Vysis, Abbott Molecular, Maidenhead, UK), and hybridisation was 
carried out overnight. The slides were then washed with 2x SSC, dried, dehydrated 
in a gradient of EtOH and mounted on glass slides with Vectashield mounting 
medium containing 4',6 diamidino-2-phenylindole (DAPI, Vector Laboratories Inc., 
Burlingame, USA).  
 
2.2.4. Microscopy 
 
 Cells were viewed on an Axioskop (ZEISS, Oberkochen, Germany) fluorescence 
microscope, using 40x oil objectives.  Images were captured using the Hamamatsu 
photonics digital camera (ORCA-ER, Hamamatsu, Dulles, USA) and processed 
using IPLab, version 3.70, Scientific Image Processing Software (Scanalytics Inc., 
Fairfax, USA). For the confocal images, cells were viewed on a Leica SP5 confocal 
microscope (Leica Microsystems, Germany) and images were processed using the 
LAS AF software (Leica Microsystems). 
 
2.2.5. Growth kinetics 
 
For the doubling time estimation, 104/cm2 cells were plated with growing medium 
and their doubling time was calculated twice a week. The cells were trypsinised and 
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centrifuged for 15 minutes at 4 ºC, 1500 RPM. The supernatant was removed and 
the pellet resuspended in 1 ml of medium. The cells were then stained with 3% 
acetic acid with methylene blue (Stem Cell Technologies, UK) and counted in a 
haemacytometer (Neubauer improved, 0,0025 mm2, Assistant, Germany). For 
growth rate estimation, cells at different concentrations were plated in a 6-well plate 
(Corning, Sigma) in DMEM culture media as described before, with or without the 
addition of 5ng/ml bFGF (R & D Systems, Minneapolis, USA) and cells counted as 
above at 2-day intervals. 
 
2.2.6. Immunofluorescence 
 
Cells were initially grown on glass coverslips. Cells were then fixed using 4% PFA 
in 125mM HEPES for 10 minutes at 4°C, followed by 8% PFA in 125mM HEPES 
for 50 minutes at 4°C. Fixed cells were then rinsed twice with PBS 
(Gibco/Invitrogen) and stored in PBS at 4°C, sealed using Parafilm. 
 
Cell-covered coverslips were transferred to 24-well plates (NunclonTM) and washed 
(for intracellular) or not (for extracellular staining) with 0.5% Triton X-100 in PBS 
for 30 minutes, shaken and then followed by 6 washes in PBS. Next, 20mM glycine 
(Sigma) in PBS was added for 30 minutes, followed by 3 washes in PBS. After that, 
PBS+ containing PBS, 0.1% casein (British Biocell, Cardiff, UK), 1% bovine serum 
albumin (BSA) (Sigma) and 0.2% fish gelatin (supplied as a 45% solution, British 
Biocell) was added for a minimum of one hour, followed by incubation with the 
fluorescein isothiocyanate (FITC)-conjugated primary antibody diluted in PBS+ for 
2 hours at room temperature or overnight at 4°C. 
 
The next step was washing the cells for one and a half hours with PBS+, followed by 
incubation with the secondary antibody for one hour and overnight wash in PBS+ at 
4°C. After this, the cells were rinsed in PBS and mounted on SuperFrost microscope 
slides (Menzel-Glaser, Braunschweig, Germany) in a drop of Vectashield mounting 
medium with DAPI (Vector Laboratories) or TOTO-3 iodide stain (Invitrogen) to 
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visualise the cell nucleus. SAOS cells were used as a control cell line, as well as 
staining without the primary antibody to test for the specificity of the secondary 
antibodies. Tables 2 and 3 give a list of all the primary and secondary antibodies 
used, respectively. Optimisation was carried out before use of the antibodies, by 
testing different dilutions for each antibody. Tables 2 and 3 show the optimised 
dilutions selected for each antibody.  
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Table 2. Primary antibodies used for immunofluorescence. (HLA: Human leukocyte 
antigen, hTert: Human telomerase reverse transcriptase; α: anti; dk: Donkey). 
Name Company Source Dilution 
AFP Abcam Mouse 1:100 
CD105 BD Biosciences Mouse 1:100 
CD14 DAKO Cytomation Ltd. Mouse 1:100 
CD29 
(Integrin 
β1) 
Abcam Mouse 1:500 
CD31 Abcam Mouse 1:500 
CD34 DAKO Cytomation Ltd. Mouse 1:100 
CD44 Abcam plc, Cambridge, UK Mouse 1:100 
CD45 DAKO Cytomation Ltd. Mouse 1:100 
CD73 BD Biosciences Mouse 1:100 
CD90 Abcam Mouse 1:100 
C-kit Santa Cruz Rabbit 1:100 
Fibronectin DAKO Cytomation Ltd. Mouse 1:100 
Gata4 Abcam Rabbit 1:100 
HLA-ABC DAKO Cytomation Ltd. Mouse 1:100 
hTert Novus Biologicals Inc, USA Mouse 1:100 
Laminin Sigma Rabbit 1:100 
Map2 Abcam Mouse 1:100 
Nanog Abcam Rabbit 1:100 
Oct-4 Chemicon International Mouse 1:100 
SSEA1 Chemicon International Mouse 1:50 
SSEA3 Chemicon International Rat 1:100 
SSEA4 Chemicon International Mouse 1:100 
Sox-2 Abcam Rabbit 1:100 
STRO-1 R&D Systems Mouse 1:100 
Tra-1-60 Chemicon International Mouse 1:100 
Tra-1-81 Chemicon International Mouse 1:100 
Vimentin DAKO Cytomation Ltd. Mouse 1:100 
VWF DAKO Cytomation Ltd. Mouse 1:100 
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Table 3. Secondary antibodies used for immunofluorescence. 
 
Name Company Source Epitope Dilution 
FITC dk α 
Mouse 
Jackson Laboratories 
Inc., USA 
Donkey Mouse 1:100 
FITC dk α 
Rabbit 
Jackson Laboratories 
Inc. 
Donkey Rabbit 1:1000 
FITC dk α 
Rat 
Jackson Laboratories 
Inc. 
Donkey Rat 1:100 
FITC dk α 
Goat 
Jackson Laboratories 
Inc. 
Donkey Goat 1:100 
Cy3 dk α 
Rabbit 
Jackson Laboratories 
Inc. 
Donkey Rabbit 1:100 
 
 
 
2.2.7. Differentiation 
 
2.2.7.1. Osteogenic 
 
The medium was freshly prepared by supplementing DMEM (Sigma) with 10% FBS 
(Gibco/Invitrogen), 2 mM L-glutamine, 500 U/ml penicillin, 50 µg/ml streptomycin 
(Gibco/Invitrogen), 10-8 M dexamethasone (Sigma), 0.2 mM ascorbic acid (0.2x10-3 
M) (Sigma) and 10 mM β-glycerophosphate (Sigma) (Campagnoli et al., 2001). 
 
For Von Kossa staining, cells were initially washed 2 times with PBS, then fixed 
with 10% formalin for 1 hour. After that, cells were washed 2 times with distilled 
water and stained with freshly made 2% silver nitrate (Sigma) in distilled water 
(w/v) for 10 minutes in the dark. Cells were then exposed to bright light for 15 
minutes, washed 2 times with distilled water and photographed using an Olympus 
CK40-SLP microscope and an Olympus C3040-ADL camera (Olympus UK Ltd, 
Hertfordshire, UK). 
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2.2.7.2. Adipogenic 
 
The medium was freshly prepared by supplementing DMEM with 10% FBS 
(Gibco/Invitrogen), 2 mM L-glutamine, 500 U/ml penicillin, 50 µg/ml streptomycin 
(Gibco/Invitrogen), 5 µg/ml insulin (Sigma), 10-6 M dexamethasone (Sigma) and 60 
µM indomethacin (Sigma) (Campagnoli et al., 2001). 
 
To prepare the stock oil red O solution, 1g of oil red O (Sigma) was mixed in 100 ml 
isopropanol (BDH Laboratory Supplies, Dorset, UK). For the working solution, 6 ml 
of oil red O stock solution were mixed with 4 ml of distilled water, at least 1 hour 
before staining. For oil red O staining, cells were initially washed 2 times with PBS, 
then fixed with 10% formalin and rinsed with 60% isopropanol (BDH Laboratory 
Supplies) in distilled water, followed by staining for 10 minutes. The cells were then 
washed 4 times with distilled water and photographed using an Olympus CK40-SLP 
microscope and an Olympus C3040-ADL camera (Olympus).  
 
2.2.7.3. Chondrogenic 
 
The medium used was freshly prepared by supplementing DMEM with 2 mM L-
glutamine, 500 U/ml penicillin, 50 µg/ml streptomycin (Gibco/Invitrogen), 0.1 µM 
dexamethasone, 0.17 mM ascorbic acid-2-phosphate, 1.0 mM sodium pyruvate, 0.35 
mM L-proline, 1% insulin-transferrin-sodium selenite (ITSS), 1.25 mg/ml BSA, 5.33 
µl/ml linoleic acid (all from Sigma-Aldrich) and 0.01 µg/ml transforming growth 
factor-β3 (TGF-β3, R&D Systems Inc.) (Mackay et al., 1998). Cells in micromass 
pellets were then allowed to grow in the differentiation medium for 21 days. The 
pellets were then dehydrated, embedded in paraffin, sectioned and mounted on 
slides. Sections were then deparaffinised, rehydrated and stained with 1% alcian 
blue. The sections were then dehydrated in a gradient of ethanol and mounted on 
glass slides. Images were then taken using an Olympus CK40-SLP microscope and 
an Olympus C3040-ADL camera (Olympus). 
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To prepare the alcian blue solution, 1 g of alcian blue powder (Sigma) was mixed 
with 2ml glacial acetic acid and 98ml distilled water, giving a 1% solution.  
 
 
2.2.8. RNA extraction/cDNA synthesis 
 
The RNAse-Free DNAse set and Rneasy mini kits (Qiagen Ltd., West Sussex, UK) 
were used for the RNA extraction, according to guidelines from the company. In 
brief, 50 µl of β-mercaptoethanol (Sigma) was added to 5 ml RLT buffer supplied 
with the kit. 700 µl of this was then added to cell pellets, followed by 700 µl of 70% 
ethanol. This mix was then applied to columns provided with the kit, centrifuged, 
washed and treated with DNAase. RNA was then eluted, quantified 
spectrophotometrically and complementary DNA (cDNA) was synthesised.  
 
For the cDNA synthesis, random primers were used for the priming as follows. 1 µg 
of RNA was mixed with 1.2 µl of random primers (Promega, Madison, USA) and 
enough diethylpyrocarbonate (DEPC) treated water (Invitrogen, Paisley, UK) to 
make up 9.3 µl of mixture, which was incubated at 75 °C for 10 minutes. 4 µl of 
MgCl2, 2 µl X10 RT buffer and 2 µl 10 mM dNTP mix (all from Promega) was then 
added and left at room temperature for 10 minutes. Finally, 0.5 µl of RNAsin 
inhibitor and 1 µl avian myeloblastosis virus reverse transcriptase (AMV RT) were 
added and incubated at 42 °C for 2 hours, followed by 75 °C for 15 minutes. 
Controls without the addition of the RT enzyme were run for all samples to test for 
genomic DNA contamination. Amplification of the control RNA without the 
addition of the enzyme did not generate products in PCR reactions. Additionally, B-
ACTIN PCR was run for all cDNA samples for sample normalisation, together with 
spectrophotometrical quantification. 
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2.2.9. RT-PCR 
 
The PCR mix for reverse transcriptase-polymerase chain reaction (RT-PCR, 20 µl 
for 1 sample) consisted of 12.7 µl of DEPC-treated water (Invitrogen), 2 µl 10X 
NH4 buffer (Bioline, London, UK), 0.6 µl 50 mM MgCl2 (Bioline), 2 µl 2.5 mM 
dNTP (Promega), 0.25 µl 20 µM forward primer (Thermo Electron Corporation, 
Ulm, Germany), 0.25 µl 20 µM reverse primer (Thermo Electron) and 0.2 µl BioTaq 
DNA polymerase (Bioline). 18 µl was added in a graduated tube (Biohit, 
Northampton, UK) for each sample, together with 2 µl of 50 ng/µl cDNA and the 
reaction was run in a Peltier thermal cycler (MJ Research Inc., Waltham, USA). The 
amplified products were then run on 1% agarose gels in 1X tris-acetate-EDTA 
(TAE) buffer containing ethidium bromide at 100V for 1 hour, following by 
exposure under UV light. Table 4 shows the primers used (Stojkovic et al., 2005). 
The primers used for the detection of STELLA, SOX17, KLF4 and C-MYC were 
from a commercially available primer kit, and the primer sequences are patented and 
not disclosed by the company (R & D Systems). All the primers used were 
optimised using amplification programs with three different annealing temperatures, 
depending on the G-C and A-T content of each primer. Optimised annealing 
temperatures are presented in table 4. 
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Table 4. Primers used for the RT-PCR. (bp: base pairs;) 
Gene 
name 
Forward 
sequence 
Reverse 
Sequence 
Amplicon 
length 
(bp) 
Annealing 
temp (°C) 
No. 
cycles 
B-
ACTIN 
CTGGAACGGTGAAG
GTGACA 
AAGGGACTTCCT
GTAACAATGCA 
100 61 25 
BMP4 GTGAGGAGCTTCCA
CCACGA 
ACTGGTCCCTGG
GATGTTCTC 
100 72 40 
CK3 5’-
CGTACAGCTGCTGA
GAATGA-3’ 
5’-
CTGAGCGATATC
CTCATACT-3’ 
100 72 40 
CK19 5’-
GGCCACACGGAGCA
GCTCCA-3’ 
5’-
CGCCTGGATATG
CGCCAGCT-3’ 
100 72 40 
GATA6 5’-
ACCACCTTATGGCG
CAGAAAC-3’ 
5’-
TTTTTCATAGCAA
GTGGTCTGGG-3’ 
100 72 40 
NANOG 5’- 
CTGAGATGCCTCAC
ACGGAGACTG-3’ 
5’- 
GTCACACCATTGC
TATTCTTC-3’ 
369 55 35 
NESTIN 5’CAGGAGAAACAG
GGCCTACA-3’ 
5’-
TGGGAGCAAAGA
TCCAAGAC-3’ 
243 55 35 
OCT-4 
 
5’-
GAAGGTATTCAGCC
AAAC –3’ 
5’-
CTTAATCCAAAA
ACCCTGG –3’ 
645 50 35 
OSTEOP
ONTIN 
5’-
GCCGACCAAGGAA
AACTCACTA-3’ 
5’-
CAGAACTTCCAG
AATCAGCCTGTT-
3’ 
160 61 35 
PPARγ 5’-
CACAAGAACAGATC
CAGTGGTTC-3’ 
5’-
GAGGCTTATTGTA
GAGCTGAGTTCT-
3’ 
160 61 35 
PAX6 5'-
AGATTCAGATGAGG
CTCAAA-3' 
5'-
AATTGGTTGGTA
GACACTGG-3' 
300 57 35 
SOX-2 5’- 
CCCCCGGCGGCAAT
AGCA-3’ 
5’- 
TCGGCGCCGGGG
AGATACAT-3’ 
448 64 40 
SRY 5’-
TGGCGATTAAGTCA
AATTCGC-3' 
5’-
CCCCCTAGTACCC
TGACAATGTATT-
3' 
136 60 35 
SYCP1 5’-
ACAGCGAAAAGCC
ATTCAGGA-3’ 
5’-
GCCTGGTTTCTTC
CCGTTCATA-3’ 
100 72 40 
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2.2.10. Telomerase activity 
 
To assess telomerase activity I followed the protocol described by Cawthon 
(Cawthon, 2002) and used by Guillot et al. (Guillot et al., 2007). In short, 100,000 
cells from each sample were treated with TRAPeze® 1X CHAPS lysis buffer 
(Chemicon International, Hampshire, UK) on ice for 30 minutes, for protein 
extraction. The lysate was there centrifuged at 14000 RPM for 10 minutes and the 
supernatant containing the proteins was aliquoted and stored at -80°C. Quantitative 
real-time PCR (qrt-PCR) was then performed on the samples using the ABI Prism 
7700 sequence detection system (Applied Biosystems, Foster City, CA, USA) and 
SYBR Green (Sigma). For the reaction, samples were incubated at 25°C for 20 
minutes, followed by 35 cycles of 2-step amplification, with incubation at 95°C for 
30 seconds and 60°C for 90 seconds. Relative levels of expression were calculated 
according to the ΔCT method, normalised to b-actin. 
 
2.2.11. Telomere length 
 
Genomic DNA was extracted using Trizol (Invitrogen), followed by ethanol 
precipitation, washing and DNA dissolution in 8mM NaOH. Qrt-PCR was then 
performed to estimate the relative telomere lengths, as described by Cawthon 
(Cawthon, 2002) and used by Guillot et al. (Guillot et al., 2007). The primers used 
detected telomere repeats (T) and a single copy gene, the 36B4 (S). Standard curves 
were generated for both genes by using serial dilutions of 293T cells, a cell line 
positive for telomerase activity. The standard curves were used to determine the 
relative quantity of telomere repeats of the samples tested. Relative telomere length 
was then expressed as the ratio of quantity of the 2 genes (T/S).  
 
2.2.12. Embryoid body (EB) formation 
 
Undifferentiated 1st trimester AF cell cultures were induced to differentiate in vitro 
into EBs by incubating cells from 5 to 6 confluent wells of a six-well plate with 1 
  69 
mg/ml type IV collagenase (Sigma) at 37°C for 10 min. The cells were then 
dissociated into small clumps using 100-µl Gilson pipette tips and cultured in 
suspension in 58-mm low attachment Petri dishes in differentiating medium 
containing 80% knockout Dulbecco’s modified Eagle’s medium (KO-DMEM, 
Gibco BRL Life Technologies) supplemented with 1 mM L-glutamine, 0.1 mM β-
mercaptoethanol, 1% non-essential amino acids stock (all Gibco BRL Life 
Technologies) and 20% FBS (Biosera). The forming spheres were allowed to 
develop into 15-day old EBs. EB suspensions were then transferred to gelatin-coated 
plates for another 7-10 days before being fixed in 4% PFA and stored at 4°C for 
subsequent immunofluorescence.  
 
2.2.13. Alkaline phosphatase staining 
 
For the alkaline phosphatase staining, a staining kit was used (Sigma). Briefly, cells 
were fixed with a solution made up of 6.5 ml acetone, 2.5 ml citrate and 0.8 ml 37% 
formaldehyde (all from Sigma). The cells were then washed with PBS and stained 
with a solution made up of 100 µl sodium citrate, 100 µl fast red violet (FRV) 
solution, 100 µl napthol alkaline and 4.5 ml distilled water (all from Sigma). The 
cells were stained for 20 minutes in the dark, washed with distilled water and 
photographed using an Olympus CK40-SLP microscope and an Olympus C3040-
ADL camera (Olympus). 
 
2.2.14. Statistical analysis 
 
Data are expressed as means plus or minus standard deviation (SD) from the mean. 
For the statistical analysis, Excel was used to generate the graphs presented and the 
standard deviation of the samples. Unpaired 2-tailed student t tests were used to test 
the differences in significance within samples, while one-way analysis of variance 
(ANOVA) tests were carried out to test the differences in significance between 
sample groups, and the P values are presented. A P value less than 0.05 was 
considered significant. One asterisk (*) indicates a P value lower than 0.05, two 
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asterisks (**) indicate a P value lower than 0.01 and three asterisks (***) indicate a 
P value lower than 0.001. 
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2.3. Results 
 
 
2.3.1. Cell isolation 
 
Samples of 1st trimester AF and placenta were collected after informed consent at 
termination of pregnancy, as described in the results section. The number of women 
giving their consent for the collection of samples was low, since only 10 women 
agreed to donate 1st trimester AF samples, 8 women agreed to donate 2nd trimester 
AF samples after amniocentesis and 17 women agreed to donate 1st trimester 
placenta samples, during the three year period of this study. Furthermore, the sample 
size for the AF was small, usually 200-300 µl, resulting to the isolation of 
approximately 10 adherent cells per sample as the initial cell population. The same 
number of cells during the initial stages in culture was also observed for the 1st 
trimester placenta samples.  
 
During the initial culture stages, the cells proliferated and contact inhibition was 
observed, with cells migrating away from each other and gradually covering the 
entire area of a 10cm cell culture plate. The initial expansion stage of each sample 
lasted 1-2 weeks, by which time the cells reached 70% confluence and the sample 
population was established. However, the AF and placenta samples did not always 
contain proliferative cells and therefore no population was established from those 
samples. 
 
Table 5 shows the gestational ages, with samples in green containing cells with stem 
cell characteristics, as assessed by immunostaining, growth kinetics and 
differentiation capacity. One representative sample was selected from each category 
for extensive characterisation, in parallel with one well-characterised fetal bone 
marrow sample, at 10+4 gestational age.  
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In 1st trimester AF, cells were successfully isolated from 7 out of 10 samples, with 
all samples between weeks 10 and 12 in gestation containing cells with stem cell 
characteristics. In the 2nd trimester AF, 5 out of 8 samples contained cells with stem 
cell characteristics. For 1st trimester placenta, cells were obtained from 10 out of 17 
samples. The remaining 7 samples became contaminated due to the non-aseptic 
collection method used to collect them, which made the isolation of cells impossible, 
despite the addition of antibiotics to the media.  
 
 
Table 5. Cell isolation and expansion from 1st trimester placenta and AF and from 
2nd trimester AF derived stem cells at various gestation ages in weeks. Samples in 
green are samples containing an established cell population with stem cell 
characteristics, as assessed by immunostaining, growth kinetics and differentiation 
capacity. 
 
Cell source 
 
Amniotic fluid Placenta 
Trimester 
 
First Second First 
Gestational age (weeks + 
days) 
9+3, 9+4 15 7+3, 7+4 
 
 
10, 10+4 16, 16, 16 8+3 
 
 
11+6 18+3 9, 9, 9+3, 9+4, 9+5, 9+6 
 12,12,12+2, 
12+4, 12+5 
19 10+3, 10+4, 10+5 
 
 
 21+5 11, 11, 11+6 
 
 
 22+4 12, 12+5 
Total of samples 
collected 
10 8 17 
No. of samples 
containing cells 
7 5 10 
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2.3.2. Cell morphology  
 
The morphology of the isolated cells from 1st and 2nd trimester AF, as well as 1st 
trimester placenta is spindle-shaped, fibroblast-like and cell size is comparable for 
all cell sources and smaller than adult MSC (Guillot et al., 2007). Figure 3A shows 
cells from human 1st trimester fetal bone marrow (passage 4), AF (Amn Fluid 1, 
passage 4) and placenta (passage 4) and human 2nd trimester AF (Amn Fluid 2, 
passage 4) in culture. The cells have been stained with crystal violet and visualised 
at low (x20) and high magnification (x40). Figure 3B shows cells visualised in a 
haemocytometer after trypsinisation (x40). At this stage, the cells had been in culture 
for a period of 3 weeks, reaching passage 4. 
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Figure 3. A: Cell culture from human 1st trimester fetal bone marrow (at passage 4), 
AF (Amn Fluid 1, at passage 4) and placenta (at passage 4) and human 2nd trimester 
AF (Amn Fluid 2, at passage 4) derived stem cells stained with crystal violet and 
visualized at low (x20) and high magnification (x40). B: Cells visualised in a 
haemocytometer after trypsinisation (x40). 
 
After sequential passaging and prolonged culture, over passage 20, the cells 
gradually lose their ability to proliferate and reach senescence. This occurs at 
passages 25-28. Figure 4 shows cells that have stopped proliferating, while increased 
cell death is observed. At this stage, increased cell death is observed, with the cells 
undergoing organelle condensation and accumulation of lipid vacuoles, indicating 
apoptosis. 
40 
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Figure 4. Cell morphology at passage 25, when senescence is reached. Increased 
cell death is observed, with the cells undergoing organelle condensation and 
accumulation of lipid vacuoles, indicating apoptosis. 
 
 
2.3.3. Cell origin 
 
To identify whether the isolated cells were of fetal or maternal origin, FISH was 
carried out using human Y (red) and X (green) probes (Figure 5A). In addition, RT-
PCR for SRY gene was carried out in three independent samples from human 1st 
Lipid vacuole 
formation 
Organelle 
condensation 
Dead cell 
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trimester AF (Amn Fluid 1) and placenta derived stem cells, along with positive 
(male sample) and negative (female sample) control (Figure 5B). 
 
Some samples were positive for the presence of the Y chromosome, as confirmed 
both by FISH and RT-PCR for the SRY gene. This confirmed that the isolated cells 
were of fetal origin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. A: Fluorescence In Situ Hybridization using human Y (red) and X (green) 
probes. B: Polymerase Chain Reaction for SRY gene in three independent samples 
from human 1st trimester AF (Amn Fluid 1) and placenta-derived stem cells, along 
with positive (male sample) and negative (female sample) control. 
 
 
 
 
 
A 
B 
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2.3.4. Kinetics 
 
To determine the expansion potential of the derived stem cells, the growth rate and 
doubling time of the samples were analysed during the exponential phase. For 
growth rate assessment (Figure 6A), cells were grown with or without 5ng/ml bFGF, 
which is a growth factor used previously for the growth of AF derived stem cells 
(Tsai et al., 2004). 1st trimester AF and placenta and 2nd trimester AF derived cells 
were seeded at 10, 100, 1000 or 10000 cells/cm2 in the presence or absence of bFGF 
(5ng/ml) estimated by the average population doubling time (hours) over 12 days 
(mean±SD) as described in Guillot et al. (Guillot et al., 2007). 
 
For the doubling time assessment (Figure 6B), AF cells were grown in media 
supplemented with bFGF. Cumulative population doublings were measured over 70 
days for 1st trimester AF (AF1-1, n=5) and placenta (P1, n=4), 2nd trimester AF 
derived cells (AF2-2, n=5) and bone marrow derived fetal MSC (BM, n=1) seeded at 
10000 cells/cm2.  
 
Unpaired 2-tailed student t tests were used to test differences in growth rate within 
sample groups with and without the addition of bFGF. One-way ANOVA tests were 
carried out to test differences in growth rate between samples from different sources, 
and the P values are presented. A P value less than 0.05 was considered significant. 
One asterisk (*) indicates a P value lower than 0.05, two asterisks (**) indicate a P 
value lower than 0.01 and three asterisks (***) indicate a P value lower than 0.001. 
 
1st and 2nd trimester AF cells grew significantly faster in the presence of bFGF 
(P<0.001), while the kinetics of placenta cells were not affected by the addition of 
the growth factor. Furthermore, cell seeding density did not affect the growth rate of 
either AF or placenta-derived cells. Also, 1st trimester AF cells grew faster than cells 
from 2nd trimester AF and 1st trimester placenta cells, while they had similar kinetics 
to cells from 1st trimester fetal bone marrow. 
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Figure 6. A: Cell growth kinetics of 1st trimester AF and placenta and 2nd trimester 
AF derived cells seeded at 10, 100, 1000 or 10000 cells/cm2 in the presence or 
absence of bFGF (5ng/ml) estimated by the average population doubling time 
(hours) over 12 days (mean±SD). B: Cumulative population doublings over 70 days 
for 1st trimester AF (AF1-1, n=5) and placenta (P1, n=4), 2nd trimester AF derived 
cells (AF2-2, n=5) and bone marrow derived fetal mesenchymal stem cells (hfMSC 
BM, n=1) seeded at 10000 cells/cm2. (*: P<0.05, **: P<0.01, ***: P<0.001). 
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2.3.5. Immunophenotype 
 
Immunophenotype was assessed by immunofluorescence. The antibodies and 
conditions used can be found in Tables 2 and 3. Figures 7-11 show staining for the 
different antibodies.  
 
Samples from all sources have comparable immunophenotypes, expressing markers 
associated with stromal cells; Endoglin, also known as SH2 or CD105, which is part 
of the TGFβ1 and β3 receptor complex and is involved in cytoskeletal organisation 
and migration (Barbara et al., 1999); CD73, also known as SH3/SH4 or 5’-
nucleotidase, used as a marker for lymphocyte differentiation (Thomson et al., 
1990); Stro-1, expressed by stromal progenitor cells in human bone marrow 
(Simmons and Torok-Storb, 1991); CD44 also known as HCAM1 or hyaluronan 
receptor, a cell surface glycoprotein involved in cell migration, adhesion and cell-
cell interaction (Terpe et al., 1994); and CD90, also known as Thy-1, believed to 
play a role in cell-cell and cell-matrix interactions (Ades et al., 1980). Cells also 
express markers important for adhesion, such as CD29 (β1-integrin) and CD31 
(PECAM-1). 
 
Cells also express intermediate filament proteins such as vimentin, laminin and 
fibronectin, which are all part of the cell cytoskeleton. In addition, the cells express 
HLA-ABC, a major histocompatibility (MHC) class I antigen, at low levels. 
 
Cells from all sources lack expression of haematopoietic and endothelial markers; 
CD14, expressed by macrophages and neutrophil granulocytes (Simmons et al., 
1989); CD34, a marker of haematopoietic cells responsible for cell-cell adhesion 
(Simmons et al., 1992); CD45, a transmembrane protein present on most 
haematopoietic cells (Ishikawa et al., 2003); and vWF, a blood glycoprotein with a 
haemostatic function (Sadler, 1998).  
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These data suggest that 1st trimester AF and placenta cells are non-hematopoietic, 
non-endothelial cells and have a comparable phenotype to stem cells isolated from 
1st trimester fetal bone marrow, blood and liver (Campagnoli et al., 2000; 
Campagnoli et al., 2001). The cells express markers associated with MSC, therefore 
the isolated cells may be stem cells of mesenchymal origin. 
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Figure 7. Immunostaining of cells derived from fetal bone marrow (FBM1), 1st (AF1) and 2nd trimester AF (AF2) and placenta (P1) 
for CD14, CD34 and CD45. Images were taken at 40x magnification, using a fluorescence microscope. 
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Figure 8. Immunostaining of cells derived from fetal bone marrow (FBM1), 1st (AF1) and 2nd trimester AF (AF2) and placenta (P1) 
for CD105, CD73 and STRO1. Images were taken at 40x magnification, using a fluorescence microscope. 
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Figure 9. Immunostaining of cells derived from fetal bone marrow (FBM1), 1st (AF1) and 2nd trimester AF (AF2) and placenta (P1) 
for CD44, CD90 and von Willebrand factor (vWF). Images were taken at 40x magnification, using a fluorescence microscope. 
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Figure 10. Immunostaining of cells derived from fetal bone marrow (FBM1), 1st (AF1) and 2nd trimester AF (AF2) and placenta (P1) 
for vimentin, laminin and fibronectin. Images were taken at 40x magnification, using a fluorescence microscope. 
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Figure 11. Immunostaining of cells derived from fetal bone marrow (FBM1), 1st (AF1) and 2nd trimester AF (AF2) and placenta (P1) 
for CD29, CD31 and HLA-ABC. Images were taken at 40x magnification, using a fluorescence microscope. 
FBM1 AF1 AF2 P1 
CD29 
CD31 
HLA-ABC 
  86 
The expression of c-Kit by 1st trimester AF cells was also assessed (Figure 12). C-
Kit, also known as CD117, is a cytokine receptor that binds to stem cell factor 
(Zsebo et al., 1990). C-Kit is usually expressed on the surface of HSC and other 
progenitor cells. C-Kit has previously been used for the selection of stem cells 
present in 2nd trimester AF (De Coppi et al., 2007a). 1st trimester AF cells expressed 
c-Kit uniformly, indicating that selection by plastic adherence isolates the same type 
of stem cells in 1st trimester AF as the ones isolated previously from 2nd trimester 
AF. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Expression of c-Kit by 1st trimester AF cells. AF cells express c-Kit 
uniformly, indicating that selection by plastic adherence isolates the same type of 
stem cells in 1st trimester AF as the ones isolated previously from 2nd trimester AF. 
The images were generated using a confocal microscope, at X63 and X280 
magnification. 
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2.3.6. Pluripotency status 
 
Immunolabelling was carried out for expression of the markers normally expressed 
by undifferentiated ESC. Oct-4, a transcription factor of the POU family is critical 
for maintenance of self-renewal and pluripotency (Scholer et al., 1990). SSEA3 and 
SSEA4 are globoseries glycolipid antigens expressed by undifferentiated ESC and 
their expression is downregulated during differentiation (Draper et al., 2002). Nanog 
is a transcription factor essential for maintenance of the undifferentiated state and 
self-renewal. Nanog works together with other transcription factors such as Sox-2 to 
maintain the undifferentiated state of ESC (Chambers et al., 2003). Tra-1-60 and 
Tra-1-81, the keratan sulphate-related antigens are also found on the surface of 
undifferentiated ESC (Andrews et al., 1984). The immunolabelling was carried out 
at passage 5 of all samples and SAOS cells were used as control (Figures 13-14).  
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Figure 13. Expression of pluripotency markers Oct-4, Nanog and SSEA3 for human 1st trimester fetal bone marrow (FBM1), AF 
(AF1) and placenta (P1) and human 2nd trimester AF (AF2) derived stem cells and negative control (SAOS cells), all at passage 5. 
Images were taken using a fluorescence microscope at X40 magnification. 
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Figure 14. Expression of pluripotency markers SSEA4, Tra-1-60 and Tra-1-81 for human 1st trimester fetal bone marrow (FBM1), AF 
(AF1) and placenta (P1) and human 2nd trimester AF (AF2) derived stem cells and negative control (SAOS cells), all at passage 5. 
Images were taken using a fluorescence microscope at X40 magnification. 
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Immunolabelling was also carried out for the detection of telomerase (hTERT). 
Progressive loss of chromosome ends (telomeres) occurs in normal mitotically active 
somatic cells until a critically short length in particular chromosomes is sensed as 
DNA damage and causes cells to exit the cell cycle and become apoptotic. 
Telomerase is a protein that adds telomere repeats onto chromosome ends to prevent 
cell cycle arrest (Mosquera et al., 1999). Figure 15 shows the results in the four 
samples. The immunolabelling was carried out at passage 5 of all samples and 
SAOS cells were used as a positive control, since it is a cell line and thus is expected 
to have telomerase activity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Expression of hTERT for human 1st trimester fetal bone marrow 
(FBM1), AF (AF1) and placenta (P1) and human 2nd trimester AF (AF2) derived 
stem cells and positive control (SAOS cells), all at passage 5. Images were taken 
using a fluorescence microscope at X40 magnification. 
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SRY-box 2 or Sox-2, is a transcription factor essential for maintenance of self-
renewal in undifferentiated ESC (Stevanovic et al., 1994). Immunolabelling for Sox-
2 on 1st trimester AF cells showed that the cells express Sox-2 (Figure 16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Expression of Sox-2 by 1st trimester AF cells at passage 5. The images 
were taken using a confocal microscope, at X63 and X280 magnification. The cells 
express Sox-2 uniformly.  
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SSEA1 is a stage specific antigen usually expressed by human EG and mouse ESC, 
but not undifferentiated human ESC. However, SSEA1 is upregulated in human 
ESC upon differentiation. 1st trimester AF cells are positive for SSEA1 as shown by 
immunofluorescence (Figure 17), indicating that these cells are of germ origin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Expression of SSEA1 by 1st trimester AF cells at passage 5. The images 
were taken using a confocal microscope, at X63 and X280 magnification. The cells 
express SSEA1 uniformly. 
 
 
The expression of pluripotency markers was also assessed at the mRNA level by 
RT-PCR. Figure 18 shows the RT-PCR results for Oct-4, Nanog, Sox-2, Stella, Sox-
17, KLF4 and c-myc for two 1st trimester AF samples. ESC were used as positive 
control. 1st trimester AF cells express Oct-4, Nanog, Sox-2, Stella, Sox-17, KLF4 
and c-myc at the mRNA level. Sox-17, which is critical for the transformation of 
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primitive mesoderm into cardiac mesoderm, and Stella are both early germ cell 
markers, while c-myc and KLF4 are both essential for the induction of pluripotency 
in fibroblast cultures (Takahashi and Yamanaka, 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. RT-PCR results for Oct-4, Nanog, Sox-2, Stella, Sox-17, KLF4 and c-
myc for two 1st trimester AF samples at passage 5. ESC were used as positive 
control and human blood cells as negative control. 
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 Alkaline phosphatase activity is high in undifferentiated, subconfluent AF cells 
(Figure 19), while only a few cells are positive for alkaline phosphatase activity in 
the overgrown population. This is because, under confluence, the majority of the 
cells undergo spontaneous differentiation, with only a few cells remaining in the 
undifferentiated state thus remaining positive for alkaline phosphatase.  
 
 
 
       Subconfluent AF                   Overgrown AF      MEF cells 
 
Figure 19. Staining of subconfluent and overgrown 1st trimester AF cells for 
alkaline phosphatase. MEF cells were used as a negative control. Alkaline 
phosphatase activity is high in undifferentiated, subconfluent AF cells, while only a 
few cells are positive for alkaline phosphatase activity in the overgrown population. 
This is because only a few cells remain in the undifferentiated state when the cells 
are overgrown.  
 
 
2.3.7. Telomere status 
 
Self-renewal is a function of stem cell populations that is tightly controlled. 
Telomeres, short double-stranded DNA sequences are essential for replicative 
stability, as they protect chromosomal ends. DNA polymerase cannot access these 
sequences, therefore they shorten with every cell division until they reach a critical 
length, which signals senescence (Epel et al., 2004). In ESC telomeres are protected 
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from shortening by the action of telomerase, an enzyme responsible for extension of 
the telomeres after cell replication (Bodnar et al., 1998). 
 
Figure 20 shows the relative telomere lengths of the isolated cells, expressed as T/S 
ratio value. The cells tested were from 1st (AF1) and 2nd trimester AF (AF2), 1st 
trimester placenta (P1), adult bone marrow and endometrial somatic cells, used as a 
low-value reference point. The cells were all from passage 5 and 293T cells were 
used as reference. The T/S value was higher in AF1 (82.3% of reference 293T 
value), followed by AF2 (76.5%) and P1 (75.5%). The values were comparable to 
those obtained for fetal MSC in a previous study (73.8%) (Guillot et al., 2007).  
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Figure 20. Mean relative telomere lengths ±SD, expressed as a percentage of the 
T/S ratio value. The fetal MSC value shown is from a previous study (Guillot et al., 
2007). The cells tested were from 1st (AF1) and 2nd trimester AF (AF2), 1st trimester 
placenta (P1), adult bone marrow and endometrial somatic cells, used as a low-value 
reference point. The T/S value was higher in AF1, followed by AF2 and P1 and 
there is no difference in telomere length when compared to fetal MSC. In contrast, 
there is a difference between the 1st and 2nd trimester sources and the adult BM cells 
(P<0.001). 
 
 
2.3.8. Telomerase activity 
 
Figure 21 shows the mean telomerase activity of the isolated cells, expressed as 
percent relative to 293T cells. The cells tested were from 1st (AF1) and 2nd trimester 
AF (AF2), 1st trimester placenta (P1), adult bone marrow and endometrial somatic 
cells, used as a low-value reference point. The cells were all from early passage. The 
values were comparable to those obtained for fetal MSC in a previous study (25.2%) 
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(Guillot et al., 2007). The relative telomerase activity was higher in 1st trimester AF 
(29.3%), followed by 1st trimester placenta (27.4%) and 2nd trimester AF (26.3%). 
 
The telomerase activity and telomere lengths of cells from all sources show that the 
cells have high self-renewal capacity, making them good candidates for use in cell 
therapy. 
 
Figure 21. Mean telomerase activity expressed as percentage of quantity relative to 
293T cells. The fetal MSC value shown is from a previous study (Guillot et al., 
2007). The cells tested were from 1st (AF1) and 2nd trimester AF (AF2), 1st trimester 
placenta (P1), adult bone marrow and endometrial somatic cells, used as a low-value 
reference point. The relative telomerase activity was higher in 1st trimester AF, 
followed by 1st trimester placenta and 2nd trimester AF and there is no significant 
difference in telomere length when compared to fetal MSC. In contrast, there is a 
significant difference between the 1st and 2nd trimester sources and the adult BM 
cells (P<0.001, using a one way- ANOVA test). 
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2.3.9. Differentiation potential 
 
To assess the multilineage potential of the derived stem cells (all at passage 5), 
normal culture medium was replaced by differentiation media for the osteogenic, 
adipogenic and chondrogenic lineage for 3 weeks. Cells grown in media without the 
addition of differentiation factors were used as a negative control. Cell staining and 
RT-PCR analysis was then carried out to confirm the upregulation of genes 
associated with lineage-specific differentiation at the RNA level. 
 
 
 
2.3.9.1. Bone 
                                                                                                                                                                                                              
Figure 22 shows Von Kossa staining of calcium deposition and RT-PCR results for 
osteopontin, a glycoprotein expressed by preosteoblasts, osteoblasts and osteoclasts 
(Reinholt et al., 1990).  
 
All samples can differentiate into bone, and the basal expression of osteopontin seen 
in undifferentiated cells is increased upon bone differentiation as shown by RT-PCR.  
Cells grown in media without the addition of differentiation factors were used as a 
negative control. Fetal bone marrow stem cells were used as an internal positive 
control. The basal level of expression of osteopontin by undifferentiated cells may 
be due to the mesodermal origin of these cells. 
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Figure 22. A: Differentiation of 1st and 2nd trimester AF, placenta and fetal bone 
marrow derived cells at passage 5 into the osteogenic pathway after 3 weeks in 
culture, visualised by von Kossa staining for mineral deposition. Controls represent 
cells grown in parallel in DMEM supplemented with 10% FBS. Images were taken 
using a light microscope at X20 magnification. B: RT-PCR for a marker of the 
osteogenic (osteopontin) lineage in undifferentiated and differentiated cells from 1st 
(1, 5) and 2nd (2, 6) trimester AF, placenta (3, 7) and fetal bone marrow (4, 8). 
Control represents a cDNA sample with no reverse transcriptase addition. All 
samples were normalised for cDNA content using b-actin. 
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2.3.9.2. Fat 
 
Figure 23 shows oil red O staining of lipid vacuoles and RT-RCR for PPARγ after 3 
weeks induction in adipogenic differentiation medium. Cells grown in media 
without the addition of differentiation factors were used as a negative control. All 
samples can differentiate down the adipogenic lineage, and the basal expression of 
PPARγ seen in undifferentiated cells is increased upon adipogenic differentiation as 
shown by RT-PCR. The basal level of expression of PPARγ by undifferentiated cells 
may be due to the mesodermal origin of these cells. 
 
Figure 23. A: Differentiation of 1st and 2nd trimester AF, placenta and fetal bone 
marrow derived cells at passage 5 into the adipogenic pathway after 3 weeks in 
culture, visualised by Oil red O for lipid vacuoles. Controls represent cells grown in 
parallel in DMEM supplemented with 10% FBS. Images were taken using a light 
microscope at X20 magnification. B: RT-PCR for a marker of the adipogenic 
(PPARγ) lineage in undifferentiated and differentiated cells from 1st (1, 5) and 2nd (2, 
6) trimester AF, placenta (3, 7) and fetal bone marrow (4, 8). Control represents a 
cDNA sample with no reverse transcriptase addition. All samples were normalised 
for cDNA content using b-actin. 
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2.3.9.3. Cartilage 
 
Figure 24 shows Alcian blue staining of collagen after 3 weeks induction in 
chondrogenic differentiation medium. Cells from all sources may be able to 
differentiate down the chondrogenic lineage, however this was not further assessed 
using alternative techniques. 
 
 
 
Figure 24. Differentiation of 1st and 2nd trimester AF, placenta and fetal bone 
marrow derived cells at passage 5 into the chondrogenic pathway after 3 weeks in 
culture, visualised by Alcian blue for collagen. Controls represent cells grown in 
parallel in DMEM supplemented with 10% FBS. Images were taken using a light 
microscope at X20 magnification. Cells from all sources may be able to differentiate 
down the chondrogenic lineage, however this was not further assessed using 
alternative techniques. 
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2.3.9.4. Embryoid body (EB) formation 
 
The differentiation potential of 1st trimester AF cells was further examined using 
embryoid body culture in low-attachment dishes. The cells initially acquired 
morphology of a spherical structure of cells within 1-2 days in culture. Figure 25 
shows images of structures formed after 2-3 weeks in culture. After this time in 
culture, the diameter of the spheres was bigger and their structure was more 
complex, with an epithelial lining in the periphery of the spheres. Some spheres also 
had a cavity formation. On one occasion, a spherical structure presented 
synchronised rhythmical contractions. These observations indicate that the structures 
formed resemble EB structures formed by ESC, however the structures require a 
much longer growth period of 2-3 weeks, compared to the 3-4 days required for the 
ESC. 
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Figure 25. Formation of EB-like structures by 1st trimester AF cells. The cells 
acquired morphology of a spherical structure of cells within 1-2 days in culture. 
After 2-3 weeks in culture, the diameter of the spheres was bigger and their structure 
was more complex, with an epithelial lining in the periphery of the spheres. Some 
spheres also had a cavity formation.  
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Differentiation into the three germ layers was assessed using immunofluorescence 
(Figure 26) and RT-PCR (Figure 27). EB-like structures expressed the ectodermal 
markers Nestin, microtubule-associated protein 2 (MAP2), paired box gene 6 
(Pax6), the mesodermal markers bone morphogenetic protein 4 (BMP4) and Gata 
binding protein 4 (Gata4), and the endodermal markers alpha-fetoprotein (AFP), 
Gata6, cytokeratin (CK) 3 and 19. The EB-like structures also expressed 
synaptonemal complex protein 1 (SYCP1), a protein expressed in testes (de Vries et 
al., 2005), indicating a possible germ-cell differentiation. In addition, no expression 
of the pluripotency markers Oct-4 and Nanog was detected, indicating that the cells 
underwent differentiation upon aggregation. 
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Figure 26. Immunofluorescence for markers of pluripotency and three-germ layer 
differentiation by EB-like structures of 1st trimester AF cells at passage 4. The cells 
express MAP2 (ectoderm), Gata4 (mesoderm) and AFP (endoderm), while they do 
not express the pluripotency markers Oct-4 and Nanog. The images were taken 
using a confocal microscope at X63 magnification. 
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Figure 27. RT-PCR for markers of pluripotency and three-germ layer differentiation 
by EB-like structures of 1st trimester AF cells. U: Undifferentiated cells (passage 5), 
EB: EB-like differentiated cells (passage 5). After EB differentiation the cells 
express Nestin (ectoderm), Pax6 (ectoderm), BMP4 (mesoderm), CK3 and CK19 
(endoderm), Gata6 (endoderm) and SYCP1 (germ cell). Upon differentiation, the 
cells lose expression of the pluripotency markers Oct-4 and Nanog. 
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2.4. Discussion 
 
In this chapter I have shown that stem cells were successfully isolated for the first 
time in 1st trimester AF. Additionally, stem cells were isolated from 2nd trimester 
AF and 1st trimester placenta as described in previous reports (De Coppi et al., 
2007a; In 't Anker et al., 2003; Kaviani et al., 2002; Kaviani et al., 2001; Portmann-
Lanz et al., 2006; Prusa et al., 2003; Tsai et al., 2004). In the early stages of this 
project, there were no reports on the presence of stem cells in 1st trimester AF and 
placenta, and very few reports in the presence of cells with pluripotency potential in 
2nd trimester AF. During this project several studies confirmed the presence of stem 
cells in 2nd trimester AF with one study showing a high pluripotency and 
differentiation potential of these cells (De Coppi et al., 2007a), while only 1 study 
reported the presence of stem cells in 1st trimester placenta (Portmann-Lanz et al., 
2006). No data have been published to date on the isolation of a stem cell population 
in 1st trimester AF. 
 
Human 1st trimester AF and placenta cells have similar morphology to fetal stem 
cells isolated before from 2nd trimester AF (De Coppi et al., 2007a; Tsai et al., 2004) 
and 1st trimester bone marrow (Campagnoli et al., 2001). Cells from all fetal sources 
have a fibroblast-like morphology with spindle-shaped cytoplasm and are similar in 
size, unlike adult MSC that are larger (Guillot et al., 2007). The small size of fetal 
stem cells when compared to adult MSC could have functional advantages, such as 
higher surface area to volume ratio with consequent faster protein transfer, lower 
energy requirements for survival and migration and more rapid trans-endothelial 
migration and dispersal throughout the body after transplantation. 
 
The isolated cells are of fetal, as opposed to maternal, origin, confirmed by RT-PCR 
for the SRY gene and FISH for the X and Y human chromosomes.  
 
The cells also have similar immunophenotype to previously isolated fetal cells, 
expressing markers usually expressed by stromal cells such as Stro-1, CD29, 
 108 
CD105, CD73, CD44, CD31, CD90, vimentin, laminin, fibronectin, which are not 
expressed by ESC. The isolated cells lack expression of hematopoietic and 
endothelial markers such as CD14, CD34 and CD45 and vWF, and have some 
expression of HLA-ABC. 1st trimester AF cells also express c-Kit, previously used 
for the isolation of stem cells in the 2nd trimester AF (De Coppi et al., 2007a), 
indicating that selection by plastic adherence isolates a population of cells that is 
positive for c-Kit expression. The immunophenotype of the isolated cells suggests 
that these cells may be mesenchymal stem cells, and that 1st trimester AF and 
placenta is a reliable source of cells with comparable immunophenotype to other 
early fetal stem cells. Table 6 summarises the immunophenotype of the isolated 
cells. 
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Table 6. Immunophenotype of stem cells isolated from 1st trimester AF, bone marrow and placenta and 2nd trimester AF. (+, positive, 
+/-, weakly positive/low expression, -, negative). 
 
                                                     1st trimester                                            2nd trimester 
     Antigen Amniotic Fluid      Placenta    Bone Marrow Amniotic Fluid 
CD14           -         -    -            - 
CD34           -               -               -            - 
CD45           -         -    -            - 
CD31           +            +    +            + 
CD29           +          +    +            + 
CD44           +        +    +            + 
CD105           +           +    +            + 
CD73           +           +    +            + 
Vimentin                  +        +    +            + 
Laminin          +            +    +            + 
Fibronectin          +                +    +            + 
HLA-ABC          +/-   +/-  +/-          +/- 
vWF           -                -     -            - 
CD90           +                +    +            + 
STRO-1         +/-  +/-  +/-          +/- 
Oct-4           +                +    +            + 
Nanog           +                +    +            + 
SSEA3          +                +    +            + 
SSEA4          +                +    +            + 
Tra-1-60                   +                +    +            + 
Tra-1-81          +                +    +            + 
C-kit          +/- 
Sox2          + 
SSEA1                    + 
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The growth kinetics of the isolated cells, estimated as the cumulative population 
doublings over an eight-week period, indicate that the cells show linear exponential 
growth and the cell population can be expanded at constant speed without becoming 
senescent. 1st and 2nd trimester AF cells grow significantly faster in the presence of 
bFGF (P<0.001), a growth factor routinely used for expansion of 2nd trimester AF 
cells (Fauza, 2004). The kinetics of placenta cells are not affected by the addition of 
the growth factor. Furthermore, cell seeding density does not affect the growth rate 
of either AF or placenta-derived cells.  
 
1st trimester AF cells grow faster than cells from 2nd trimester AF and 1st trimester 
placenta cells, while they have comparable population doubling to cells from 1st 
trimester fetal bone marrow. 1st trimester AF cells have much lower population 
doubling time than adult bone marrow MSC (Guillot et al., 2007), but grow as fast 
as ESC (Field et al., 1992) and can be easily maintained in culture and expanded to 
numbers relevant for clinical applications. 
 
1st trimester AF and placenta cells express pluripotency markers essential for the 
maintenance of ESC in the undifferentiated state, such as Oct-4, Nanog, SSEA3, 
SSEA4, Tra-1-60, Tra-1-81. These markers are not expressed by adult MSC (Guillot 
et al., 2007). 1st trimester AF cells also express SSEA1, Sox-2, Stella, Sox-17, KLF4 
and c-myc at the mRNA level. These results indicate that 1st trimester AF and 
placenta cells are cells with pluripotency potential, unlike adult MSC. In addition, 
some of the cells are positive for alkaline phosphatase, a germ cell marker. When the 
cells become overconfluent however, AF cells compact, spontaneously produce lipid 
droplets and minerals and only a few of the cells remain positive for alkaline 
phosphatase, indicating that the cells undergo spontaneous differentiation upon 
confluence.  
 
The telomere length and telomerase activity of the isolated AF and placenta cells 
indicate that the telomeric status of these cells is similar to 1st trimester fetal MSC 
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(Guillot et al., 2007), with longer telomeres and higher telomerase activity than adult 
MSC and endometrial cells. These results indicate that 1st trimester AF and placenta 
cells and 2nd trimester AF cells are cells with high proliferation capacity that can 
easily be expanded in culture without reaching senescence. 
 
Cells from all sources can differentiate into the mesodermal osteogenic and 
adipogenic lineages in vitro, as shown by staining and RT-PCR for lineage-specific 
markers. Cells from all sources may also be able to differentiate into the 
chondrogenic lineage. Also, 1st trimester AF cells, like ESC but not adult MSC, can 
form EB-like structures when grown in low-attachment conditions. The EB-like 
spheres express markers of the three germ layers and lose the expression of the 
pluripotency markers Oct-4 and Nanog, as shown by immunofluorescence and RT-
PCR, indicating that the cells undergo differentiation upon aggregation.  
 
Taken together, the results show for the first time that 1st trimester AF and placenta 
contain stem cells of fetal origin, with similar characteristics to fetal but not adult 
MSC, which express pluripotency markers also expressed by undifferentiated ESC. 
Moreover, 1st trimester AF cells, like ESC, can form EB-like structures that lose the 
expression of pluripotency markers and express markers of the three germ layers, 
indicating differentiation. In conclusion, AF cells are an alternative source of early 
fetal stem cells with potential for clinical use.  
 
One limitation encountered during this project was the availability of the cells, since 
few samples were successfully collected after consenting in three years, which in 
combination with the reaching of senescence of the cells at passage 25 did not allow 
for the completion of extensive experiments. If the availability of cells was higher, 
monitoring of the phenotype of the isolated cells throughout their lifespan would be 
of great interest, to observe the maintenance or loss of the proliferation and 
differentiation potential of the cells, as well as the effect of long-term culture on the 
immunophenotype of the cells and the expression of pluripotency markers. 
Additionally, the immunophenotype of the cells could be assessed by quantitative 
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methods, FACS for instance, to establish the percentage of the population positive 
for each marker, and the comparative analysis of each subpopulation in the instance 
where not all the cells within one sample express the same markers. 
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Chapter 3: Migration of fetal stem 
cells to tissue injury 
 
3.1. Introduction 
 
The mechanisms by which MSC migrate and engraft to bone marrow and other 
organs are still largely unknown. Studies of endogenous mechanisms have shown 
that MSC can detect tissue injury and respond by migrating to the site of damage, 
where they differentiate, thus promoting structural and functional repair. This has 
been observed in various conditions, including genetic defect (Horwitz et al., 2002), 
irradiation (Chapel et al., 2003), myeloablative therapy (Koc et al., 2000) and 
myocardial infarction (Kawada et al., 2004). 
 
 SDF-1 and HGF are upregulated at the site of tissue injury, indicating that these 
factors and the pathways involved may play a role in MSC migration (Kucia et al., 
2004; Ponomaryov et al., 2000). Members of the PDGF signalling pathway have 
also been implicated in endogenous MSC recruitment to bone, and subsequent 
differentiation of the cells to osteoblasts (Fiedler et al., 2002; Jung et al., 2006). 
Additionally, it has recently been reported that inflammatory cytokines such as TNF-
α can stimulate and upregulate the response of MSC to the signalling pathways 
(Ponte et al., 2007). 
 
A few recent studies have attempted to delineate the role of the SDF-1/CXCR4 axis 
in MSC migration and engraftment to tissues. Son et al. working with adult and cord 
blood-derived MSC confirmed the involvement of the SDF-1/CXCR4 axis in MSC 
migration, in conjunction with the HGF axis and dependence on MMPs (Son et al., 
2006). Jung et al. provide evidence of stem cell recruitment to the developing 
marrow, by an SDF-1 gradient created between the marrow with an increased 
expression of SDF-1 and the serum with a decreased SDF-1 expression (Jung et al., 
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2006). Wynn et al. showed that CXCR4 is present at low levels at the surface of 
MSC, being primarily located intracellularly, and that CXCR4 is involved in 
migration of MSC to the bone marrow (Wynn et al., 2004). Although these studies 
have provided an insight into the involvement of the SDF-1-CXCR4 axis in MSC 
migration, these results refer mainly to adult MSC, leaving the fetal MSC migration 
mechanisms largely unknown. 
 
In this chapter I will present work carried out in the third year of my project, to 
generate pilot data for a project funded for 1 year by the Hammersmith Hospital 
Trustee’s Research Committee, investigating the mechanisms involved in trafficking 
of donor human fetal stem cells to bone after intrauterine transplantation in a model 
of OI. 
 
 
In this chapter I will examine the following: 
 
• Intracellular and extracellular expression of CXCR4 by fetal stem cells 
• Alteration in expression pattern of CXCR4 in cells stimulated with cytokines 
or tissues from oim and wild type mice 
• Expression and up- or down-regulation of SDF-1 in injured and non-injured 
tissues from oim and wild type (WT) mice 
• Migration potential of cells non-stimulated or pre-treated with a variety of 
cytokines, towards chemokines or tissues from oim and WT mice 
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3.2. Methods 
 
3.2.1. Cell culture 
 
Stem cell culture was carried out as described before in chapter 2. For the isolation 
and culture of oim and WT bone marrow and bone cells, bone marrow was flushed 
out in medium from bones using a 1ml microsyringe (Becton Dickinson), plated and 
cultured for 1 week in DMEM supplemented with 10% FBS (Gibco/Invitrogen), 2 
mM L-glutamine, 500 U/ml penicillin, 50 µg/ml streptomycin (Gibco/Invitrogen 
Ltd., Paisley, UK) in a 95% humidified 5% CO2 chamber at 37 ºC (incubator by 
BINDER, Incheon, Korea). For the bone cells, all muscle was thoroughly removed 
from bones, bone marrow was flushed and the bones were then fractured using a 
scalpel, plated in medium and cultured for 1 week in plastic, adherent culture dishes. 
Isolated cells that adhered to the plastic were then trypsinised and used for the 
migration assays or frozen for future use. 
 
 
3.2.2. Flow cytometric analysis 
 
Cell expression of surface or intracellular markers was assessed by flow cytometry. 
The cells were firstly trypsinised for 5 minutes, harvested and centrifuged for 5 
minutes at 1500 RPM, the supernatant was removed the pellet was resuspended in 
1ml of PBS and the cells were counted. The Fix & Perm kit (Invitrogen) was then 
used for permeabilisation and fixation of the cells. For the cell surface markers, 5 x 
105 cells were mixed with the antibody or isotype control, incubated for 15 minutes 
at room temperature in the dark, followed by addition of fixation medium provided 
with the kit. The cells were then incubated for 15 minutes, washed once in 3 ml PBS 
supplemented with 0.1% NaN3 and 5% FBS, centrifuged for 5 minutes at 1500 
RPM, the supernatant was removed and the pellet was resuspended. 
Permeabilisation medium was then added, together with the intracellular antibody or 
isotype control, the cells were incubated for 15 minutes, washed once as above, 
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centrifuged and the pellet were resuspended in PBS for analysis. Cells were then 
analysed in a FACScalibur (Becton Dickinson). Table 7 shows the different 
antibodies used. 
 
3.2.3. Immunofluorescence 
 
The same immunofluorescence protocol was used as described in chapter 2. Table 7 
shows the different antibodies used. 
 
Table 7. Antibodies used for flow cytometric analysis and immunofluorescence. 
 
Name Company Source Epitope Dilution Application 
 
CXCR4-PE R&D Systems Mouse CXCR4 1:50 Flow cytometry 
IgG2A 
isotype 
control-PE 
R&D Systems Mouse IgG2A 1:50 Flow cytometry 
CXCR4 
(fusin) 
R&D Systems Mouse CXCR4 1:100 Immunofluorescence 
FITC dk α 
Mouse 
Jackson 
Laboratories 
Inc., USA 
Donkey Mouse 1:100 Immunofluorescence 
 
 
3.2.4. Cell migration assays 
 
12-well and single well chemotaxis chambers (Neuroprobe) were used for the cell 
migration assays, following the protocol suggested by the company. The 
polycarbonate filters used had 12 µm pore diameter (Neuroprobe). Briefly, the 
bottom well of the chamber was filled with chemoattractant or control media, the 
polycarbonate filter was then applied, and non-stimulated cells or pre-stimulated 
cells were added in the upper well, at a concentration of 4,000,000 cells/ml. The 
cells were then placed in a 95% humidified 5% CO2 chamber at 37 ºC and allowed 
to migrate for various amounts of time. The upper side of membranes was then 
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washed twice with PBS to remove any cells that did not migrate, fixed with cold 
methanol for 5 minutes and stained with haematoxylin for 5 minutes, then rinsed in 
running water and left to dry. Migrated cells were then photographed using an 
Olympus CK40-SLP microscope and an Olympus C3040-ADL camera (Olympus). 
Five fields were photographed for each sample and migrated cells were counted. 
Figure 28 shows images of fields containing (B) and not containing (A) migrated 
cells. Table 8 gives a list of the chemoattractants used. 
 
For cell stimulation, cells were stimulated overnight with SDF-1, blood plasma, 
bone marrow or bone cells from WT and oim mice, by adding 100 µl of each 
stimulating solution to a plate of cells growing in 4 ml of media and allowing the 
cells to grow in a 95% humidified 5% CO2 chamber at 37 ºC. SDF-1 was added at 
concentrations of 1, 30, 50 and 100 ng/ml final concentration. For cell blocking, the 
cells were trypsinised and incubated for different time intervals (5, 10, 30, 60 or 120 
minutes) in media containing CXCR4 or AMD3100, acting as antagonists, in a 95% 
humidified 5% CO2 chamber at 37 ºC.  
 
 
Table 8. Cytokines used for stimulation, blocking and chemoattraction of cells. 
 
Name Company Source Final 
concentration 
Application 
 
SDF-1 R&D Systems Mouse Various Chemoattraction/ 
Stimulation 
CXCR4 
clone 12G5 
R&D Systems Mouse 10 µg/ml Blocking 
AMD3100 Sigma Synthetic 100 µg/ml Blocking 
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Figure 28. Fields lacking (A) and containing (B) migrated cells, stained with 
hematoxylin.  
 
3.2.5. Breeding and maintenance of oim mice 
 
Oim (C57Bl6C3Fe oim/oim), a mouse model of type III OI, suffer from recurrent 
fractures, swollen joints, skeletal deformities and osteopenia, consecutive to 
mutation(s) in type I collagen, abnormalities similar to those observed in humans 
(Glorieux et al., 1998). Homozygous mice were generated from heterozygous 
matings (1:4 genetic ratio). 
 
3.2.6. Genotyping 
 
For genotyping of the oim mice, ear tissue was digested overnight at 55 °C in 
digestion buffer, containing 500mM KCl, 100mM Tris-HCl pH8.3, 0.1 mg/ml 
gelatin, 0.45% v/v Tween 20, 0.45% v/v Nonidet P40 and 5 mg/ml proteinase K (all 
from Sigma). PCR was then carried out using the primers (Thermo) listed in Table 9, 
adding 5 µl buffer, 4 µl dNTPs, 2 µl each primer, 0.25 µl Taq polymerase, 35.75 µl 
water and 1 µl of non-purified DNA per sample (all reagents from Qiagen). The 
PCR program used was 95 °C for 3 minutes, followed by 35 cycles of 95 °C for 30 
A B 
40x 40x 
 119 
seconds, 64 °C for 30 seconds, 72 °C for 1 minute, and a final step of 72 °C for 3 
minutes. The PCR product was then cleaned using the PCR purification kit by 
Qiagen, DNA concentration was measured and the product was sent to Cogenics for 
sequencing (Cogenics Lark, Essex, UK). The results were analysed using the 
software 4Peaks (downloaded from http://mekentosj.com/). Figures 29 to 31 show 
the sequencing results for an oim/oim, a wt/oim and a wt/wt sample. 
 
Table 9. Primers used for the genotyping of oim mice. 
Gene name Forward sequence Reverse Sequence Lengt
h (bp) 
Temp 
(°C) 
No. 
cycles 
Col1a2 
 
5’-
CACCACACACA
TACAAGATATG
C-3’ 
5’-
TGGTCAGCACCAC
CAATGTCC-3’ 
410 64 35 
 
 
 
 
Figure 29. Sequencing of an oim/oim sample. The G deletion occurs after the 
marked A base.  
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Figure 30. Sequencing of a wt/oim sample. The two peaks for A and G are visible at 
the marked region and after that the frame shift is visible by the presence of double 
peaks. 
 
  
Figure 31. Sequencing of a wt/wt sample. The G nucleotide is present at the marked 
position. 
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3.2.7. Dissection and organ collection 
 
Oim homozygous mice and WT mice were dissected and bones, spleen, liver, heart, 
lungs and brain were removed and stored at -80 ºC for RNA extraction. 
 
 
3.2.8. RNA extraction/cDNA synthesis 
 
RNA was extracted from oim and WT organs by homogenising tissues in trizol 
(Invitrogen), followed by addition of chloroform and centrifugation. The top 
aqueous phase containing the RNA was then transferred to a new tube, equal volume 
of isopropanol was added and the tube was centrifuged. The resulting pellet was 
washed with 70% ethanol, then ethanol was removed and pellet was allowed to dry 
and resuspended in DEPC-treated water. For the cDNA synthesis, the same protocol 
as described in chapter 2 was followed. 
 
3.2.9. Quantitative real-time PCR 
 
SDF-1 expression was determined using quantitative real-time RT-PCR. The 
concentration of reagents in the PCR amplification reaction was 12.5 µl of 2X 
SYBR Green PCR Master Mix (Applied Biosystems) with 900 nM each of forward 
and reverse primers, listed in Table 10, in a total volume of 25 µl. The thermal 
cycling conditions started with 95 ºC for 10 min followed by 40 cycles of 95ºC for 
15 seconds, 60 ºC for 30 seconds and 72 ºC for 30 seconds. Ct values in 
experimental samples were determined from semi-log amplification plots and the 
standard curve was used to determine the quantity of product, while all samples were 
normalised to b-actin. 
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Table 10. Primer sequences of murine b-actin and SDF-1, and human b-actin and 
CXCR4 used for qrt-PCR. 
Gene name Forward 
sequence 
Reverse 
Sequence 
Length 
(bp) 
Temp 
(°C) 
No. 
cycles 
Murine SDF-1 
 
5’-
TGAGGCCAGG
GAAGAGTGAG
-3’ 
5’-
GACACATGG
CGATGAATG
GA-3’ 
100 60 40 
Murine b-
actin 
5’-
AGAGGGAAAT
CGTGCGTGAC
A-3’ 
5’-
CACTGTGTT
GGCATAGAG
GTC-3’ 
100 60 40 
Human B-
ACTIN 
5’-
CTGGAACGGT
GAAGGTGACA
-3’ 
5’-
AAGGGACTT
CCTGTAACA
ATGCA-3’ 
100 61 25 
Human 
CXCR4 
5’-
AATCTTCCTGC
CCACCATCT-3’ 
5’-
GACGCCAAC
ATAGACCAC
CT-3’ 
120 61 40 
 
Figure 32 shows the amplification of a sample in duplicate. The amplification curves 
are identical, showing accuracy of pippeting technique. 
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Figure 32. Duplicate of a sample, amplified for SDF-1 by quantitative real time 
PCR. The amplification curves are identical, indicating that there was no difference 
in amplification between the two duplicates. 
 
3.2.10. Statistical analysis 
 
Data are expressed as means plus or minus standard deviation (SD) from the mean. 
For the statistical analysis, Excel was used to generate the graphs presented and the 
standard deviation of the samples. Unpaired 2-tailed student t tests and one-way 
ANOVA tests were carried out, and the P values are presented. A P value less than 
0.05 was considered significant. One asterisk (*) indicates a P value lower than 0.05, 
two asterisks (**) indicate a P value lower than 0.01 and three asterisks (***) 
indicate a P value lower than 0.001. 
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3.3. Results 
 
3.3.1. CXCR4 expression 
 
The intracellular and membrane-bound expression of CXCR4 by non-stimulated 
fetal blood (passage 5) cells was tested by flow cytometry (Figure 33) and 
immunofluorescence (Figure 34). Non-stimulated cells from both sources express 
CXCR4 intracellularly (98.88% ±0.10) but not bound on the cell membrane (0.12% 
±0.05). CXCR4 is found in the cytoplasm, and in the nucleoli of the nucleus after 
permeabilisation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33. Flow cytometry histograms for intracellular (A) and membrane-bound 
(B) CXCR4 expression in fetal blood stem cells at passage 5. Red histograms 
represent % of CXCR4 positive cells within the sample population. Black peak 
represents cells stained for IgG control. Cells express CXCR4 intracellularly 
(98.8%, n=4, SD ± 0.09), but not on the cell membrane (0.2%, n=4, SD ± 0.04). 
 
A B 
98.8% 0.2% 
Intracellular      Membrane-bound 
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Figure 34. Immunofluorescence showing distribution of CXCR4 in non-
permeabilised (A) and permeabilised (B) fetal blood stem cells at passage 5. TOTO-
3 stain is used to visualise the nucleus. CXCR4 is found in the cytoplasm, and in the 
nucleoli of the nucleus after permeabilisation. 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
TOTO3      FITC       Merge 
Nucleolus 
CXCR4 
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3.3.2. SDF-1 expression in mice tissues 
 
The next step was to assess quantitative real time expression of SDF-1 in various 
tissues (bone, spleen, liver, heart, lungs, brain) in oim (n=3) and WT (n=3) mice. 
Figure 35 shows the SDF-1 expression in oim and WT tissues detected by 
quantitative real time RT-PCR. One-way ANOVA was carried out to test the 
difference between samples. All data are expressed as mean ± SD. SDF-1 is 
significantly more highly expressed in oim bone than in WT bone or in any other 
oim or WT tissue. Bone is an inflamed tissue in oim but not in WT, therefore 
upregulation of SDF-1 in this tissue compared to other non-injured oim organs 
indicates that injury triggers upregulation of SDF-1 and activation of the SDF-
1/CXCR4 axis.  
 
 
Figure 35. SDF-1 expression in oim and WT tissues by quantitative real time PCR. 
Relative gene expression was calculated relative to β-actin. One-way ANOVA was 
carried out to test the difference between samples. All data are expressed as mean ± 
SD. There is a significant difference in expression between oim bone and all other 
oim and WT organs (***: P<0.001, n=3).  
*** 
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3.3.3. CXCR4 expression after stimulation 
 
After establishing that 1st trimester fetal cells express CXCR4, I tested the CXCR4 
expression in cells after stimulation with oim or WT blood plasma, and primary cells 
isolated from bone marrow and bone. Figure 36 shows the intracellular and 
membrane-bound expression of CXCR4 by fetal blood cells at passage 5 after 
stimulation with plasma, Figure 37 after stimulation with bone marrow cells and 
Figure 38 after stimulation with bone cells. A fraction of CXCR4 is externalised on 
the cell membrane after cell stimulation with oim plasma or bone marrow cells, but 
not WT plasma or bone marrow cells. Bone cells from WT and oim trigger CXCR4 
externalisation, with oim inducing a stronger response.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36. Intracellular and membrane-bound expression of CXCR4 by fetal blood 
cells at passage 5 after stimulation with oim and WT plasma. Red histograms 
represent % of CXCR4 positive cells within the sample population (n=3). Black 
peak represents cells stained for IgG control. A fraction of CXCR4 is externalised 
after cell stimulation with oim but not WT plasma. 
intracellular              membrane-bound 
  WT 
plasma 
 
 
 
 
Oim 
plasma 
95% 0.3% 
89% 48% 
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Figure 37. Intracellular and membrane-bound expression of CXCR4 by fetal blood 
cells at passage 5 after stimulation with oim and WT bone marrow. Red histograms 
represent % of CXCR4 positive cells within the sample population (n=3). Black 
peak represents cells stained for IgG control. A small fraction of CXCR4 is 
externalised after cell stimulation with oim but not WT bone marrow cells. 
 
 
 
 
 
 
 
 
 
 
 
 
  WT 
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bone 
marrow 
89% 0.4% 
88% 1.4% 
intracellular           membrane-bound 
 129 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38. Intracellular and membrane-bound expression of CXCR4 by fetal blood 
cells at passage 5 after stimulation with oim and WT bone. Red histograms represent 
% of CXCR4 positive cells within the sample population (n=3). Black peak 
represents cells stained for IgG control. Bone cells from WT and oim trigger CXCR4 
externalisation to the cell membrane, with oim inducing a stronger response. 
 
 
 
 
 
 
 
 
 
 
 
WT 
bone 
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CXCR4 expression by stimulated fetal blood cells at passage 5 was also assessed by 
quantitative real time RT-PCR (Figure 39). Samples were normalised to b-actin. 
CXCR4 is significantly more expressed when fetal blood stem cells are stimulated 
by plasma and bone from oim compared to WT. The same is not observed however 
when the cells are stimulated with oim or WT bone marrow.  
 
 
 
 
 
 
Figure 39. Quantitative real time expression of CXCR4 by fetal blood cells at 
passage 5 after stimulation with SDF-1, oim or WT plasma, bone marrow or bone. 
Samples were normalised to b-actin. CXCR4 is significantly more expressed when 
fetal blood stem cells are stimulated by plasma and bone from oim compared to WT 
(**: P<0.01, n=3). The same is not observed however when the cells are stimulated 
with oim or WT bone marrow. 
 
 
** ** 
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Fetal stem cells from 1st trimester blood express CXCR4 intracellularly but not on 
the cell membrane. A small fraction of CXCR4 is externalised after cell stimulation 
with oim plasma or bone marrow cells, but not WT plasma or bone marrow cells. 
Bone cells from WT and oim trigger CXCR4 externalisation, with oim inducing a 
stronger response as shown by flow cytometric analysis.   
 
At the mRNA level, unstimulated fetal stem cells express CXCR4, at levels higher 
than adult MSC. CXCR4 is upregulated when fetal stem cells are stimulated by bone 
marrow and bone from oim compared to WT, while plasma from oim or WT have a 
similar effect on the CXCR4 level. 
 
 
3.3.4. In vitro chemotaxis 
 
After confirming that fetal stem cells express CXCR4, in vitro chemotaxis was 
carried out to test whether the cells migrate in response to the ligand of CXCR4, 
SDF-1, as previously observed for adult MSC (Wynn et al., 2004).  
 
The first experiment was to test the chemotactic response of fetal blood cells at 
passage 5 to a gradient of SDF-1. Figure 40 shows in vitro migration of fetal cells 
(n=2) to a gradient of SDF-1 for 1 hour. All data are expressed as the average 
number of cells in 5 fields, at 40x magnification. Data are normalised to control 
background migration (cells migrating to medium without the addition of SDF-1). A 
trend towards dose-dependent migration was observed, with concentrations of 30 
and 50 ng/ml SDF-1 inducing a higher chemotactic response than 1 or 100 ng/ml 
SDF-1.  
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Figure 40. In vitro migration of fetal blood cells (n=2) at passage 5 to a gradient of 
SDF-1 for 1 hour. All data are expressed as the average number of cells in 5 fields. 
Data are normalised to control background migration (cells migrating to medium 
without the addition of SDF-1). A trend towards dose-dependent migration was 
observed and concentrations of 30 and 50 ng/ml SDF-1 induce a higher chemotactic 
response.  
 
 
Next, fetal blood stem cells at passage 5 were allowed to migrate towards 30ng/ml 
SDF-1 for different time intervals (Figure 41). All data are expressed as the average 
number of cells in 5 fields. Data are normalised to control background migration 
(cells migrating to medium without the addition of SDF-1). A trend towards time-
dependent migration effect was observed, with higher number of cells migrating 
after overnight incubation. 
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Figure 41. Migration of fetal blood cells at passage 5 to SDF-1 for different time 
intervals. All data are expressed as the average number of cells in 5 fields (n=2). 
Data are normalised to control background migration (cells migrating to medium 
without the addition of SDF-1). A trend towards time-dependent migration effect 
was observed, with higher number of cells migrating after overnight incubation. 
 
 
After establishing that unstimulated cells migrate to SDF-1 in an in vitro chemotaxis 
assay, fetal blood stem cells were stimulated overnight oim or WT plasma and then 
allowed to migrate to 30 ng/ml SDF-1 for 1 hour. Figure 42 shows the migration of 
stimulated and unstimulated cells to SDF-1 for 1 hour (n=2). All data are expressed 
as the average number of cells in 5 fields. There is a clear trend that oim stimulated 
cells migrate more than naïve and WT stimulated cells. 
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Figure 42. Migration of unstimulated (naïve), and stimulated fetal blood cells at 
passage 5 with oim (oim stimul) or WT (wt stimul) plasma to 30ng/ml SDF-1 for 1 
hour (n=2). All data are expressed as the average number of cells in 5 fields. Data 
are normalised to control background migration (cells migrating to medium without 
the addition of SDF-1). Oim stimulated cells migrate more than naïve and WT 
stimulated cells to 30ng/ml SDF-1. 
 
 
 
Next, the migration of unstimulated fetal blood cells at passage 5 towards WT and 
oim bone and bone marrow cells was tested. The same was also tested for cells pre-
stimulated overnight with oim or WT plasma. The cells were allowed to migrate for 
1 hour and cell migration to DMEM was used as a control. Figure 43 shows the 
migration of the unstimulated and pre-stimulated fetal blood cells towards WT and 
oim bone and bone marrow cells, as well as DMEM control (n=2). All data are 
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expressed as the average number of cells in 5 fields. Unstimulated cells migrate 
more to oim bone and bone marrow, compared to WT bone and bone marrow cells. 
 
 
Figure 43. Migration of fetal blood cells at passage 5 unstimulated or pre-stimulated 
overnight with WT or oim plasma, towards WT and oim bone and bone marrow 
cells. All data are expressed as the average number of cells in 5 fields (n=2). The 
cells were allowed to migrate for 1 hour, and migration to DMEM was used as a 
control.  
 
After establishing that fetal blood cells migrate towards SDF-1 and WT and oim 
tissues, I decided to test the migration potential of 1st trimester AF stem cells at 
passage 6, unstimulated and stimulated overnight with oim plasma, towards SDF-1, 
oim bone and oim bone marrow cells for 1 hour (Figure 44). All data are expressed 
as the average number of cells in 5 fields (n=2). Data are normalised to control 
background migration (cells migrating to medium only). There is a clear trend 
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indicating stronger migration of stimulated cells towards oim bone, while there is no 
difference in migration towards SDF-1 and oim bone marrow between unstimulated 
and stimulated cells. 
 
 
Figure 44. Migration of 1st trimester AF stem cells at passage 6, unstimulated 
(Naïve) and stimulated (Stim) overnight with oim plasma, towards SDF-1, oim bone 
and oim bone marrow cells for 1 hour. All data are expressed as the average number 
of cells in 5 fields (n=2). Data are normalised to control background migration (cells 
migrating to medium only). There is a clear trend indicating stronger migration of 
stimulated cells towards oim bone, while there is no difference in migration towards 
SDF-1 and oim bone marrow between unstimulated and stimulated cells. 
 
From the previous set of experiments I concluded that unstimulated fetal blood stem 
cells migrate more to oim bone and bone marrow, compared to WT bone and bone 
marrow cells. Oim plasma stimulated cells migrate more than naïve and WT 
stimulated cells to 30ng/ml SDF-1. Oim plasma stimulated cells also migrate more 
to oim bone compared to WT bone cells, while there is no difference in migration 
towards oim and WT bone marrow cells. WT plasma stimulated cells migrate more 
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to oim bone and bone marrow, compared to WT bone and bone marrow cells. For 
the 1st trimester AF stem cells, there is a difference in migration towards oim bone 
between unstimulated and stimulated cells, while there is no difference in migration 
towards SDF-1 and oim bone marrow between unstimulated and stimulated cells. 
 
Oim tissues, expressing higher SDF-1 levels than WT tissues, have a stronger 
chemoattractant effect on stem cells from 1st trimester fetal blood and AF. Pre-
stimulation of the cells with oim or WT plasma also increases migration of cells 
towards some tissues in vitro. These results indicate that the SDF-1/CXCR4 axis is 
involved in stem cell migration.  
 
 
 
3.3.5. In vitro chemotaxis after blocking with CXCR4 antagonists 
 
In order to confirm the involvement of the SDF-1/CXCR4 axis in fetal stem cell 
migration, I tested whether blocking of the CXCR4 receptor with a CXCR4 antibody 
or AMD3100, a CXCR4 antagonist, has an effect on migration of the cells towards 
SDF-1. Fetal blood cells at passage 5 were blocked for different time intervals and 
then allowed to migrate towards 30 ng/ml SDF-1 for 1 hour. Figure 45 shows 
migration of fetal blood stem cells blocked with AMD3100 towards SDF-1 for 1 
hour, together with cells migrating towards DMEM as a control. All data are 
expressed as the average number of cells in 5 fields (n=2). Migration appeared to be 
lower after 10 minutes of blocking. 
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Figure 45. Migration of fetal blood stem cells at passage 5 blocked with AMD3100 
for different time intervals, towards SDF-1 for 1 hour. Cells migrating towards 
DMEM served as a control. All data are expressed as the average number of cells in 
5 fields (n=2). Migration appeared to be lower after 10 minutes of blocking. 
 
 
Figure 46 shows migration of fetal blood stem cells at passage 5 blocked with a 
CXCR4 antibody towards SDF-1 for 1 hour, together with cells migrating towards 
DMEM as a control. All data are expressed as the average number of cells in 5 fields 
(n=2). Migration appeared to be lower after 10 minutes of blocking. 
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Figure 46. Migration of fetal blood stem cells at passage 5 blocked with a CXCR4 
antibody for different time intervals, towards SDF-1 for 1 hour. Cells migrating 
towards DMEM served as a control. All data are expressed as the average number of 
cells in 5 fields (n=2). Migration appeared to be lower after 10 minutes of blocking. 
 
When migration levels before and after blocking with AMD3100 are compared 
(Figure 47), there is a decrease in migration levels both towards oim bone (n=2) and 
towards oim bone marrow (n=2). All data are expressed as the average number of 
cells in 5 fields. This confirms that the SDF-1/CXCR4 axis is involved in fetal stem 
cell migration towards oim bone and bone marrow. 
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Figure 47. Migration of blocked and non-blocked fetal blood cells at passage 5 with 
AMD3100. All data are expressed as the average number of cells in 5 fields. When 
migration levels before and after blocking are compared, there is a decrease in 
migration levels both towards oim bone (n=2) and towards oim bone marrow (n=2). 
This confirms that the SDF-1/CXCR4 axis is involved in fetal stem cell migration 
towards oim bone and bone marrow. 
 
Similarly, when migration levels before and after blocking with a CXCR4 antibody 
are compared (Figure 48), there is a significant decrease in migration levels both 
towards oim bone and towards oim bone marrow. All data are expressed as the 
average number of cells in 5 fields (n=2). This further confirms that the SDF-
1/CXCR4 axis is involved in fetal stem cell migration towards oim bone and bone 
marrow. 
 
 141 
 
 
Figure 48. Migration of blocked and non-blocked fetal blood cells at passage 5 with 
a CXCR4 antibody. All data are expressed as the average number of cells in 5 fields. 
When migration levels before and after blocking are compared, there is a significant 
decrease in migration levels both towards oim bone (n=2) and towards oim bone 
marrow (n=2). This further confirms that the SDF-1/CXCR4 axis is involved in fetal 
stem cell migration towards oim bone and bone marrow. 
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3.4. Discussion 
 
In this chapter I have examined the involvement of the SDF-1/CXCR4 axis in 
migration of fetal stem cells towards sites of injury, using in vitro migration assays.  
 
I found that non-stimulated cells from 1st trimester fetal blood cells express CXCR4 
intracellularly (98.88% ±0.10) but not on the cell membrane (0.12% ±0.05). CXCR4 
is expressed in the cytoplasm, and can also be found in the nucleus, stored in the 
nucleoli, after permeabilisation. 
 
I also found that SDF-1 is expressed at the mRNA level in both oim and WT tissues, 
but expression is higher in oim bone, compared to WT bone and all other oim and 
WT organs. Bone is an inflamed organ in oim but not in WT, therefore upregulation 
of SDF-1 in this tissue compared to other non-inflamed oim organs indicates that 
injury triggers upregulation of SDF-1 and activation of the SDF-1/CXCR4 axis. 
 
After establishing that 1st trimester fetal cells express CXCR4, I tested the CXCR4 
expression by cells in response to stimulation with oim and WT blood plasma, and 
primary cells isolated from bone marrow and bone. A small fraction of CXCR4 is 
externalised after cell stimulation with oim plasma or bone marrow, but not WT 
plasma or bone marrow. Bone from WT and oim trigger CXCR4 externalisation, 
with oim inducing a stronger response. At the mRNA level, unstimulated fetal stem 
cells express CXCR4, to levels higher than adult MSC. CXCR4 is upregulated when 
fetal stem cells are stimulated by bone marrow and bone from oim compared to WT, 
while plasma from oim or WT have a similar effect on the CXCR4 level. 
 
After confirming that fetal stem cells express CXCR4, in vitro chemotaxis was 
carried out to test whether the cells migrate in response to the ligand of CXCR4, 
SDF-1, as previously observed for adult MSC (Wynn et al., 2004).  
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Unstimulated fetal blood stem cells migrate more to oim bone and bone marrow, 
compared to WT bone and bone marrow cells. Oim plasma stimulated cells migrate 
more than naïve and WT stimulated cells to 30ng/ml SDF-1. Oim plasma stimulated 
cells also migrate more to oim bone compared to WT bone cells, while there is no 
difference in migration towards oim and WT bone marrow cells. WT plasma 
stimulated cells migrate more to oim bone and bone marrow, compared to WT bone 
and bone marrow cells. For the 1st trimester AF stem cells, there is a difference in 
migration towards oim bone between unstimulated and stimulated cells, while there 
is no difference in migration towards SDF-1 and oim bone marrow between 
unstimulated and stimulated cells. 
 
Oim tissues, expressing higher SDF-1 levels than WT tissues, have a stronger 
chemoattractant effect on stem cells from 1st trimester fetal blood and AF, indicating 
that SDF-1 is upregulated at the site of injury and may act as a chemoattractant for 
CXCR4-expressing donor cells. Pre-stimulation of the cells with oim or WT plasma 
also increases migration of cells towards some tissues in vitro. These results indicate 
that the SDF-1/CXCR4 axis is involved in stem cell migration.  
 
In order to confirm the involvement of the SDF-1/CXCR4 axis in fetal stem cell 
migration, I tested whether blocking of the CXCR4 receptor with a CXCR4 antibody 
or AMD3100, a CXCR4 antagonist, has an effect on migration of the cells towards 
SDF-1. When migration levels before and after blocking with a CXCR4 antibody 
and with a CXCR4 antagonist (AMD3100) are compared, there is a decrease in 
migration levels both towards oim bone and towards oim bone marrow. This further 
confirms that the SDF-1/CXCR4 axis is involved in fetal stem cell migration 
towards oim bone and bone marrow. 
 
Overall, the SDF-1/CXCR4 axis is involved in migration of 1st trimester fetal stem 
cells from blood and AF. The cells express CXCR4 as previously reported for adult 
bone marrow MSC and cord blood MSC (Son et al., 2006; Wynn et al., 2004). SDF-
1 is upregulated in injured oim tissues as found previously in other models of injury 
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(Ponomaryov et al., 2000; Togel et al., 2005). 1st trimester fetal stem cells migrate to 
SDF-1 as reported previously for adult bone marrow MSC (Ponte et al., 2007). Cell 
migration is higher towards oim tissues compared to WT tissues. Taken together, 
these results confirm that the SDF-1/CXCR4 axis is involved in recruitment of 1st 
trimester stem cells to sites of injury.  
 
To confirm the preliminary findings presented in this chapter, further experiments 
with higher sample numbers would test the statistical significance of the findings. In 
addition, other chemoattractants could be tested, in order to gain a better 
understanding of the complex pathways controlling the migration of fetal stem cells, 
and further confirm the involvement of the SDF-1-CXCR4 axis in this process. 
Furthermore, in vivo experiments could be carried out to test the involvement of the 
axis in fetal stem cell migration, by blocking CXCR4 and observing whether the 
cells would migrate to sites of injury.  
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Chapter 4: Cell transfection using non-
viral transfection methods 
 
 
 
4.1. Introduction 
 
 
Autologous stem cells, isolated from the same individual rather than a donor, could 
potentially be used for cell therapy of genetic conditions. However, all the cells of an 
individual with a genetic defect will carry the mutation, including any isolated stem 
cells. Thus, stem cells would have to be genetically manipulated ex vivo to correct 
the genetic mutation before they can be used for cell therapy. Genetic manipulation 
in this setting would have to confer a permanent transgene expression, to avoid 
repeated cell administration. 
 
Viral methods for gene manipulation are the most efficient and confer sustained 
transgene expression, but are associated with important risks. The viral nature of the 
vectors can cause a lethal inflammatory response (Hollon, 2000). Insertional 
mutagenesis, where the transgene integration disrupts the function of tumour-
suppressor genes or oncogenes, leading to carcinogenesis, is also a cause of concern 
when using viral methods. It has recently been shown that lentiviral and murine 
leukaemia virus vectors preferentially integrate into transcriptional hotspots 
(Schroder et al., 2002; Wu et al., 2003), making insertional mutagenesis less rare 
than previously believed. 
 
In this regard, the use of non-viral methods would be a safer alternative. However, 
the transgene expression conferred by simple transfection is only transient, as the 
gene is only delivered to the nucleus and not integrated into the genome. In the 
setting of cell therapy, the transgene would have to be retained into the nucleus, 
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safely integrated into the genome without disrupting normal gene function and 
segregated after cell division. A combined approach would need to be applied to 
achieve permanent gene integration, by using non-viral transfection methods for 
gene delivery to the nucleus as the first step, and non-viral integration systems such 
as transposons for integration of the gene to a selected site in the genome. However, 
there are still a number of hurdles to overcome before non-viral gene manipulation 
can be used efficiently for therapy. The efficiency levels achieved with most 
liposome-based transfection systems are very low for some primary cells, including 
MSC (Hamm et al., 2002). Another disadvantage is that most non-viral transfection 
methods deliver the nucleic acids to the cytoplasm rather than the nucleus, making 
them more prone to degradation. Novel transfection methods like nucleofection, 
which deliver the nucleic acids directly to the nucleus, could provide an alternative 
and more efficient transfection method as a first step towards safe, non-viral gene 
therapy. 
 
This chapter covers work which was carried out as part of a multidisciplinary, 
specific targeted research project with the acronym “SyntheGeneDelivery’, funded 
by the European Union and shared by groups at Imperial College London, 
University of Tours, France, University of Oxford and Karolinska Institute, Sweden, 
as well as two commercial partners, In Cell Art (http://www.incellart.com) and 
Avaris (http://www.avaris.se). Details of the project and participants can be found at: 
http://gicc.univ-tours.fr/recherche/projets/strep.php. The aim of the project was to 
develop a new ex-vivo gene delivery protocol to provide stable long-term expression 
of integrated transgenes, with the ultimate aim being to treat genetic diseases of the 
neuromuscular and skeletal systems.  
 
The protocol of the project was designed in an attempt to overcome three key 
barriers associated with ex-vivo gene delivery: internalisation of the transgene in 
stem cells, by successfully passing the cell membrane, transport of the transgene 
across the nuclear membrane and integration at a predefined genomic locus, selected 
for its safety in order to avoid disruption of normal gene function and insertional 
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mutagenesis. The solution suggested for the first key barrier, the internalisation into 
the cell, was the optimisation of the use of block co-polymers manufactured by In 
Cell Art. The group at University of Tours carried out the optimisation stages for 
this part of the project on human cancer and insect cell line systems. For the second 
barrier, the transport of the transgene into the nuclear membrane, the development of 
a novel targeted transposition system was suggested, using transposons of the Mos1 
mariner family. Work on this part of the project was also carried out at University of 
Tours, with the aim to optimise the cellular internalisation and nuclear import steps 
in order to allow the cells to be treated with a minimal amount of the transgene. This 
would allow the assay to be efficient, while maintaining a high level of safety by 
preventing cell transformation by illegitimate integration events. Finally, a group at 
Karolinska Institute was responsible for overcoming the third barrier, the integration 
at a specific, pre-selected specific locus, by using zinc-finger technology. The 
duration of the project was 3 years, and at the end of each year one optimised system 
would be tested into fetal stem cells, to assess the efficiency and safety of the 
process.  
 
The initial objective of the project undertaken by Imperial College was to obtain the 
optimised versions of lipid complexes used for cell internalisation of the transgene, 
combine this with the optimised transposon system and zinc finger technology, 
transfect fetal stem cells, and once the transgenes were successfully integrated into 
the genome of the fetal stem cells, test the effects of the process on the stem cell 
properties of fetal stem cells, including proliferation rate, differentiation potency and 
maintenance of expression of phenotypic markers. Once the transfection, transposon 
and transgene integration systems had all been optimised, and the safety of the 
procedure had been established, the reporter genes would be replaced by transgenes 
targeted to correct genetic defects ex vivo. 
 
Many problems were encountered throughout this project, with the optimisation 
steps during years 1 and 2 of the project being delayed due to low efficiency of the 
lipid complexes and the transposon systems developed, hence by the end of year 2 
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no optimised system could yet be tested in fetal stem cells. It was therefore decided 
to run preliminary experiments transfecting the cells with the lipid complexes 
developed so far, in order to assess the efficiency of these complexes in fetal stem 
cells. Plasmids carrying reporter genes were initially used, which would be replaced 
by the transposon system once that had been developed. In year 3, it was decided 
that the transposon system based on Mos1 mariner was inefficient in human cells 
and was therefore not tested in fetal stem cells.  
 
 
 
In this chapter I will present work on lipofection and nucleofection as methods for 
non-viral stem cell transfection. More specifically I will examine: 
 
• Efficiency of lipofection on stem cells from 1st trimester fetal blood, using a 
variety of lipid constructs for encapsulation of plasmid DNA 
•  Efficiency of nucleofection as a way of transient transfection for cells 
isolated from 1st trimester fetal blood, AF and placenta and 2nd trimester AF 
• Transfection of different types of nucleic acids 
• Effect of transfection to the properties of the cells (kinetics, differentiation, 
expression of pluripotency markers) 
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4.2. Methods 
 
4.2.1. Plasmid preparation 
 
For cell transfection I used the commercially available pEGFP-C1 as a reporter 
plasmid, a cytomegalovirus (CMV)-driven enhanced green fluorescent protein 
(EGFP) plasmid (Clontech, BD Biosciences) (Figure 49). I also used pRL-CMV 
(Figure 50), which carries a Renilla luciferase gene under a T7 promoter (Promega) 
and pGL4.13 (Figure 51), which carries a firefly luciferase gene under an SV40 
promoter (Promega). The plasmids were initially transformed into competent E.coli 
cells (Invitrogen). For this, 50 ng of DNA were added to 1 x 107 competent cells, 
mixed by tapping and incubated in ice for 30 minutes. The cells were then heat-
shocked at 42 °C for 30 seconds, followed by addition of super optimal broth with 
catabolite repression (SOC) medium (Invitrogen) and incubation at 37 °C for 1 hour. 
 
The cells were then grown on agar plates (Sigma) supplemented with the appropriate 
antibiotic. For pEGFP-C1, kanamycin (Sigma) was used at 50 µg/ml, while for pRL-
CMV and pGL4.13 ampicillin (Sigma) was used at 100 µg/ml. Colonies were 
selected and propagated by overnight incubation at 37 °C in 1ml of Lysogeny broth 
(LB, Sigma). The cultures were further expanded by inoculating 100 ml of LB, 
supplemented with the appropriate antibiotic, with the initial 1 ml of culture and 
incubating overnight at 37 °C.  
 
Plasmid purification was carried out using a commercially available kit (Plasmid 
Maxi kit, Qiagen).  For this, the cells were harvested by centrifugation at 6,000 RPM 
for 10 minutes. The supernatant was removed and the pellet was resuspended in 10 
ml buffer P1, provided in the kit. The cells were then lysed in 10 ml of buffer P2, 
incubated at room temperature for 5 minutes, followed by addition of 10 ml of 
buffer P3. The lysate was then incubated on ice for 20 minutes, centrifuged at 
15,000 RPM for 30 minutes, filtered using the filters provided in the kit and eluted 
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using buffer QF. Finally, the DNA was precipitated in 500 µl of isopropanol 
(VWR), centrifuged at 15,000 RPM for 30 minutes, the supernatant was removed, 
the pellet was washed in 70% ethanol, allowed to dry and resuspended in distilled 
water. The DNA was then aliquoted and stored at -20 °C for future use.  
 
 
 
Figure 49. Map of plasmid pEGFP-C1, carrying an EGFP gene under a CMV 
promoter (Image taken from Clontech website). 
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Figure 50.  Map of plasmid pRL-CMV, carrying a Renilla luciferase gene under a 
T7 promoter (Image taken from Promega website). 
 
 
 
 
Figure 51.  Map of plasmid pGL4.13, carrying a Firefly luciferase gene under an 
SV40 promoter (Image taken from Promega website). 
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4.2.2. In vitro RNA transcription 
 
For in vitro RNA transcription, pRL-CMV plasmid was digested using the digestion 
enzymes HindIII and BamHI (Promega) for 1 hour at 37 °C. The digested, linearised 
plasmid was then run on a 0.7% agarose gel (Invitrogen) at 100V for 1 hour (Figure 
52). The first lane contains a ladder used as reference (Promega), followed by two 
empty lanes and the digested plasmid in the fourth lane. The desired band indicated 
by the arrow on the gel was cut out and purified using a gel purification kit (Qiagen). 
DNA concentration was then measured and RNA was produced using an in vitro 
RNA transcription kit (Megascript, Ambion, Applied Biosystems). For this, 1 µg of 
template DNA was mixed with 10x reaction buffer, nuclease-free water, nucleotides 
and enzyme mix provided in the kit, and was incubated at 37 °C for 4 hours. 
DNAase was then added, also provided in the kit, and RNA was cleaned using a 
cleaning kit (Megaclear, Ambion, Applied Biosystems). 
 
 
 
 
 
           
          
 
 
 
 
 
 
Figure 52. Agarose gel purification of digested pRL-CMV plasmid using HindIII 
and BamHI. The digested plasmid was run on a 0.7% agarose gel at 100V for 1 
hour. The first lane contains a ladder used as reference, followed by two empty lanes 
and the digested plasmid in the fourth lane. Arrow indicates the plasmid part 
containing the Renilla luciferase gene, of 1503 bp size.  
 
 
1503 bp 
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4.2.3. Luminescence detection 
 
After transfection of cells with luciferase constructs, the cells were lysed using the 
passive lysis buffer provided with the dual luciferase reporter assay kit (Promega), 
the lysate was mixed in the buffer provided and Renilla luciferase luminescence was 
measured using the Victor 2 multilabel counter (Perkin Elmer Wallac) and the 
Wallac Patha luminescence software (Perkin Elmer Wallac). Following the first 
measurement, the stop & glo reagent provided with the kit was added and firefly 
luciferase luminescence was measured. Luminescence was expressed as counts per 
second (CPS).  
 
 
4.2.4. Lipid transfection 
 
For the lipofection experiments, the protocol developed for adult MSC by Hoelters 
et al. was used (Hoelters et al., 2005). In short, different cell numbers were plated in 
6-well plates. The following day, cells were transfected using varying amounts and 
types of lipid compounds provided by our collaborator B. Pitard, In Cell Art, France, 
as shared material within the EU Synthegene Consortium or using Lipofectamine 
2000 (Invitrogen). The lipids provided by In Cell Art were the ICA-B, ICA-P and 
ICA-PD. The ratio of lipid: transfected DNA used was the one optimised by 
Hoelters et al (1:2 ratio). The DNA chosen for fetal stem cell transfection was 
EGFP-C1. The cells were harvested 24 hours after transfection, and GFP expression 
was assessed using FACScan (Becton Dickinson, Oxford, UK). Data were collected 
and analysed using the CellQuest software (Becton Dickinson, Oxford, UK).  
 
 
4.2.5. DNA dilution by polyglutamic acid 
 
As mentioned previously, random integration is one main problem of gene therapy. 
However some lipofection methods require high copy numbers of plasmid DNA to 
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achieve high efficiency. When less overall amount of DNA is added, there is poor 
lipid-DNA complex formation that leads to lower transfection efficiency. To 
overcome this issue, I used polyglutamic acid (PG) as reported previously (Kichler 
et al., 2005) to dilute out the amount of DNA transfected, in an attempt to have as 
little DNA as possible but still efficient transfection. This would theoretically lower 
the probability of random integration. According to calculations, 0.5µg of PG (MW 
97800; polymerisation degree = 648) has an equivalent charge to 1µg of DNA. 
Table 11 shows the amounts of DNA and PG required for an overall charge 
equivalent to 1µg of DNA. 
 
 
 
Table 11. Amounts of DNA and PG required for overall charge equivalent to 1µg of 
DNA. 
DNA template amount (µg) Amount of PG (µg) 
0.1 0.45 
0.2 0.4 
0.4 0.3 
0.6 0.2 
0.8 0.1 
1 0 
 
 
4.2.6. Nucleofection 
 
The protocol recommended by Amaxa Ltd. was followed for the nucleofection 
experiments. Briefly, 5 x 105 cells per sample were resuspended in 100 µl 
supplemented Human MSC Nucleofector solution, provided with the Human MSC 
nucleofection kit (Amaxa GmBH, Germany). Varying amounts and types of nucleic 
acid were then added to the solution, depending on the experiment, and the cells 
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were transferred to an Amaxa certified cuvette. The cells were nucleofected using 
two settings of different intensity, a harsh indicated for high transfection efficiency 
(U23) and a mild one indicated for high cell survival (C17).  The two programs 
differ in the strength and the duration of electrical current administered to the cells, 
but the exact settings of each program are under patent. The cells were exposed to 
the nucleofection solution for the minimum time possible to avoid toxicity. Finally, 
the cells were plated in 6-well plates containing pre-warmed DMEM supplemented 
with 2 mM L-glutamine, 500 U/ml penicillin, 50 µg/ml streptomycin and 10% FBS. 
72 hours later, the cells were harvested and GFP expression was assessed using 
FACScan. The data were collected and analysed using the CellQuest software. 
Staining with 0.5 mg/ml propidium iodide (PI, Sigma) was also used to estimate the 
viability of the population. Viability refers to the percentage of cells that did not take 
up PI. Efficiency represents the percentage of GFP positive cells. The transfection 
yield represents the percentage of viable cells that were GFP positive. 
 
 
 
4.2.7. Statistical analysis 
 
Data are expressed as means plus or minus standard deviation (SD) from the mean. 
For the statistical analysis, Excel was used to generate the graphs presented and the 
standard deviation of the samples. Unpaired 2-tailed student t tests and one-way 
ANOVA were carried out, and the P values are presented. A P value less than 0.05 
was considered significant. One asterisk (*) indicates a P value lower than 0.05, two 
asterisks (**) indicate a P value lower than 0.01 and three asterisks (***) indicate a 
P value lower than 0.001. 
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4.3. Results 
 
 
4.3.1. Lipofection  
 
Lipofectamine 2000 is a transfection agent used routinely for a variety of cell lines. 
During the optimisation experiments carried out at Tours University, Lipofectamine 
was being used as a positive control solution, while testing the lipid complexes 
developed during the project. Data from our collaborator, B. Pitard indicate that 
adult bone marrow MSC can efficiently be transfected using Lipofectamine 2000 as 
the transfecting agent, while ESC transfection is lower. Based on this result, it was 
decided to use Lipofectamine 2000 to transfect fetal MSC, to test whether 
lipofection is an efficient method for the transfection of fetal stem cells. 
 
For the first set of experiments I used well-characterised samples from fetal blood, 
as these cells have previously been used in a mouse model for genetic disease, where 
they showed a therapeutic effect in bone and kidney (Guillot et al., 2008a; Guillot et 
al., 2008b). After testing the experimental conditions and assessing the efficiency of 
different transfection methods, I carried out experiments using 1st trimester AF cells, 
which are more relevant for cell therapy as discussed in chapter 2. 
 
For the first lipofection experiment, I used 1 µg of EGFP-C1 plasmid for detection 
and Lipofectamine 2000 or ICA-B for gene delivery into the cells. I also titrated the 
cell number, plating 0.375, 0.75 or 1.5 x 105 cells. The cells used for this 
optimisation experiment were MSC from fetal blood at 11+4 gestational age, at 
passage 11. This was a sample well characterised for properties representative of the 
cell population. Figure 53 shows the expression levels of GFP obtained for each 
compound and cell concentration. Each condition was run in duplicate and data are 
normalised to background control (non-transfected cells). 
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The lowest concentration of cells had higher transfection levels for Lipofectamine 
2000 over the middle concentration of 0.75 105 and the higher concentration of 1.5 
105. Similarly, using the ICA-B, the lower concentration was more efficient than the 
higher concentration of cells. 
 
 
 
Figure 53. Percentage of MSC isolated from fetal blood 11+4 from cell passage 11 
expressing GFP obtained for Lipofectamine 2000 or ICA-B and different cell 
concentrations (n=2). Data are normalised to background control (non-transfected 
cells). The lowest concentration of cells had higher transfection levels for 
Lipofectamine 2000 over the middle concentration of 0.75 105 and the higher 
concentration of 1.5 105. Similarly, using the ICA-B, the lower concentration was 
more efficient than the higher concentration of cells.  
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From the first experiment, I concluded that the highest activity was achieved with 
0.375 x 105 cells (mean efficiency 18.64%, SD ± 0.1). Also, at this cell 
concentration, the ICA-B appeared to perform very poorly in comparison to the 
Lipofectamine 2000. However, the efficiency of the transfection was still fairly low, 
less than 20 per cent.  
 
Next, I tested other compounds provided by B.Pitard, named ICA-P and ICA-PD, 
while I repeated the experiment at the optimised conditions for the ICA-B and 
Lipofectamine 2000 from the previous experiment. The aim of this experiment was 
to test the functionality of different novel lipid compounds developed by our 
collaborator and compare it to the commercially available Lipofectamine 2000 at the 
optimised conditions. I again used 1 µg of DNA for this and 0.375 x 105 fetal blood 
11+4 cells at passage 11 per well. I also added PG in different amounts as outlined in 
the materials & methods section to dilute the transfected DNA. Each sample was run 
in duplicate.  
 
Figure 54 shows the transfection efficiency for Lipofectamine 2000, ICA-B, ICA-P 
and ICA-PD at different DNA concentrations, with or without the addition of PG. 
The transfection efficiency is very low for all the compounds tested, less than 5%, 
and the dilution of DNA does not enhance the efficiency.  
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Figure 54. Transfection efficiency for LF2000 (LF2K), ICA-B, ICA-P and ICA-PD at different DNA concentrations, with or without 
the addition of PG (n=2). Cells used were 0.375 x 105 MSC isolated from fetal blood 11+4 gestation, at passage 11. The transfection 
efficiency is very low for all the compounds used, less than 5%, and dilution of DNA with PG does not enhance the level of 
efficiency.
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These two experiments show that that lipofection is not an efficient method for MSC 
transfection. The efficiency levels varied between experiments with identical conditions. 
For instance, using Lipofectamine 2000 and 0.375 x 105 fetal blood 11+4 cells at passage 
11 in the first experiment (Figure 53) the mean efficiency was 18.64%, while for 
Lipofectamine 2000 and the same cell type, passage and cell concentration in the second 
experiment (Figure 54) the efficiency was 3.05%. This is a major problem when trying to 
compare the efficiency of various transfection reagents and methods. The transfection 
efficiencies observed were extremely low, which could have implications in gene 
modification of cells for use in therapy, as far larger numbers of cells would need to be 
manipulated in order to obtain a high enough number of genetically modified cells to be 
clinically relevant. However, viability studies were not carried out for each reagent used 
for lipofection, therefore the low levels of transfection could be due to toxicity associated 
with the process that was accounted for.  
 
 
From these two experiments I concluded that an alternative method of transfection should 
be used for fetal MSC, to achieve higher transfection efficiency levels with clinical 
relevance. 
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4.3.2. Nucleofection 
 
After establishing that lipofection is not an efficient method to transfect the cells and the 
results obtained are not consistent, I concluded that an alternative method would have to 
be tested to transfect the cells efficiently. 
 
The next step was test another approach for transfection (Zaragosi et al., 2007), the 
nucleofection system by Amaxa. For these experiments, I followed the protocol 
recommended by the company for adult MSC and used the same DNA plasmid as for the 
lipofection, EGFP-C1. The cells used for this set of experiments were MSC from fetal 
blood at 12+4 gestational age, because of the limited availability of the fetal blood 11+4 
cells used in the previous experiments. In each experiment, 5 x 105 cells were 
nucleofected using two settings of different intensity, a harsh indicated for high 
transfection efficiency (U23) and a mild one indicated for high cell survival (C17). Aluigi 
et al. and Wiehe et al. use 2 µg of plasmid DNA, while Zaragosi et al. use 3 µg of 
plasmid DNA (Aluigi et al., 2006; Wiehe et al., 2007; Zaragosi et al., 2007) to nucleofect 
adult MSC. Hamm et al. use 5 µg of plasmid DNA (Hamm et al., 2002). Therefore, I 
decided to use 1, 2 and 5 µg of plasmid DNA to test the effect on cell viability and 
nucleofection yield. 
 
Staining with 0.5 mg/ml PI was used to estimate the viability of the population, as live 
cells do not take up PI. Viability refers to the percentage of cells that did not take up PI. 
Figure 55 shows the viability of the cells 72 hours after transfection with different 
amounts of DNA, using the two different programs. Each sample was run in triplicate and 
data are expressed as mean ± SD. Data are normalised to background control (non-
transfected cells). Cells have high viability with both programs and there is no significant 
difference in viability between the two programs for any of the DNA concentrations, with 
p values of 0.25 for 1 µg of DNA, 0.43 for 2 µg and 0.57 for 5 µg of DNA. 
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Figure 55. Viability of the fetal blood 12+4 MSC at passage 11, 72 hours after 
transfection with different amounts of DNA, using the two different programs, U23 and 
C17. Viability refers to the percentage of cells that did not take up PI. The experiment 
was performed in triplicate (n=3) and data are expressed as mean ± SD. Data are 
normalised to background control (non-transfected cells). There is no significant 
difference in viability between the two programs for any of the three DNA 
concentrations.   
 
Figure 56 shows the yield of the transfected cells at different conditions. The p values for 
1 µg and 2 µg of DNA, 0.76 and 0.40 respectively, show that there is no significant 
difference between the two programs, while for 5 µg the p value is 0.02, which indicates 
that C17 is better for this condition.  
 
NS 
NS 
NS 
 163 
 
Figure 56. Yield of the fetal blood MSC 12+4 cells at passage 11, 72 hours after 
transfection with different amounts of DNA, using the two different programs, C17 and 
U23. Yield represents the percentage of viable cells that were GFP positive. The 
experiment was performed in triplicate (n=3) and data are expressed as mean ± SD. Data 
are normalised to background control (non-transfected cells). The p values at 1 µg and 2 
µg of DNA, 0.76 and 0.40 respectively, indicate no significant difference between the 
two programs, while for 5 µg the p value is 0.02 (*: P<0.05), which indicates 
significance.  
 
After this experiment, I decided that the best program for nucleofection of the cells was 
C17, as it administers a milder current dose on the cells, gives good viability results and 
was significantly better when used with the higher amount of DNA. This would ensure to 
a greater extent that the nucleofection process would not affect the stem cell properties of 
the cells. 
NS 
NS 
* 
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After I established that fetal MSC can successfully be transfected using the nucleofector 
technology, I decided to carry out a series of optimisation experiments to test whether 
different nucleic acids can be efficiently transfected into the cells. This was done because 
the initial step of the transposon system was to transfect cells with the transposon and the 
transposase both in the form of DNA plasmids, to test the efficiency of the process. When 
this was established, the transposase DNA plasmid would then be replaced by 
transposase RNA, in order to have better control of the process by allowing enough 
transposition to take place for the process to be efficient, but also avoid illegitimate 
transposition. Finally, in the final optimised version of the transposition system, the 
transposase would be delivered in a protein form, which would allow even further control 
over the process. 
 
5 x 105 fetal blood 12+4 cells were nucleofected at passage 11 with various concentrations 
of pRL-CMV plasmid DNA and in vitro transcribed RNA as described in the methods 
section. Wiehe et al. successfully nucleofected cells with 5 µg of RNA (Wiehe et al., 
2007), therefore I decided to test concentrations of 2, 4 and 8 µg of RNA. The 
nucleofector program used was the milder C17. After 24 hours the cells were lysed and 
luminescence was measured. Figure 57 shows the luminescence measured for each 
construct at different concentrations (n=2), as counts per second (CPS). Both RNA and 
plasmid DNA can successfully be transfected into fetal blood MSC at different 
concentrations. 
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Figure 57. Luminescence measured for fetal blood 12+4 cells at passage 11 nucleofected 
with pRL-CMV plasmid DNA carrying a Renilla luciferase gene or in vitro transcribed 
RNA from the same plasmid. X-axis shows different concentrations of nucleic acids 
used. Each sample was run in duplicate (n=2). Data are normalised to background control 
(non-transfected cells).  Both RNA and plasmid DNA can successfully be transfected into 
fetal blood MSC at different concentrations.  
 
The next experiment I carried out was to test whether cells from different sources can be 
transfected effectively using nucleofection. Figure 58 shows the transfection yield after 
nucleofection of cells isolated from different fetal sources. The cells used were from fetal 
bone marrow 10+4 at passage 7 (FBM, n=2), fetal blood 12+4 at passage 9 (FBL, n=2), 1st 
trimester AF at passage 7 (AF10, n=2) and 2nd trimester AF at passage 8 (AF16-II, n=2). 
5 x 105 cells were transfected for each sample using 2 µg of EGFP-C1 plasmid. The cells 
were harvested 72 hours after transfection and GFP expression was analysed by FACS. 
Normal samples represent non-nucleofected cells of the same passage, and mock samples 
represent nucleofected samples of the same samples without the addition of DNA. Cells 
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from all sources can be transfected efficiently using nucleofection and 2 µg of reporter 
plasmid. 
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Figure 58. Yield of cells from different sources 72 hours after transfection with different amounts of DNA, using the C17 
nucleofection program. The cells used were from fetal bone marrow 10+4 at passage 7 (FBM, n=2), fetal blood 12+4 at passage 9 (FBL, 
n=2), 1st trimester AF at passage 7 (AF10, n=2) and 2nd trimester AF at passage 8 (AF16-II, n=2). Normal samples represent non-
nucleofected cells of the same passage, and mock samples represent nucleofected samples of the same samples without the addition of 
DNA. 
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As seen in the previous experiment, cells from all sources can efficiently be 
transfected using the nucleofector. I then decided to test whether a different DNA 
plasmid, the pGL4.13 carrying a firefly luciferase reporter gene, and in vitro 
transcribed RNA from the pRL-CMV used in Figure 57 can also be successfully 
nucleofected into cells from different sources. The cells used were 1st trimester AF 
(AF1, n=3) at passage 7, 2nd trimester AF (AF2, n=3) at passage 7 and 1st trimester 
placenta (P1, n=3) also at passage 7. Each sample of 5 x 105 cells was nucleofected 
using 2µg of Renilla RNA or firefly DNA and the C17 nucleofection program. The 
cells were harvested 24 hours after nucleofection, lysed and luminescence was 
measured. Figure 59 shows the Renilla luciferase luminescence measured for each 
construct at different concentrations. There was no significant difference in Renilla 
expression between AF1 and AF2 (p=0.16), while P1 had higher Renilla expression 
than AF1 and AF2 (p=0.01 for both). 
 
 
Figure 59. Luminescence measured for cells from different sources and gestation at 
passage 7 nucleofected with 2µg in vitro transcribed RNA. The cells used were 1st 
trimester AF (AF1, passage 7, n=3), 2nd trimester AF (AF2, passage 7, n=3) and 1st 
trimester placenta (P1, passage 7, n=3). Data are expressed as mean ± SD (*: P<0.05). 
 
NS 
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Figure 60 shows the luminescence measured for the cells transfected with 2µg firefly 
DNA. Again, each sample was run in triplicate. There was no significant different in 
firefly expression between AF1 and AF2 (p=0.22), while firefly expression was 
higher for P1 than AF1 and AF2 (p=0.02 and p=0.04 respectively). 
 
 
 
Figure 60. Luminescence measured for cells from different sources and gestation at 
passage 7, nucleofected with 2 µg pGL4.13 DNA carrying a firefly luciferase gene. 
The cells used were 1st trimester AF (AF1, passage 7, n=3), 2nd trimester AF (AF2, 
passage 7, n=3) and 1st trimester placenta (P1, passage 7, n=3) and data are expressed 
as mean ± SD (*: P<0.05).  
 
The following experiment was to test whether nucleofection affects the stem cell 
properties of the cells. For this experiment I used the GFP plasmid used previously, 
EGFP-C1 and transfected 2 µg of DNA per 5 x 105 cell sample, using the C17 
nucleofection program. The cells used were 2 samples of 1st trimester AF, AF10 and 
AF12 at passage 7. Cells were harvested 72 hours after nucleofection and transfection 
efficiency was analysed by FACS. Data are expressed as mean Figure 61 shows the 
NS * 
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transfection efficiency observed. Both AF10 (n=4) and AF12 (n=4) have a 
significantly higher transfection efficiency compared to mock (n=4) transfected cells 
(p=0.00009 and p=0.00008 respectively), while AF10 had higher transfection 
efficiency than AF12 (p=0.05). 
 
 
 
Figure 61. Transfection efficiency of two 1st trimester AF samples at passage 7 
transfected with 2 µg of EGFP-C1 plasmid DNA, using the C-17 nucleofection 
program. Mock cells were cells nucleofected without the addition of plasmid DNA. 
The experiment was performed in quadruplicate (n=4) and data are expressed as mean 
± SD (*: P<0.05, ***: P<0.001). 
 
I also wanted to know the distribution of the GFP expression, in order to see the 
distribution of GFP expression in the cell population. For this, I took fluorescence 
images of the cells 72 hours after nucleofection. Figure 62 shows bright field, GFP 
fluorescence and an overlay of the two images for AF10 nucleofected with 2 µg of 
EGFP-C1 plasmid DNA or with no DNA (Mock). The distribution of GFP expression 
is uniform across the population, for the cells that have successfully taken up the GFP 
plasmid. 
 
* 
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Figure 62. Nucleofected and mock nucleofected cells, without the addition of plasmid 
DNA, from 1st trimester AF (AF10) at passage 7. Bright field, GFP fluorescence and 
an overlay of the two can be seen. The images were taken 72 hours after 
nucleofection. The distribution of GFP expression is uniform across the population, 
for the cells that have successfully taken up the GFP plasmid. 
 
 
In Figure 61, the nucleofection efficiency was high for both 1st trimester AF samples. 
The next step was to assess whether the proliferation capacity of the cells was 
affected due to the uptake of plasmid DNA after nucleofection. For this, the doubling 
time of each sample was calculated for 4 passages, starting at passage 7 (n=3). Figure 
20x 
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63 shows the population doubling time of nucleofected and control cells of the two 1st 
trimester AF samples. Data are expressed as mean ± SD. There is no significant 
difference in population doubling time between nucleofected and control cells for any 
of the samples (p=0.89 for AF10, p=0.38 for AF12). 
 
 
 
Figure 63. Population doubling time of nucleofected and control cells of two 1st 
trimester AF samples, AF10 and AF12. Data are expressed as mean ± SD. There is no 
significant difference in population doubling time between nucleofected and control 
cells for any of the samples (p=0.89 for AF10, p=0.38 for AF12). 
 
The following step was to assess the effect of nucleofection on expression of the 
pluripotency markers Oct-4 and Nanog. Figure 64 shows images of nucleofected cells 
at passage 7 stained for Oct-4 and Nanog, 24 hours after nucleofection. GFP-positive 
cells retain the expression of both Oct-4 and Nanog, indicating that nucleofection and 
plasmid uptake do not affect the expression of pluripotency markers. 
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Figure 64. Nucleofected cells at passage 7 stained for Oct-4 and Nanog 24 hours after 
nucleofection. GFP-positive cells retain the expression of both Oct-4 and Nanog, 
indicating that nucleofection and plasmid uptake do not affect the expression of 
pluripotency markers. 
 
 
The next step was to assess the differentiation potential of the cells after 
nucleofection. To do this, nucleofected cells with and without the addition of plasmid 
DNA (mock nucleofected control) were grown in the presence of bone and fat 
induction media. The composition of the differentiation media is mentioned in section 
2.2.7. Figure 65 shows Von Kossa staining for calcium deposition and Oil Red O 
staining for lipid deposition. The cells retain their ability to differentiate into bone and 
fat after nucleofection. This is true for cells that do and cells that do not take up 
plasmid DNA.   
 
 
 
TOTO-3 GFP Oct-4 overlay 
TOTO-3 GFP Nanog overlay 
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Figure 65. Von Kossa staining for calcium deposition and Oil Red O for lipid 
deposition. 1st trimester AF cells were nucleofected using 2 µg of EGFP-C1 or no 
DNA (Mock control) and grown in the presence of bone and fat induction media. The 
cells retain their ability to differentiate into bone and fat after nucleofection. This is 
true for cells that do (nucleofected) and cells that do not take up plasmid DNA 
(control).   
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4.4. Discussion 
 
In this chapter I tested lipofection and nucleofection as methods for the transient 
transfection of stem cells from 1st trimester fetal blood, AF and placenta and 2nd 
trimester AF. For the first set of experiments I used well characterised samples from 
1st trimester fetal blood, as these cells have previously been used in a mouse model 
for human disease, where they showed a therapeutic effect in bone and kidney 
(Guillot et al., 2008a; Guillot et al., 2008b). I then carried out experiments using 1st 
trimester AF and placenta cells and 2nd trimester AF cells, which are more relevant for 
cell therapy as they can be isolated without endangering the fetus. 
 
This chapter covers work which was carried out as part of a multidisciplinary, specific 
targeted research project with the acronym “SyntheGeneDelivery’, funded by the 
European Union. The aim of the project was to develop a new ex-vivo gene delivery 
protocol to provide stable long-term expression of integrated transgenes, with the 
ultimate aim being to treat genetic diseases of the neuromuscular and skeletal 
systems. The part of the project presented in this chapter was initially going to involve 
tests on the effect of the transposon system on stem cell proliferation and 
differentiation potential and the maintenance of stem cell immunophenotype. 
However, the many problems were encountered throughout the three years making 
the initial aim of this project non-feasible due to the unavailability of an optimised 
transposition system. Hence, several small-scale optimisation experiments were 
carried out to test whether different components of the initial system have any adverse 
effects on fetal stem cells.   
 
The initial experiments involved testing whether lipofection is an efficient method for 
fetal stem cell transfection. For the lipofection experiments, I used Lipofectamine 
2000 and other lipids provided by B. Pitard, our collaborator. The ratio of lipid: 
transfected DNA that I used was the one optimised by Hoelters et al. for adult MSC 
(Hoelters et al., 2005). 
 
As a first step I titrated the cell number, transfecting 0.375, 0.75 or 1.5 x 105 cells and 
found that the lowest concentration of cells (mean efficiency 18.64%, ± 0.1) had 
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higher transfection levels for Lipofectamine 2000 and ICA-B. However the 
transfection efficiency of ICA-B was lower than 5%. In the second experiment I also 
added PG in different amounts to dilute the transfected DNA, in an attempt to lower 
the copy number of DNA molecules. This was done in order to see if transfection 
efficiency with delivery of fewer DNA molecules per cell could be as efficient as the 
standard method, which could be important when the transposon strategy would be 
tested, as less transposon DNA would perhaps lower the probability of insertional 
mutagenesis, without affecting the efficiency of the system. I observed that the 
transfection efficiency for Lipofectamine 2000, ICA-B, ICA-P and ICA-PD was very 
low for all the compounds tested, less than 5%, and the dilution of DNA did not 
enhance the efficiency. PG did not appear to have any effect on cell survival, 
therefore the low transfection levels is not likely to have been cause by cell toxicity. 
 
These two experiments showed that that lipofection is not an efficient method for 
MSC transfection. The efficiency levels varied between experiments with identical 
conditions. For instance, using Lipofectamine 2000 and 0.375 x 105 fetal blood 11+4 
cells at passage 11 in the first experiment (Figure 53) the mean efficiency was 
18.64%, while for Lipofectamine 2000 and the same cell type, passage and cell 
concentration in the second experiment (Figure 54) the efficiency was 3.05%. This is 
a major problem when trying to compare the efficiency of various transfection 
reagents and methods. The transfection efficiencies observed were extremely low, 
which could have implications in genetic modification of cells for use in therapy, as 
far larger numbers of cells would need to be manipulated in order to obtain a high 
enough number of genetically modified cells to be clinically relevant. The limitation 
of this part of the project was that viability studies were not carried out for each 
reagent used for lipofection, therefore the low levels of transfection could be due to 
toxicity associated with the process that was accounted for. 
 
I then tested nucleofection, previously used for primary cells as a transfection method 
with high efficiency (Hamm et al., 2002). For the first experiment I tested two 
programs suggested by Amaxa with different intensity, a harsh indicated for high 
transfection efficiency (U23) and a mild one indicated for high cell survival (C17). 
Aluigi et al. and Wiehe et al. used 2 µg of plasmid DNA, while Zaragosi et al. used 3 
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µg of plasmid DNA (Aluigi et al., 2006; Wiehe et al., 2007; Zaragosi et al., 2007) to 
nucleofect adult MSC. Therefore, I decided to use 1, 2 and 5 µg of plasmid DNA to 
test the effect on cell viability and nucleofection yield. Cells had high viability with 
both programs and there was no significant difference in viability between the two 
programs for any of the DNA concentrations, with p values of 0.25 for 1 µg of DNA, 
0.43 for 2 µg and 0.57 for 5 µg of DNA. 
 
After this experiment, I decided that the best program for nucleofection of the cells 
was C17, as it administers a milder current dose on the cells, gives good viability 
results and was significantly better when used with the higher amount of DNA. This 
would ensure to a greater extent that the nucleofection process would not affect the 
stem cell properties of the cells. 
 
I then tested whether different nucleic acids can effectively be nucleofected into 1st 
trimester fetal blood cells. Wiehe et al. successfully nucleofected cells with 5 µg of 
RNA (Wiehe et al., 2007), therefore I decided to test concentrations of 2, 4 and 8 µg 
of RNA. Both RNA and plasmid DNA were successfully transfected into fetal blood 
MSC at different concentrations.  
 
The next experiment I carried out was to test whether cells from different sources 
could be transfected effectively using nucleofection. The cells used were from 1st 
trimester bone marrow, blood and AF and 2nd trimester AF. Cells from all sources can 
efficiently be transfected using the nucleofector.  
 
I then decided to test whether different nucleic acids can be successfully nucleofected 
into cells from different sources, as for 1st trimester fetal blood stem cells. 1st trimester 
AF and placenta and 2nd trimester AF stem cells can successfully be transfected with 
plasmid DNA and RNA. 
 
Next, I tested whether nucleofection and plasmid uptake affects the properties of the 
stem cells, by assessing their doubling time, maintenance of expression of 
pluripotency markers and differentiation potential into adipocytes and osteocytes. I 
found that there was no significant difference in population doubling time between 
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nucleofected and control cells for any of the samples (p=0.89 for AF10, p=0.38 for 
AF12). Also, GFP-positive cells retained the expression of both Oct-4 and Nanog, 
indicating that nucleofection and plasmid uptake do not affect the expression of 
pluripotency markers. Finally, the cells retained their ability to differentiate into bone 
and fat after nucleofection. This was true for cells that do and cells that do not take up 
plasmid DNA.   
 
Overall, my results confirm the results previously obtained by others on adult MSC 
on the low efficiency of lipofection as a transfection method for primary cells (Aluigi 
et al., 2006; Hamm et al., 2002; Zaragosi et al., 2007). Also, I have shown that 
nucleofection is an efficient method for transfection of stem cells from various 1st and 
2nd trimester fetal sources, both with plasmid DNA and RNA, as previously reported 
for adult MSC (Wiehe et al., 2007) and ESC (Hohenstein et al., 2008; Lakshmipathy 
et al., 2004; Siemen et al., 2008).  
 
The amount of reporter vector transfected, 2-8 µg of nucleic acid depending on the 
experiment, are comparable to those used in experiments reported before with a 
variety of transposon vectors (Wilson et al., 2007; Yant et al., 2007). The only 
transposition system that is functional with lower amounts, around 100 ng, is the 
Sleepy Beauty transposon system (Ivics et al., 2007), yet nucleofection could still 
potentially be used to transfect lower amounts of nucleic acids.  
 
I have also shown that nucleofection and plasmid uptake does not affect population 
doubling, differentiation and expression of pluripotency markers by the cells. 
Nucleofection can therefore be an efficient transfection method to deliver nucleic 
acids to the nucleus of 1st and 2nd trimester fetal cells, as a first step towards ex vivo 
gene manipulation of cells prior to cells therapy. In conclusion, fetal stem cells can be 
used for gene delivery using nucleofection, a method that does not affect cell 
plasticity. The next step, once a suitable and efficient system is available, would be to 
assess whether the use of a transposition system to confer permanent or transient 
transfection of genes of interest, depending on the condition, would affect any of 
these properties.  
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One of the limitations encountered during this work was that no viability studies were 
carried out when assessing the transfection efficiency of each lipid transfection 
method. Viability studies could give an indication as to whether the lipids are not 
mediating DNA internalisation into the cells, or whether the low efficiency is 
attributed to high toxicity. In addition, the CMV promoter of the reporter plasmid 
used could also contribute to the problem of low efficiency, as this promoter is of 
limited value due to silencing events. However at this part of the study long-term 
expression was not desired anyway.  
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5. Discussion chapter 
 
 
In this thesis I isolated and characterised in depth populations of fetal stem cells in the 
1st trimester AF and placenta. Biological properties investigated included the 
migratory potential of these cells towards sites of injury, using in vitro migration 
assays. Additionally, I examined the transfectability of the cells using non-viral 
methods of cell transfection. 
 
I found that 1st trimester AF and placenta contain fetal stem cells that express the 
markers Stro-1, CD29, CD105, CD73, CD44, CD31, CD90, vimentin, laminin, 
fibronectin and the pluripotency markers Oct-4, Nanog, SSEA3, SSEA4, Tra-1-60, 
Tra-1-81. 1st trimester AF cells grow faster than cells from 2nd trimester AF and 1st 
trimester placenta cells, while they have comparable population doubling to cells 
from 1st trimester fetal bone marrow. 1st trimester AF cells have much lower 
population doubling time than adult bone marrow MSC (Guillot et al., 2007), but 
grow as fast as ESC (Field et al., 1992). In addition, the isolated cells have long 
telomeres and high telomerase activity, indicating that these cells can easily be 
expanded in culture without reaching senescence, to numbers relevant for clinical 
applications. Furthermore, the cells can differentiate into the mesodermal osteogenic, 
adipogenic and chondrogenic lineages in vitro. Also, 1st trimester AF cells, like ESC 
but contrary to adult MSC, can form EB-like structures when grown in low-
attachment conditions. The EB-like spheres express markers of the three germ layers 
and lose the expression of the pluripotency markers Oct-4 and Nanog, as shown by 
immunofluorescence and RT-PCR, indicating that the cells undergo differentiation 
upon aggregation. 
 
In addition, I found that the SDF-1/CXCR4 axis is involved in migration of 1st 
trimester fetal stem cells from blood and AF. The cells express CXCR4 as previously 
reported for adult bone marrow MSC and cord blood MSC (Son et al., 2006; Wynn et 
al., 2004). SDF-1 is upregulated in injured oim tissues as found previously in other 
models of injury (Ponomaryov et al., 2000; Togel et al., 2005). 1st trimester fetal stem 
cells migrate to SDF-1 as reported previously for adult bone marrow MSC (Ponte et 
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al., 2007). Cell migration is higher towards oim tissues compared to WT tissues. 
Taken together, these results confirm that the SDF-1/CXCR4 axis is involved in 
recruitment of 1st trimester stem cells to sites of injury.  
 
I also confirmed the low efficiency of lipofection as a transfection method for primary 
cells. Additionally, I have shown that nucleofection is an efficient method for 
transfection of stem cells from various 1st and 2nd trimester fetal sources, both with 
plasmid DNA and RNA. Furthermore, I have shown that nucleofection and plasmid 
uptake does not affect population doubling, differentiation and expression of 
pluripotency markers by the cells. Nucleofection can therefore be an efficient 
transfection method to deliver nucleic acids to the nucleus of 1st and 2nd trimester fetal 
cells, as a first step towards ex vivo gene manipulation of cells prior to cells therapy. 
 
 
5.1. Origin of the cells 
 
Although the presence of stem cells in 2nd trimester AF has been confirmed by many 
groups, the origin of these cells is still largely unknown. During early development, at 
day 8-9 after fertilisation, the inner cell mass of the blastocyst forms two layers, the 
epiblast and the hypoblast. Epiblast cells develop further to form the embryonic 
epiblast and the amnionic ectoderm that line the amnionic cavity. This cavity is later 
filled with AF (Moore, 1998). Thus, early in development cells present in the AF are 
likely to originate from the amnion surrounding the amniotic cavity. As early as 1982, 
Harris speculated that cells present in AF are of extra-embryonic origin, coming from 
the amnion (Harris, 1982). As the embryo develops further, the cell types present in 
the AF also change. During the 1st trimester, cells present in the AF could also 
originate from embryonic skin, being shed as the skin is formed.  
 
The hypoblast, also known as primitive or visceral endoderm, later develops into the 
extraembryonic tissues, contributing to the formation of the fetal part of the placenta. 
The fetal part of the placenta consists of the amnion and chorion (Moore, 1998). Thus, 
the cells I have isolated from 1st trimester placenta could either have the same 
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developmental origin as AF cells if coming from the amnion, or different if they 
originate from the chorion. 
 
 
5.2. Comparative analysis with all stem cell types 
 
Human 1st trimester AF and placenta cells have similar morphology to fetal stem cells 
isolated before from 2nd trimester AF (De Coppi et al., 2007a; Tsai et al., 2004) and 
1st trimester bone marrow (Campagnoli et al., 2001). Cells from all fetal sources have 
a fibroblast-like morphology with spindle-shaped cytoplasm and are similar in size, 
unlike adult MSC that are larger (Guillot et al., 2007). The small size of fetal stem 
cells when compared to adult MSC could have functional advantages, such as higher 
surface area to volume ratio with consequent faster protein transfer, lower energy 
requirements for survival and migration and more rapid trans-endothelial migration 
and dispersal throughout the body after transplantation. 
 
The cells isolated in the present study from 1st trimester AF and placenta are fetal, 
non-hematopoietic cells, shown by presence of the SRY gene and lack of expression 
of hematopoietic markers. They express a variety of stromal markers as described 
before for cells from 1st trimester blood, liver and bone marrow (Campagnoli et al., 
2001), 2nd trimester AF (In 't Anker et al., 2003) and placenta stem cells (Igura et al., 
2004). The cells also express markers of pluripotency as described before for 1st 
trimester fetal blood, liver and bone marrow MSC (Guillot et al., 2007), 2nd trimester 
AF (De Coppi et al., 2007a; Prusa et al., 2003) and placenta stem cells (Battula et al., 
2007; Yen et al., 2005) which is indicative of their intermediate developmental stage 
between the pluripotent ESC and the more lineage-restricted adult stem cells. The 
immunophenotype of the isolated cells suggests that these cells may be mesenchymal 
stem cells, and that 1st trimester AF and placenta is a reliable source of cells with 
comparable immunophenotype to other early fetal stem cells. 
 
In addition, 1st trimester AF and placenta cells are fast proliferating cell populations, 
with a doubling time of around 33 hours and 39 hours respectively, which is 
comparable to results obtained previously for 2nd trimester AF stem cells (De Coppi et 
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al., 2007a) and 1st trimester fetal blood, liver and bone marrow stem cells (Guillot et 
al., 2007). 1st trimester AF and placenta cells have much lower population doubling 
time than adult bone marrow MSC (Guillot et al., 2007), but grow as fast as ESC 
(Field et al., 1992) and can be easily maintained in culture and expanded to numbers 
relevant for clinical applications. The proliferation rate and expansion ability of the 
cells is also demonstrated by their telomerase activity and telomere length, which is 
comparable to 1st trimester fetal MSC (Guillot et al., 2007), with longer telomeres and 
higher telomerase activity than adult MSC and endometrial cells. 
 
1st trimester AF cells also express c-Kit, previously used for the isolation of stem cells 
in the 2nd trimester AF (De Coppi et al., 2007a), indicating that selection by plastic 
adherence isolates a population of cells that is positive for c-Kit expression. C-Kit is 
expressed on human ESC (Hoffman and Carpenter, 2005), primordial germ cells and 
some somatic cells, including cells of the neural crest (Crane and Trainor, 2006).  
 
In terms of their differentiation potential, 1st trimester AF and placenta cells can 
differentiate into the mesodermal osteogenic, adipogenic and chondrogenic lineages 
in vitro, as described before (De Gemmis et al., 2006; Portmann-Lanz et al., 2006). 
Also, 1st trimester AF cells, like ES cells but not adult MSC, can form EB-like 
structures when grown in low-attachment conditions. The EB-like spheres express 
markers of the three germ layers and lose the expression of the pluripotency markers 
Oct-4 and Nanog, as shown by immunofluorescence and RT-PCR, indicating that the 
cells undergo differentiation upon aggregation. This is the first time EB formation has 
been reported for stem cells obtained from AF. 
 
Taken together, the results suggest that 1st trimester AF and placenta contain stem 
cells of fetal origin, with similar characteristics to fetal but not adult MSC, which 
express pluripotency markers also expressed by undifferentiated ESC. Moreover, 1st 
trimester AF cells, like ESC, can form EB-like structures that lose the expression of 
pluripotency markers and express markers of the three germ layers, indicating 
differentiation. 
 
I also found that 1st trimester fetal stem cells from blood and AF express CXCR4 as 
previously reported for adult bone marrow MSC and cord blood MSC(Son et al., 
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2006; Wynn et al., 2004). SDF-1 is upregulated in oim injured tissues as found 
previously in other models of injury (Ponomaryov et al., 2000; Togel et al., 2005). 1st 
trimester fetal stem cells migrate to SDF-1 as reported previously for adult bone 
marrow MSC (Ponte et al., 2007). Cell migration is higher towards oim tissues 
compared to WT tissues. Taken together, these results confirm that the SDF-
1/CXCR4 axis is involved in recruitment of 1st trimester stem cells to sites of injury.  
 
I have confirmed also the low efficiency of lipofection as a transfection method for 
primary cells (Aluigi et al., 2006; Hamm et al., 2002; Zaragosi et al., 2007). 
Additionally, I have shown that nucleofection is an efficient method for transfection 
of stem cells from various 1st and 2nd trimester fetal sources, both with plasmid DNA 
and RNA as shown previously for primary cells (Hamm et al., 2002). Furthermore, I 
have shown that nucleofection and plasmid uptake does not affect population 
doubling, differentiation and expression of pluripotency markers by the cells. 
Nucleofection can therefore be an efficient transfection method to deliver nucleic 
acids to the nucleus of 1st and 2nd trimester fetal cells, as previously reported for adult 
MSC (Wiehe et al., 2007) and ESC (Hohenstein et al., 2008; Lakshmipathy et al., 
2004; Siemen et al., 2008). 
 
 
5.3. Type of isolated stem cells 
 
Recently, a novel population of stem cells has been identified in murine adult bone 
marrow, termed very small embryonic-like (VSEL) cells (Kucia et al., 2006). This 
population of cells is very rare in the bone marrow, accounting for only 0.02% of 
bone marrow nucleated cells. VSEL cells are small, 2-4 µm in diameter, express the 
pluripotency markers SSEA-1, Oct-4, Nanog and Rex-1 at the mRNA and protein 
level, have open-type euchromatin and at their undifferentiated state, express markers 
of several lineages including myogenic, cardiomyogenic, hepatic, pancreatic and 
others at the mRNA level. VSEL cells also express CXCR4 and migrate towards 
SDF-1 in vitro, indicating that the CXCR4/SDF-1 is involved in the trafficking of 
these cells (Kucia et al., 2005). However the cells cannot proliferate or differentiate in 
vitro, unless they are seeded on feeder cells.  
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The isolated cells from 1st trimester AF and placenta share many characteristics with 
VSEL cells, making it a possibility that these cells are in fact the same population, 
only localised in different niches at different developmental stages. As Kucia et al. 
suggest, it is likely that similar populations of non-hematopoietic stem cells found in 
many fetal and adult tissues are in fact the same population, described by different 
researchers with different names.   
 
 
5.4. Importance of stem cell presence during 1st trimester 
 
The presence of fetal stem cells during 1st trimester would be highly beneficial for 
conditions with early onset where intrauterine cell therapy would be applicable, 
because the cells could be isolated, expanded and transplanted in time to correct or 
prevent the condition as early as possible. In addition, fetal stem cells have some 
characteristics, including pluripotency and proliferation potential that make them a 
more attractive cell source than ASC for therapeutic applications. 
 
As shown by Campagnoli et al., fetal stem cells are available in fetal blood during the 
1st trimester (Campagnoli et al., 2001) and they can be used both for autologous and 
for allogeneic applications. However, a recent study has shown that the isolation 
efficiency of fetal blood sampling is 67% and cells can only be isolated in two-thirds 
of the cases (Chan et al., 2008). An additional drawback is that the procedure is 
invasive, technically challenging and is associated with a pregnancy loss rate of 5% 
(Orlandi et al., 1990). The availability of stem cells in 1st trimester AF and placenta is 
very important, as stem cells from these two sources can be isolated both for 
autologous and for allogeneic therapy. Prenatal diagnosis procedures such as 
amniocentesis and CVS make these cells accessible in the 1st trimester, with sampling 
efficiency and safety as high as mid-trimester amniocentesis, as long as the operator 
has the required skills and training (Brambati and Tului, 2005; Rousseau et al., 1995). 
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5.5. Originality of the thesis 
 
In this study, I have shown for the first time that 1st trimester AF contains a 
population of pluripotent stem cells with an intermediate phenotype between ESC and 
adult MSC. I have also shown for the first time that fetal cells can form EB structures 
when grown in low-attachment conditions and in culture medium used for ESC 
culture. The EB-like spheres express markers of the three germ layers and lose the 
expression of the pluripotency markers Oct-4 and Nanog, as shown by 
immunofluorescence and RT-PCR, indicating that the cells undergo differentiation 
upon aggregation.  
 
Additionally, I showed that fetal stem cells express CXCR4 intracellularly but not on 
the cell membrane in the unstimulated state, while they partly externalise the receptor 
upon stimulation with SDF-1 or oim tissues. I have also confirmed the involvement of 
the CXCR4/SDF-1 axis in fetal stem cell homing towards injured tissues, using in 
vitro migration assays.  
 
Furthermore, I showed for the first time that 1st trimester fetal stem cells from various 
sources can successfully be transfected with a variety of RNA and DNA reporter 
constructs, without losing their proliferation and differentiation potential and 
expression of the pluripotency markers Oct-4 and Nanog. 
 
 
5.6. Future applications 
 
The main finding of my thesis is that 1st trimester AF and placenta contain a 
population of primitive stem cells with kinetic advantage, pluripotency potential and 
capacity to migrate to chemokines and cells derived from injured tissues. These 
results are important because the availability of stem cells in 1st trimester AF and 
placenta improves the prospects for stem cell therapeutic applications, as stem cells 
from these two sources can be isolated both for autologous and for allogeneic prenatal 
therapy. Prenatal diagnosis procedures such as amniocentesis and CVS make these 
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cells accessible in the 1st trimester, with sampling efficiency and safety as high as mid 
trimester amniocentesis, as long as the operator has the required skills and training. In 
addition, by understanding how stem cells respond to signalling and home towards 
sites of injury, the pathways involved can be manipulated to increase stem cell 
response and thus potentially increase the therapeutic effect these cells have.  
 
The next step will be to use cells from 1st trimester AF and placenta in in vivo models 
of human disease, to assess their therapeutic potential. A good model to test this is the 
Alport syndrome mouse model. Alport syndrome is a hereditary glomerulopathy, also 
affecting hearing and vision. It is caused by a mutation in one of the genes encoding 
the α3, α4 or α5 chains of collagen type IV. Patients with Alport syndrome 
progressively develop end stage renal failure in the second to fourth decade in life and 
the only available treatment currently is renal transplantation. 1st trimester AF and 
placenta cells could be used to transplant mice with Alport syndrome, where they 
could potentially engraft to the diseased kidneys, repair the basement membrane 
collagen defects and prevent or reverse kidney pathology. 
 
1st trimester AF and placenta stem cells can also be used in early development studies. 
The evolution of stemness during fetal development is a largely unknown area. |By 
examining whether the stem properties of cells are maintained throughout gestation in 
placenta and AF, and comparing these cells to developmentally earlier (ESC and EG 
cells) and later cells (ASC), it can be possible to get a better understanding on how 
stem cells arise and evolve during development. 
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